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Akin to the exponential growth of genomic sequencing data, high-throughput techniques in
proteomics and biotechnology have been creating ever-expanding repositories of proteomic,
pharmacological, and interactomic data. Other molecular data, including expression profiles,
genomic mutations and cell conditions, have also been massively generated and they are
further refining our understanding of disease mechanisms. In addition, patient data, gathered
by electronic medical record systems and social medias, complement biological data and
pave the way for personalized treatment strategies. Therefore, efficiently and effectively
integrating and mining these invaluable data hold the great promising of making precision
medicine a reality.
However, integrating and mining these large-scale, heterogeneous, and noisy dataset pose
several fundamental computational challenges and have therefore become a bottleneck to
clinical decision making and medical knowledge discovery. This thesis is a systematic study
of mining these biological and healthcare data for precision medicine. I take a network
perspective and integrate these datasets into a large knowledge network where nodes are
biological concepts and links are biological relationships. I then propose a novel computa-
tional framework to mine these knowledge networks. To demonstrate the effectiveness of
mining knowledge networks, I will introduce how this framework can be used to understand
molecular functions, accelerate drug discovery, and support clinical decision making. To
understand molecular functions, I will show how a knowledge network can substantially im-
prove gene function prediction performance and further annotate novel gene sets by mining
scientific literature-based knowledge network. To accelerate drug discovery, I will use the
knowledge network to predict drug targets and identify drug associated pathways. To sup-
port clinical decision making, I will discuss our efforts in integrating genomics data with
clinical data to cluster patients, predict patient survival and visualize patient records. Fi-
nally, I will conclude this thesis by summarizing how mining knowledge networks advance
precision medicine and discussing the promising future work of this thesis.
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CHAPTER 1: INTRODUCTION
Akin to the exponential growth of genomic sequencing data, high-throughput techniques
in proteomics and biotechnology have been creating ever-expanding repositories of genomic,
proteomic, and interactomic data, leading to significant breakthroughs in precision medicine
[1, 2, 3, 4, 5, 6, 7, 8]. Other molecular data, including expression profiles, genomic muta-
tions and cell conditions, have also been massively generated and they are further refining
our understanding of disease progression and drug mechanisms of action [9, 10, 11, 12, 13,
14, 15]. Patients data, including clinical data collected in electronic medical records and
user-generated online social media data, is also of considerable interest due to its unique
value in clinical data mining tasks such as adverse drug reactions detection, patient survival
prediction, patient subtyping, and treatment recommendation [16, 17, 18, 19, 20, 21].
These datasets contain valuable knowledge about biological systems, human diseases, and
drug mechanisms, creating an unprecedented opportunity for accelerating scientific discov-
ery via discovery of knowledge from these data as well as optimizing clinical decisions and
improving healthcare by developing intelligent machine learning-based decision support sys-
tems. Moreover, it becomes even more pronounced when we jointly mine these heterogeneous
dataset. For example, we can use large-scale genome-wide association studies to interpret
unexpected adverse drug reactions identified in electronic medical records [22, 23]. Patient’s
response to small molecular inhibitors can also be used to refine our understanding of genetic
interaction in cancer [24, 25, 26].
In this thesis, I systematically studied how to leverage knowledge networks to discover
new biomedical knowledge and support clinical decision making. Despite the success of pre-
vious data-driven approaches, they suffer from the noise and missing values in biomedical
datasets. Intuitively, integrating different biomedical datasets reduces noise in biomedical
dataset, leading to less false-positive results. However, jointly mining different biomedical
datasets is more challenging due to the heterogeneity of biomedical datasets. To address
these challenges, I propose to integrate different biomedical datasets into a large-scale, het-
erogeneous knowledge network. In this knowledge network, nodes are biomedical entities
such as drugs, diseases, and genes. Links are relations such as drug a inhibits gene b, gene c
’is mutated ’ in patient d, and gene e interacts with gene f . This knowledge network’s poten-
tial for advancing precision medicine is based on the following two factors. First, integrating
knowledge from different datasets offers a multi-perspective view of disease progression and
drug mechanisms. Applying ‘guilt by association’ rule [27] to this knowledge network boosts
the inference of new knowledge by combining information from different sources. Secondly,
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despite the success of existing biomedical data mining approaches, many of them still suf-
fer from noisy and missing data. Using a network-based approach mitigates the noise by
correcting the features or attributes according to neighbors, leading to less false-positive
results.
This thesis aims to tap into this exciting opportunity of mining knowledge network for
precision medicine. I will first propose the framework of mining knowledge networks. This
framework consists of three network modeling approaches including diffusion model, ho-
mogeneous network embedding model, and hetergeneous network embedding model. I will
propose two novel network embedding methods which learnt compact representations for
nodes in homogeneous networks and heterogeneous networks, respectively. After that, I will
demonstrate how this framework can be used in key precision medicine tasks such as gene
function annotation, drug discovery, and clinical decision making. In addition to the com-
putational contribution introduced in this thesis, I have also developed relevant practical
tools and software in this direction. Consequently, this thesis benefits a large population
including working biologists, physicians and patients.
The organization of this thesis is as follows. In Chapter 2, I will propose the framework of
mining knowledge networks. In Chapter 3, I will introduce how this framework can be used
to annotate gene functions. In Chapter 4, I will introduce how I use a pharmacogenmics
knowledge network to accelerate drug discovery. In Chapter 5, I will introduce how I use a
clnical knowledge network to support clinical decision making. Finally, I will conclude this
thesis and propose existing future directions.
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CHAPTER 2: A FRAMEWORK FOR MINING KNOWLEDGE NETWORKS
Knowledge networks integrate biomedical relations from different datasets. In knowledge
networks, nodes are biomedical entities such as drug, disease, and gene. Links are relations
such as drug a inhibits gene b, gene c is mutated in patient d, and gene e interacts with
gene f . By integrating selective biomedical datasets according to downstream tasks, we can
obtain different knowledge networks. In this thesis, I will demonstrate the value of mining
these four knowledge networks:
1. A pharmacogenomics network. In this knowledge network, nodes are drugs, diseases,
and genes. Links includes drug-target interactions, protein-protein interactions, and drug-
disease associations. This network can be used to infer novel pharmacogenomics knowledge
such as drug-drug interactions, drug-target interactions, and drug repurposing.
2. A multi-species network. In this knowledge network, nodes are genes belong to dif-
ferent species. Links are protein-protein interactions and homology. This network can be
used to transfer biomedical discovery from model organisms to human.
3. A clinical knowledge network. In this knowledge network, nodes are drugs, symptoms,
and patients. Links are extracted from patient profiles in electronic medical records. This
network can be used to support clinical decision making such as finding similar patients,
patient stratification, and treatment recommendation.
4. A biomedical text network. In this knowledge network, nodes are biomedical terms.
Links are biomedical terms frequently co-occured in scientific papers. This network can
be used to retrieve and summarize existing biomedical knowledge. It could also be used
to discover new knowledge such as adverse drug reactions.
These knowledge networks are useful because of the following two reasons. Firstly, knowl-
edge networks can be used to address missing values and noise in biomedical datasets ac-
cording to the “guilt by association” rule. Secondly, knowledge networks provide a multi-
perspective view and thus boost the prediction performance. However, mining knowl-
edge networks poses unique computational challenges due to the scale, heterogeneity, high-
dimensionality, and noise of knowledge networks.
2.1 COMPUTATIONAL APPROACHES FOR MINING KNOWLEDGE NETWORKS
To tackle these computational challenges, I applied three different network modeling ap-
proaches to mining knowledge networks. The goal of these three methods is to convert a
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given knowledge network into feature vectors. In particular, we want to obtain a feature
vector for each node and later use these feature vectors in downstream prediction tasks.
1. Diffusion model. Diffusion model is developed based on random walk with restart
(RWR) which calculates the probability that each node can be reached by other nodes in
the network. Although the diffusion model is effective in many applications, the resulted
feature vectors are high-dimensional and noisy, leading to overfitting in downstream clas-
sification tasks. This method is suitable for analyzing small-scale (i.e., < 10K nodes) and
homogeneous knowledge networks.
2. Homogeneous network embedding. To tackle the overfitting problem due to the
high-dimensional feature vectors generated by diffusion model, I propose a novel net-
work embedding approach which projects high-dimensional networks into low-dimensional
space. The feature vector would be the compact representation for each node in the low-
dimensional space. Comparing to feature vectors generated from diffusion models, feature
vectors generated from network embedding models are less noisy. This method is suitable
for analyzing medium-scale (i.e., < 20K nodes) and homogeneous knowledge networks.
3. Heterogeneous network embedding. Homogeneous network embedding is effective
in decomposing a network with a single node type (e.g., a human protein-protein in-
teraction network). However, it is not able to model more sophisticated heterogeneous
networks which have multiple types of node and link. To this end, I propose a novel
heterogeneous network embedding algorithm to project heterogeneous networks into low-
dimensional space. Moreover, heterogeneous networks could be very large due to the
integration of different biomedical datasets. I propose a fast learning algorithm which
significantly reduces the time complexity. Consequently, the proposed method scales to
very large networks which have millions of nodes. This method is suitable for analyzing
large-scale and heterogeneous knowledge networks.
Next, I will introduce these three models in detail. I will first briefly introduce the diffusion
model which serves as the basis for embedding methods. I will then propose two network
embedding methods for decomposing homogeneous networks and heterogeneous networks,
respectively.
2.1.1 Diffusion model
The goal of diffusion model is to generate equilibrium probability vectors for each node.
It runs random walk with restart (RWR) on each node in each network (e.g. protein-protein
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interaction or co-expression network) to compute the ‘diffusion state’ of each node, which
summarizes local topology. RWR is different from conventional random walks in that it
introduces a pre-defined probability of restarting at the initial node after every iteration.
Formally, let A denote the weighted adjacency matrix of a network with n nodes. Each
entry Bi,j in the transition matrix B represents the probability of a transition from node i





Next, letting Sti be an n-dimensional distribution vector in which each entry stores the
probability of a node being visited from node i after t steps, RWR from node i with restart
probability pr is defined as:
St+1i = (1− pr)StiB + prqi, (2.2)
where qi is an n-dimensional distribution vector with qi(i) = 1 and qi(j) = 0 ∀i 6= j .
Note that the restart probability controls the relative influence of global and local topolog-
ical information in the diffusion, where a larger value places greater emphasis on the local
structure. We can obtain the stationary distribution S∞i of RWR at the fixed point of this
iteration, and we refer to this as the ‘diffusion state’ Si of node i (i.e. Si = S
∞
i ) , using the
same definition as previous work [28]. Intuitively, the jth entry Sij stores the probability
that RWR starts at node i and ends up at node j in equilibrium. The fact that two nodes
having similar diffusion states implies they are in similar positions with respect to other
nodes in the graph, which may reflect functional similarity.
2.1.2 Homogeneous network embedding
Diffusion states are not entirely accurate, partially due to the noisy and incomplete na-
ture of interactomes. Moreover, high dimensionality imposes additional computational con-
straints on directly using the diffusion states as features for classification or regression tasks.
To address this issue, Cho et al. proposed DCA which employs the following dimensionality












where ∀i, wi, xi ∈ Rd for d  n. DCA refers to wi as the context feature and xi as the
node feature of node i both capturing the topological properties of the network. If xi and wj
are close in direction and have large inner product, then it is likely that node j is frequently
visited in the random walk starting from node i. DCA takes a set of observed diffusion states










The original framework uses a standard quasi-Newton method L-BFGS [29] to solve this opti-
mization problem. Although the learnt low-dimensional vector representation can effectively
capture the network structure, we found that optimizing in this way is time consuming.
New contributions
To make DCA more scalable to large networks, we developed a fast, matrix factorization-
based approach to decompose the diffusion states. Based on the definition of Ŝij , we have:
log Ŝij = x
T





i wj′ . (2.5)
The first term in the above equation corresponds to the low-dimensional approximation of
Ŝij , while the second term is the normalization factor that enforces si ∈ ∆n, where ∆n is
the n-dimensional probability simplex. In our new formulation, we relax the constraint that
the entries in factorization-based approach to decompose the diffusion states. In particular,
we drop the second term in the above equation. While the resulting low-dimensional ap-
proximations of diffusion states are no longer strictly valid probability distributions, we find
that the approximations are close enough to the true distribution that the relaxation has a
negligible impact. As a result, Ŝij can be simplified as:
log Ŝij = x
T
i wj. (2.6)
In addition, instead of optimizing the relative entropy between the true and the approxi-








(xTi wj − logSij)2. (2.7)
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Now, the resulting optimization problem can be easily solved by the classic singular value
decomposition (SVD) [30]. To avoid taking a logarithm of zeros, we added a small positive
constant to sij and computed the logarithm diffusion state matrix L as:
L = ln(S + Q)− ln(Q). (2.8)
where Q ∈ Rn×n with Qij = 1n ,∀i, j, and S ∈ R
n×n is the concatenation of si, . . . , sn.
With SVD, we decompose L into three matrices U , Σ and V :
L = UΣVT , (2.9)
where U ∈ Rn×n, V ∈ Rn×n , and Σ ∈ Rn×n is the diagonal singular value matrix. To ob-
tain the low-dimensional vectors wj and xi with d dimensions, we simply choose the first d sin-
gular vectors Ud, Vd and the first d singular values Σd . More precisely, let X = {x1, . . . , xn}
denote the low-dimensional vector representation matrix, and W = {w1, . . . , wn} denote the








The key benefit of this new optimization procedure is significantly reduced computational
time. For example, decomposing the STRING yeast network with around 6,000 nodes into
500-dimensional vectors takes < 5 min on a standard server (with six 3.07 GHz Intel Xeon
CPUs and 32GB RAM) for SVD, while the original approach with L-BFGS takes more than
2 hours. We noticed that the prediction accuracies for both methods are almost identical in
predicting yeast gene function.
To integrate multiple network data, we extend the above single-network DCA to multiple
networks. Let L = {L1, . . . ,Lk} denote the set of logarithm diffusion state matrices based













j − logLrij)2. (2.12)
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where for each node i in network r, we assign a network-specific context feature wri , which
encodes the intrinsic topological properties of node i in network r. The node features x
are shared across all k networks to be able to capture more global patterns. This objective
function can be also optimized by SVD. It is worth noting that it is possible to weight each
network differently when concatenating the networks, but we give equal importance to each
network in this work for simplicity. In the following sections, we use X = {x1, . . . , xn} as
the low-dimensional vector representations of genes. Note that one can also use w, but we
observed that the performances of these two representations are quite similar.
2.1.3 Heterogeneous network embedding
For heterogeneous networks that have multiple node types and edge types, I propose a
novel heterogeneous network embedding approach called ProSNet. As an overview, ProSNet
first constructs a heterogeneous biomedical network by integrating different datasets. It
then performs a novel dimensionality reduction algorithm on this heterogeneous network to
optimize a low-dimensional vector representation for each nodes. The vectors of two nodes
will be co-localized in the low-dimensional space if these two nodes are close to each other
in the heterogeneous biological network. A key computational contribution is that ProSNet
obtains low-dimensional vectors through a fast online learning algorithm instead of the batch
learning algorithm used by previous work [31, 32]. In each iteration, ProSNet samples a path
from the heterogeneous network and optimizes low-dimensional vectors based on this path
instead of all pairs of nodes. Therefore, it can easily scale to large networks containing
hundreds of thousands or even millions of links and nodes.
Definition 2.1 Heterogeneous Biomedical Networks (HBNs) are biomedical net-
works where both nodes and edges are associated with different types. In an HBN G =
(V,E,R), V is the set of typed nodes (i.e., each node has its own type), R is the set of edge
types in the network, and E is the set of typed edges. An edge e ∈ E in a heterogeneous
biomedical network is an ordered triplet e = 〈u, v, r〉, where u ∈ V and v ∈ V are two typed
nodes associated with this edge and r ∈ R is the edge type.
Definition 2.2 In an HBN G = (V,E,R), a heterogeneous path is a sequence of com-
patible edge types M = 〈r1, r2, . . . , rL〉, ∀i, ri ∈ R. The outgoing node type of ri should
match the incoming node type of ri+1. Any path Pe1 eL = 〈e1, e2, . . . , eL〉 connecting node
u1 and uL+1 is a heterogeneous path instance following M, iff ∀i, ei is of type ri.
In particular, any edge type r is a length-1 heterogeneous path M = 〈r〉. We show a toy
example of an HBN under our function prediction framework in Fig. 2.1.
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Figure 2.1: An example of the heterogeneous biological network under our function
prediction framework. The node set V consists of four types, {“Human protein”, “Yeast
protein”, “Mouse protein”, and “Gene Ontology term”}. The edge type set R consists of
five types, {“Sequence similarity”, “Protein function annotation”,“Gene Ontology
relationship”,“Experimental”, and “Co-expression” }. This HBN explicitly captures
interolog and transfer of annotation through heterogeneous paths across different species.
Low-dimensional vector learning in the heterogeneous biological network
ProSNet finds the low-dimensional vector for each node through first sampling a large
number of heterogeneous path instances according to the HBN. It then finds the optimal
low-dimensional vector so that nodes that appear together in many instances turn to have
similar vector representations. We first define the conditional probability of node v connected
to node u by a heterogeneous path M as:




where f is a scoring function modeling the relevance between u and v conditioned on M.
Inspired from the previous work[33], we define the following scoring function:
f(u, v,M) = µM + pMTxu + qMTxv + xuTxv. (2.14)
Here, µM ∈ R is the global bias of the heterogeneous path M. pM and qM ∈ Rd are local
bias d dimensional vectors of the heterogeneous pathM. xu and xv ∈ Rd are low-dimensional
vectors for nodes u and v respectively. Our framework models different heterogeneous paths
differently by using pM and qM to weight different dimensions of node vectors according to
the heterogeneous path M.
For a heterogeneous path instance Pe1 eL = 〈e1 = 〈u1, v1, r1〉, . . . , eL = 〈uL, vL, rL〉〉
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following M = 〈r1, r2, . . . , rL〉, we propose the following approximation.
Pr(Pe1 eL |M) ∝ C(u1, 1|M)
γ × Pr(Pe1 eL |u1,M), (2.15)
where C(u, i|M) represents the count of path instances followingM with the ith node being
u. C(u, i|M) can be efficiently computed through a dynamic programming algorithm. γ is
a widely used parameter to control the effect of overly-popular nodes, which is set to 0.75
in previous work [34]. We assume that each node on the path only depends on its previous
node. Then we have




Given the conditional distribution defined in Eq. (3.8) and (2.15), the maximum likelihood
training is tractable but expensive because computing the gradient of the log-likelihood takes
time linear in the number of nodes. Following the noise-contrastive estimation (NCE)[35], we
reduce the problem of density estimation to a binary classification, discriminating between
samples from path instances following the heterogeneous path and samples from a known
noise distribution. In particular, we assume these samples come from the following mixture.
1
θ + 1
Pr+(Pe1 eL |M) +
θ
θ + 1
Pr−(Pe1 eL |M), (2.17)
where θ is the negative sampling weight and Pr+(Pe1 eL|M) denotes the distribution of
path instances in the HBN following the heterogeneous pathM. Pr−(Pe1 eL|M) is a noise
distribution, and for simplicity we set
Pr−(Pe1 eL |M) ∝
L+1∏
i=1
C(ui, i |M)γ . (2.18)
We further assume noise samples are θ times more frequent than positive path instance
samples. The posterior probability that a given sample D came from positive path instance
samples following the given heterogeneous path is
Pr(D = 1|Pe1 eL ,M) =
Pr+(Pe1 eL |M)
Pr+(Pe1 eL |M) + θ · Pr−(Pe1 eL |M)
, (2.19)
where D ∈ {0, 1} is the label of the binary classification. Since we would like to fit





Pr(Pe1 eL |M) + θ · Pr−(Pe1 eL |M)
]
+ θ · EPr−
[
log
θ · Pr−(Pe1 eL |M)





The loss function can be derived as
LM ≈
∑




















where σ(·) is the sigmoid function. Note that when deriving the above equation we used
exp(f(u, v,M)) in place of Pr(v|u,M), ignoring the normalization term in Eq. (3.8). We
can do this because the NCE objective encourages the model to be approximately normalized
and recovers a perfectly normalized model if the model class contains the data distribution
[35]. Following the idea of negative sampling [34], we also replaced
∑L







i=1 f(ui, vi, ri) for ease of computation. We optimize parameters
xu,xv,pr,qr, and µr based on Eq. (2.21).
Runtime improvements through online learning
Like diffusion component analysis[31], the number of pairs of nodes 〈u, v〉 that are con-
nected by some path instances following at least one of the paths is O(|V |2) in the worst
case. This is too large for storage or processing when |V | is at the order of hundreds of
thousands. Therefore, sampling a subset of path instances according to their distribution
is the most feasible choice when optimizing, instead of going through every path instance
per iteration. Thus, our method is still very efficient for networks containing large num-
bers of edges. Based on Eq. (2.15), we can sample a path instance by sampling the nodes
on the heterogeneous path one by one. Once a path instance has been sampled, we use
gradient descent to update the parameters xu,xv,pr,qr, and µr based on Eq. (2.21). As
a result, our sampling-based framework becomes a stochastic gradient descent framework.
The derivations of these gradients are trivial and thus are omitted. Moreover, since stochas-
tic gradient descent can generally be parallelized without locks, we can further optimize
via multi-threading. Decomposing a heterogeneous network with more than sixty thousand
nodes and ten million edges into a 500-dimensional vector space takes less than 30 minutes
on a 12-core 3.07GZ Intel Xeon CPU through this online learning framework.
2.2 RELATED WORK
In this section, I will review previous works that are related to this thesis. In particular, I
will introduce related works on extensively studied biomedical datasets including genomics
data, electronic medical records, and scientific literature data.
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Large-scale cancer genomics projects, such as the Cancer Genome Atlas [36], the Cancer
Genome project [37], and the Cancer Cell Line Encyclopedia project [1], as well as cancer
pharmacology projects, such as the Genomics of Drug Sensitivity in Cancer project [38],
have generated large volumes of genomics and pharmacological profiling data. As a result,
there is an unprecedented opportunity of linking these pharmacological and genomic data to
identify therapeutic biomarkers [39, 40, 41]. Large-scale cancer genomics projects, such as
the Cancer Genome Atlas [36], the Cancer Genome project [37], and the Cancer Cell Line
Encyclopedia project [1], as well as cancer pharmacology projects, such as the Genomics
of Drug Sensitivity in Cancer project [38], have generated large volumes of genomics and
pharmacological profiling data. As a result, there is an unprecedented opportunity of linking
these pharmacological and genomic data to identify therapeutic biomarkers [39, 40, 41]. In
pursuit of this vision, significant efforts have been invested in identifying the genetic basis
of drug response variation among individual patients [42, 9, 43]. Electronic medical records
are also of great interest to health informatics researchers [44, 45, 16, 46]. For example,
recent study shows that high quality knowledge graphs can be constructed from medical
records by using simple concept extraction [47]. In addition to electronic medical records,
we showed that using knowledge network constructed from other datasets (e.g., genomics
data, literature data) can substantially help electronic medical records analysis. Scientific
paper data is another important source to discover medical knowledge [48, 49, 50]. For
example, Hoon et al. used advance natural language processing methods to identify gene
regulatory networks from millions of PubMed papers [51]. Despite the encouraging results
of previous work, they didn’t integrate literature data with molecular data. We showed
more promising results by using the additional information in molecular data while mining
literature data.
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CHAPTER 3: KNOWLEDGE NETWORK ASSISTED GENE FUNCTION
ANNOTATION
To evaluate the performance of the proposed network embedding methods, I applied these
two methods to gene function annotation. Automatic annotating functions of genes is a
fundamental task in life sciences and has significant impact in drug discovery. In particular,
I applied these three network models to three different gene annotation tasks. First, I used
the proposed homogeneous network embedding approach to predict gene function based
on molecular networks. Experiment results show that the proposed network embedding
approach has a much better performance in comparison to other network-based approaches.
Secondly, I used the heterogeneous network embedding approach to integrate information
from different species. Experimental results demonstrate the effectiveness of jointly learning
from multiple species. Finally, I used the diffusion model to annotate novel gene sets by
mining a network constructed from scientific papers and molecular networks. I proposed
NetAnt which annotates novel gene sets by mining millions of PubMed papers. NetAnt
helps doctors and biologists understand function of novel gene sets without spending a huge
amount of time reading scientific papers.
3.1 HOMOGENEOUS NETWORK EMBEDDING FOR GENE FUNCTION
PREDICTION
Systematically predicting gene (or protein) function based on molecular interaction net-
works has become an important tool in refining and enhancing the existing annotation
catalogs, such as the Gene Ontology (GO) database [52, 53]. Fortunately, an increasing
compendium of genomic, proteomic and interactomic data allows us to extract patterns
from functionally well-characterized genes (or proteins) to accurately infer functional prop-
erties of lesser-known ones. In particular, recently developed high-throughput experimental
techniques, such as yeast two-hybrid screens and genetic interaction assays, have helped to
build molecular interaction networks in bulk. Topological structures of these networks can be
exploited for function prediction using the ‘guilt-by-association’ principle, which states that
genes (or proteins) that share similar neighbors or other topological properties in interaction
networks are more likely to be functionally related.
To this end, a variety of graph-theoretic and machine learning algorithms [54, 55, 56,
57, 56] have been developed to provide a way of refining and enhancing existing functional
annotations (e.g. Gene Ontology database [58]) based on network data. A popular class of
graph-theoretic algorithms uses a diffusion process to examine the local topology of nodes,
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Figure 3.1: A breakdown of GO labels by the number of annotated genes in (a) human and
(b) yeast.
exploiting both direct and indirect linkages [59, 60, 61, 28]. Alternatively, the number of
occurrences of different elementary subgraphs (known as graphlets) in the neighborhood
can be used to characterize each node and to establish pairwise affinity scores [62, 63].
More sophisticated machine learning algorithms, such as GeneMANIA [64, 65], have also
been proposed. GeneMANIA uses label propagation on an integrated network specifically
constructed for each functional label, and is currently available as the state-of-the-art web
interface for gene function prediction in multiple organisms.
Despite the success of existing algorithms, a major difficulty that has not been sufficiently
addressed is that of predicting rare labels. Because many molecular functions (MFs) are
inherently specific in their scope, a large number of functional labels have only a few anno-
tated genes (or positive annotations); for instance, in the human GO annotation database
[58], there are currently 8626 GO labels with at least 3 annotations, 4178 of which have less
than 10 annotated genes and 7905 labels have less than 100 genes. The distributions of GO
labels with different numbers of annotations in yeast and human are shown in Figure 3.1.
Nearly half of the GO labels have less than 10 annotations in both species.
Predicting new associations for these sparsely annotated labels is substantially more chal-
lenging than those for labels with a lot of annotations, because patterns extracted from the
few known genes are more likely to be statistical artifacts that cannot be generalized, which
is commonly known as the ‘overfitting’ problem in machine learning and statistics.
One way to mitigate overfitting is to take similarities between labels into account. For
instance, if we have a priori knowledge that two labels reflect similar MFs (e.g. they are
both children of the same parent in the ontology graph), we would also expect the two
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corresponding sets of genes (or proteins) to be similar. If one of the gene sets contains only
a few genes, then the other may provide valuable information about missing associations.
Thus, by propagating information along the edges in the ontology graph, one can pool
available data together for increased robustness to overfitting.
Notably, previous efforts to incorporate label similarity into function prediction algorithms
have largely been unsuccessful. They formulated the problem as a single structured-output
hierarchical classification (HC) instead of binary classification, but its predictive performance
for sparsely annotated functional labels is far from satisfactory [66, 67, 68, 69, 70, 71, 72].
Another related work [73] exploited the similarity between 17 Munich Information Center
for Protein Sequences (MIPS) functional categories via a regularization scheme. However,
this approach does not scale to tens of thousands of sparse GO annotations in human, as it
employs a computationally expensive optimization.
Our solution to this problem is based on diffusion component analysis (DCA) [59], a
recently developed algorithm that combines network diffusion, such as random walk with
restart (RWR) [60], with dimensionality reduction to obtain low-dimensional vector rep-
resentations of nodes in a graph that capture topological properties. Topological features
extracted from interaction networks in this manner can be used in conjunction with k-nearest
neighbors (kNNs) or support vector machines (SVMs) to outperform the corresponding state-
of-the-art for predicting hundreds of MIPS labels in yeast [59]. However, DCA also suffers
from overfitting for sparsely annotated labels when predicting GO labels for a larger human
interactome, if we want to train label-wise classifiers for all labels.
To solve this problem, we introduce clusDCA, an improved function prediction algorithm
based on DCA, which (i) incorporates the similarity between functional labels and (ii) scales
to a large number of annotations. The key idea of clusDCA is to perform DCA also on the
ontology graph to obtain compact vector representations of labels. The gene vectors from
the original method are then projected onto the space of label vectors so that the projections
of positively annotated genes are geometrically close to their assigned labels. Because labels
that are similar to each other in the ontology graph are co-localized in the label vector space,
classifiers for sparsely annotated labels will now favor genes associated with other similar
labels in the neighborhood. This is how information is transferred between labels to avoid
overfitting in our approach.
When compared with state-of-the-art methods that do not incorporate label similarity, our
experiments on yeast, mouse and human datasets demonstrate that our method substantially
improves the predictive accuracy of sparsely annotated labels while achieving comparable
performance for GO labels with sufficiently many genes. We also demonstrate the perfor-
mance improvement of clusDCA over an alternative approach to utilizing the ontology graphs
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based on HC. Furthermore, our method can be used to predict new genes for a given GO
label, even in the extreme case where there are no existing gene annotations and the only
information available is the label’s position in the ontology graph and the genes associated
with other labels. In addition to improving function prediction on its own, this demonstrates
the potential for our method to be used in conjunction with recent methods that extract
new ontology terms from data [74, 75] to provide an improved way of refining and extending
our knowledge of gene or protein function.
3.1.1 Methods
As an overview, clusDCA first computes the ‘diffusion state’ of each node by performing a
RWR on each input network, and subsequently finds a low-dimensional vector representation
for each gene via an efficient matrix factorization of the diffusion states. A key contribution
is that clusDCA then follows an analogous procedure to obtain a low-dimensional vector
representation of each functional label based on the ontology graph. Intuitively, the gene
vectors encode the topology of the interactome, which in turn reflects gene function, while
the label vectors encode the topology of the ontology graph, which reflects the semantic
and relational properties of the labels. Given both the gene and the label vectors, clusDCA
novelly finds the best projection of the gene vectors onto the label vector space, thus keeping
the projected gene vectors geometrically close to their known labels. In the final step,
clusDCA computes its predictions for an uncharacterized gene by sorting the candidate
functions by their proximity to the projected gene vector, based on the optimal projection.
An illustration of this pipeline is given in Figure 3.2. We give a more detailed description of
this pipeline below.
3.1.2 Low-dimensional vector representations of functional labels
The GO graph is a directed acyclic graph (DAG) over functional labels where the edges
represent various semantic relationships. We only consider the ‘is a’ and ‘part of’ edges,
which result in a hierarchy of labels with edges going from the more specific to the more
generic terms. As a consequence of this hierarchical structure, which is generally not present
in molecular networks, a naive application of RWR on the ontology graph where the edges are
treated as undirected unfairly favors high-level nodes, which tend to have higher centrality.
On the other hand, allowing a random walk to only move from high- to low-level nodes
would greatly restrict the portion of the graph a random walk can explore.
To address these issues, we allow both edge directions but with different weights, whose
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Figure 3.2: Overview of clusDCA
17
ratio is controlled by the ‘back propagation’ parameter α. With B denoting the transition
matrix of the original graph with unidirectional edges, our modified RWR for the ontology
graph is defined as
St+1i = (1− pr)Sti ((1− α)B + αBTB) + prqi, (3.1)
We chose a value for α that generally shrinks the diffusion scores of high-level nodes, and
confirmed that the final prediction performance is stable for different values of α between
0.5 and 0.8. Based on the diffusion states from this modified random walk, we learned a low-
dimensional vector representation of the ontology graph using the same procedure as the one
for molecular networks. Importantly, our representation captures not only single-hop parent-
child relationships, but also more global patterns such as long-range sibling relationships in
the network.
In the following sections, we use Y = {y1, . . . , ym} to denote the low-dimensional vector
representation matrix of functional labels. yj is the vector for function j.
3.1.3 Projecting gene vectors into ontology label space
After obtaining the low-dimensional vector representations of both genes and functional
labels, we use these vectors to predict gene function. Because the vectors reflect the topo-
logical structure of nodes in the network, genes that are close in their vector directions are
more likely to be similar in their functions. Analogously, functional labels that are close in
their vector directions may be more semantically similar. Based on this intuition, we use a
transformation matrix W to project genes from the gene vector space to the function vector
space, which allows us to match genes to functions based on geometric proximity. Let y
′
i be
the projection of the gene vector xi:
y
′
i = xiW. (3.2)





A larger zij indicates that gene i is more likely to be annotated with function j.
We want to optimize W so that positively annotated genes are geometrically similar to
their assigned GO labels. We use the inner product zij = 〈y
′
j, yj〉 as the similarity func-
tion. We also explored the L2 distance, but it performed generally worse than the inner
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product, possibly due to the fact that the inner product explicitly models both positive and
negative annotations. Next, we define fposj (f
neg
j ) as the set of genes that are positively
(negatively) annotated with function j. Note that whenever a gene is positively annotated
with a particular function we also positively annotated all of its ancestors with the gene.
Our constrained optimization problem for finding the best projection that incorporates both

















where the weights 1|fnegj |
and 1|fposj |
correct for the imbalance in the training data. Instead
of simply maximizing the affinity scores of positive annotations, this formulation aims at
maximizing the margin between the affinity scores of positive and negative annotations.





where F is a weight matrix with Fij = |fnegj |,∀i ∈ f
pos
j and Fij = |f
pos
j |,∀i ∈ f
neg
j .
Because modeling the complex relationship between genes and functional labels with a
single transformation matrix may be overly restrictive, we group functions into different
clusters and learn a separate projection model for each cluster. For the main results, we
divide the GO labels into the following four groups based on the number of annotated
genes in the training data: [3−10], [11−30], [31−100] and [101−300]. We also tested using




We obtained a collection of six molecular networks each for human, yeast and mouse from
the STRING database v9.1 [76]. These networks are built from heterogeneous data sources,
including high-throughput interaction assays, curated protein-protein interaction databases,
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and conserved co-expression. We excluded text mining-based networks to avoid confounding
by links based on functional similarity. There were 16,662 nodes in human, 6,311 in yeast
and 18,248 in mouse. The number of edges in these networks varied from 1,183 to 673,410 in
human, from 1,059 to 293,921 in yeast and from 3,917 to 1,638,107 in mouse. Note that each
edge is associated with a weight between 0 and 1 representing the confidence of interaction.
Next, we obtained gene-function associations and the ontology of functional labels from the
GO Consortium [58]. We built a DAG of GO labels from all three categories [biological
process (BP), molecular function (MF), cellular component (CC)] based only on the ‘is
a’ and ‘part of’ relationships for each species. Labels without any associated genes were
removed, resulting in three species-specific ontology graphs for yeast, human and mouse.
The human ontology graph had 13,708 functions and 19,206 edges, the yeast ontology graph
had 4,240 functions and 4,804 edges and the mouse ontology graph had 13,807 functions and
19,704 edges.
Experimental setting
Following previous work [65], we used 3-fold cross-validation to evaluate our method,
where a randomly chosen subset of one-third of the genes are held out as the test set. After
computing the optimal projection of gene vectors into the functional label space based only
on the training data, we calculated the affinity scores to get a ranked list of test genes for
each function. Then we measured the extent to which true annotations are concentrated
near the top of the list by calculating the area under the receiver operating characteristic
curve (AUROC) and the area under the precision recall curve (AUPRC), which are standard
performance metrics in this field [65]. To summarize results across different labels, we
used both micro- and macro-averages. The micro-average directly combines the entries in
the confusion matrix constructed from different labels prior to calculating the predictive
performance, and the macro-average calculates the areas under the curves for each label
independently and then takes the average.
We compared clusDCA to two state-of-the-art network-based function prediction algo-
rithms, GeneMANIA [65] and DCA [59], and another algorithm based on HC [72], which
exploits the hierarchical structure of functional labels. For consistency, we used the same
dataset (i.e. annotations, genes, networks) and the same evaluation scheme for every method
we tested.
We obtained the original MATLAB implementation of GeneMANIA from http://morrislab.
med.utoronto.ca/Data/GB08/. For DCA, we tested only the kNN version, because
the SVM version seriously suffers from overfitting for sparsely annotated labels and also
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Table 3.1: Number of GO terms in different sparsity levels
3-10 11-30 31-100 101-300
Human MF 886 390 222 99
Human BP 2940 1677 1122 553
Yeast MF 351 156 92 29
Yeast BP 815 408 235 87
Mouse MF 188 215 165 84
Mouse BP 337 568 678 329
does not scale to the human dataset. Importantly, neither GeneMANIA nor DCA lever-
ages topological information from the GO graph. Noting that the original formulation of
HC does not scale to large datasets, we instead implemented an efficient version that uti-
lizes the clusDCA framework. In particular, we associate each gene with a ‘macro-label’
Y = {y1, . . . , yk} ∈ {0, 1}k, where yi is a ‘micro-label’ which is set to 1 when the gene is
positively annotated with label i and 0 otherwise. Following HC, we impose a constraint
that if yi = 1 then yj = 1 for every ancestor j of i. We then find the optimal projection
from DCA gene vectors to the space of macro-labels using the same optimization problem
we introduced in Equation 16. After solving the optimization problem, we use the optimized
transformation matrix W∗ to compute the pairwise affinity score zij between gene i and
function j.
For clusDCA, we set the back propagation parameter α to 0.8 and the restart probability
to 0.8 for the GO graph. We observed that our performance is stable for different values
of α between 0.5 and 0.8. For the molecular networks, we used a restart probability of 0.5,
adopted from our previous work [59]. We set a larger restart probability for the GO graphs
because they are generally much sparser. We used d = 2500 as the dimensionality of the
learned vectors for the main results.
We followed the same procedure as the one in GeneMANIA to group the GO labels into
two major gene ontologies: ‘BP’ and ‘MF’. For both ontologies, we further binned GO labels
into four sparsity levels, each consisting of GO labels with [3−10], [11−30], [31−100] and
[101−300] annotated genes (see Table 3.1). Although we used all of the GO terms in human
and yeast, for mouse, we used only the GO terms with evidence codes that are also used in
the evaluation of GeneMANIA [65]: TAS, RCA, ND, NAS, ISS, IPI, IMP, IGI, IEP, IEA,
IDA and IC [77].
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GO label vectors capture semantic similarity
Unlike some of the previous work [65, 73] that did not explicitly incorporate the GO graph,
our approach exploits the ontology structure to learn a low-dimensional vector representation
of each GO label. If these vectors can be clustered into semantically meaningful clusters, it
would validate our attempt to enforce gene assignments to be similar between labels that are
geometrically close in the label vector space as being well founded. To test this hypothesis, we
used K-means to cluster the GO labels based on the cosine similarity of our low-dimensional
vector representations of labels. We determined the number of clusters by restricting the
largest cluster to have at most 80% of the total number of labels. In Supplementary Figure
S1 (Supplementary Data), two of the 41 clusters we identified are visualized with Cytoscape
[78]. The complete list of clusters can be found in Supplementary Data. In the visualization,
the node size reflects the number of genes that the corresponding function is annotated with,
and the edge width reflects the cosine similarity between the vector representations of the
two nodes. The first cluster represents functions related to molecular binding, such as cation
binding, metal ion binding, nucleotide binding and NAD binding, whereas the second cluster
represents functions related to different transmembrane transporter activity. The fact that
the set of GO labels in each of these clusters is highly consistent in function provides evidence
that the learned vectors faithfully reflect the semantic relationships among the labels.
clusDCA substantially improves prediction of sparsely annotated GO labels
To evaluate clusDCA, we performed large-scale function prediction for human, yeast and
mouse. The results are summarized in Figure 3.3 and Supplementary Figure S2 (Supplemen-
tary Data). It is clear that our approach significantly outperforms other methods on sparsely
annotated labels in all three datasets. For example, in human, our method achieved 0.8491
micro-AUROC and 0.8648 macro-AUROC on BP labels with 3-10 annotations, which is much
higher than 0.5815 (micro), 0.5857 (macro) for DCA and 0.7288 (micro), 0.8002 (macro) for
GeneMANIA. It is worth noting that DCA performs consistently worse than GeneMANIA
at this task, possibly due to the fact that GeneMANIA adaptively integrates the input
networks for each functional label to optimize performance on training data. In yeast, clus-
DCA achieved 0.9025 micro-AUROC on BP labels with 3−10 annotations, which is again
substantially higher than 0.6645 for DCA and 0.8504 for GeneMANIA. In mouse, clusDCA
achieved 0.8627 micro-AUROC and 0.8802 macro-AUROC on BP labels with 3-10 annota-
tions, which is again substantially higher than 0.5873 (micro), 0.5937 (macro) for DCA and
0.7609 (micro), 0.8245 (macro) for GeneMANIA. A similar improvement was observed for
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functional labels with 11−30 annotations and also for the MF labels in human, yeast and
mouse (Fig. 3.3 and Supplementary Fig. S2). We found most of the improvements to be
statistically significant (P < 0.05; paired Wilcoxon signed-rank test). The improvement was
most pronounced in human overall, presumably because the human dataset is much sparser
than the other two.
The above results suggest that the topological information in ontology graphs can be
exploited to greatly improve function prediction performance for sparse labels. It remains to
be shown whether clusDCA is better than other approaches to incorporating the ontology.
To this end, we found that clusDCA substantially outperforms HC. For instance, in human,
our method achieved 0.8984 micro-AUROC and 0.9135 macro-AUROC on MF labels with
3−10 annotations, which is much higher than 0.7435 (micro), 0.7580 (macro) for HC. The
improvement was more pronounced where the number of GO labels was large (e.g. human
BP). This is likely because the number of candidate predictions for HC grows exponentially
with the number of GO labels. As a result, HC is highly prone to overfitting in a dataset with
a large number of labels. Notably, HC also invariably performed worse than GeneMANIA
in most of our experiments.
In addition, we observed consistent improvements over GeneMANIA with respect to the
AUPRC. In human, our method achieved 0.0429 macro-AUPRC on BP labels with 3−10
annotations, which is higher (better) than 0.0368 AUPRC for GeneMANIA. In yeast, clus-
DCA achieved 0.1360 AUPRC on MF labels with 3−10 annotations, which is substantially
higher than 0.1075 macro-AUPRC for GeneMANIA. Similarly, in mouse, clusDCA achieved
0.0516 macro-AUPRC on BP labels with 3−10 annotations, which is substantially higher
than 0.0389 macro-AUPRC for GeneMANIA
Interestingly, we note that the improvement of our method is negatively correlated with
the number of annotations of the GO labels. In other words, we observed a greater improve-
ment of clusDCA over previous methods for sparser labels. This observation suggests that
clusDCA indeed addresses the overfitting issue, which has more significant impact on the
sparsely annotated labels.
In addition to sparsely annotated labels, our approach also achieved a performance compa-
rable to GeneMANIA and greatly outperformed HC and DCA on labels with a large number
of annotations (i.e. 31−100 and 101−300) with respect to both AUROC and AUPRC. The
difference between clusDCA and GeneMANIA is not statistically significant in this case, but
clusDCA is still marginally better than GeneMANIA on most categories.
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Figure 3.3: Comparison of our approach with other methods in terms of micro-AUROC.
Asterisk indicates that our approach is statistically significant in comparison with
GeneMANIA. Performance is evaluated for different subsets of GO labels with varying
sparsity levels as shown on the x-axis
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clusDCA accurately predicts genes for new GO labels
Given that the current GO database is likely incomplete, in the event that a new GO
label is created, we hope to automatically find genes that this label may be associated with.
Remarkably, our framework can be directly used to tag genes with a newly created GO
label using only the topological information from the ontology graph and other annotated
labels. When the new GO labels are added to the ontology graph, we first obtain the low-
dimensional vectors of these labels with DCA. Then, given the low-dimensional vectors for
both genes and functions, we can inversely project function vectors onto the gene vector space
and predict associated genes for the new GO labels. This approach can also potentially help
to refine and enhance the current GO annotation database, thus serving as a verification
platform.
As a proof-of-concept, we repeatedly held out one-third of the GO labels as the validation
set of ‘uncharacterized’ labels. We then used the remaining two-third GO labels to learn
the projection model and to predict genes that are associated with the held out labels.
Figure 3.4 shows the result of this experiment in yeast. We observed that our framework
achieves a promising performance on all categories with micro-AUROC ranging from 0.81
to 0.87. It is worth noting that, to our best knowledge, no other existing method is able to
predict associated genes for new GO labels without any existing annotations. Disease gene
prioritization is a closely related task where the goal is to predict genes associated with a
particular disease, but most algorithms proposed for this problem also require an initial set
of associated genes to be able to make predictions.
3.1.5 Conclusion
We introduced a novel algorithm, clusDCA, for gene function prediction. The major
idea of clusDCA is to leverage similarity between functional labels in addition to similarity
between genes to prevent overfitting of sparsely annotated GO labels. We achieve this goal
by learning low-dimensional vector representations of genes and functions and matching
gene vectors to function vectors via a projection that best preserves known gene-function
associations. Similar labels are co-localized in the vector space, which allows the transfer of
information between neighboring functions when genes are assigned to them. Since learning
the projection solves the prediction of all labels simultaneously, our method has the added
benefit of being scalable to datasets with a large number of annotations.
Although based on DCA, clusDCA is a substantial advance, as evidenced by its supe-
rior performance over DCA, as well as GeneMANIA and HC, on sparsely annotated GO
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Figure 3.4: Micro ROC curve of predicting genes for new GO labels on MF in yeast
labels, while maintaining a comparable performance on labels with many genes. Moreover,
we demonstrated clusDCAs ability to identify putatively associated genes for newly created
GO labels without any annotations, which suggests that our method can be used to im-
prove poorly annotated labels and thus takes a significant step towards more comprehensive
understanding of gene or protein function in various organisms.
Supplementary Data: https://academic.oup.com/bioinformatics/article/
31/12/i357/216487
3.2 INTEGRATING HETEROGENEOUS INFORMATION FOR GENE FUNCTION
PREDICTION
The above homogeneous network embedding based function prediction only used the infor-
mation from a single species. Intuitively, integrating molecular networks from multi-species
reduces noise in each species and thus may boost the function annotation performance.
Consequently, I used the proposed heterogeneous network embedding approach to develop
an integrated, multi-species function prediction pipeline which integrates information from
homology data and molecular networks [79]. This is the first work that integrates molecular
networks from multiple species into a large heterogeneous network for function prediction.
To scale our network embedding approach to massive heterogeneous graphs, I performed ran-
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dom walks on-the-fly from each node and applied the noise-contrastive estimation approach
to optimize the low-dimensional gene vectors. Importantly, the impact of the proposed
approaches goes beyond function prediction. First, since proteins of different species are
projected into the same low-dimensional space, these vector representations can be used to
translate discoveries from model organisms to humans for accelerating the process of biomed-
ical research. Secondly, our method can be applied to analyzing other heterogeneous data.
For example, we constructed a large drug-gene-disease network and observed promising re-
sults in medical record retrieval [80], survival analysis [81], medical record visualization [82],
and patient clustering [83].
3.2.1 Introduction
Computational prediction of protein function has been extensively studied in the context of
molecular evolution. Homologous proteins have most likely evolved from a common ancestor.
They often carry out similar protein functions, because functions are generally conserved dur-
ing molecular evolution. Consequently, computational approaches can predict the function
of query proteins by transferring those of their annotated homologs. In addition to automatic
annotations based on orthology or domain information or pre-existing cross-references and
keywords [84], a variety of machine learning algorithms [85, 86, 87, 88, 89, 90, 91] have been
proposed to extract annotations based on sequence similarity-detection tools such as BLAST,
PSI-BLAST[92], and phylogenetic analysis [93, 94]. Despite the success of homology-based
approaches, their major constraint arises from a lack of annotated sequences[69]. In fact,
among over 65 million protein sequences in publicly accessible databases [95], only 2 million
of them are manually curated [96]. Consequently, the predictive power of homology-based
methods suffers from the scarcity of annotations. Furthermore, reliable homology relation-
ships are sparse between distantly related species, thus posing computational and statistical
challenges when making faithful predictions.
Fortunately, the rapidly growing interactome data from high-throughput experimental
techniques allows us to extract patterns from neighbors in molecular networks [97, 98, 99]
in addition to homologous proteins. This idea is supported by the established “guilt-by-
association” principle, which states that proteins that are associated or interacting in the
network are more likely to be functionally related [100]. Recently, this “guilt-by-association”
principle has become the foundation of many network-based function prediction algorithms
[31, 101, 102, 28, 103, 104, 61, 105]. Among them, GeneMANIA [106] and clusDCA [32] are
state-of-the-art network-based function prediction approaches. In addition to incorporat-
ing network topology, clusDCA also leverages the similarity between GO labels and obtains
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substantial improvement on sparsely annotated functions. GeneMANIA uses a label propa-
gation algorithm on an integrated network specifically constructed for each functional label,
and is currently available as a state-of-the-art web interface for gene function prediction for
many organisms.
Intuitively, integrating homology data with molecular networks can synergistically improve
function prediction results. On one hand, it enables us to transfer annotations from func-
tionally well-characterized neighbors in the molecular network as well as from homologous
proteins with conserved similar functions. On the other hand, homology data can further
mitigate the incomplete and noisy nature of molecular networks through interologs[107],
which states that a conserved interaction occurs between a pair of proteins that have inter-
acting homologs in another organism [108].
Nevertheless, integrating homology data with molecular networks is both computationally
and statistically challenging. Since they are heterogeneous data sources, it is likely sub-
optimal to integrate them in an additive way which simply averages the prediction results
of either of these two data sources. Moreover, we also need an efficient algorithm that scales
to hundreds of thousands of proteins from multiple species. One way to integrate these
two heterogeneous data sources seamlessly is to construct a multiple species heterogeneous
network in which both nodes and edges are associated with different types. With this
network, we can predict functions for query proteins based on annotations extracted from
both their homologs and their neighbors in molecular networks. Furthermore, information
can also be transferred between two proteins that are neither homologs nor neighbors in
molecular networks. Notably, the only previous attempt to integrate these two heterogeneous
data sources is using multi-view learning[109]. However, it does not scale to multiple species.
In addition, they formulated protein function prediction as a structured-output hierarchical
classification problem whose performance for sparsely annotated functional labels is far from
satisfactory [32].
Here, we introduce ProSNet, a novel Protein function prediction algorithm which ef-
ficiently integrates Sequence data with molecular Network data across multiple species.
Specifically, an integrated heterogeneous network is first constructed to include all molecu-
lar networks of multiple species, in which homologous proteins across multiple species are
also linked together. Based on this integrated network, a novel dimensionality reduction
algorithm is applied to obtain compact low-dimensional vectors for proteins in the network.
Proteins that are topologically close in the molecular networks and/or have similar sequences
are co-localized in this low-dimensional space based on their vectors. These low-dimensional
vectors are then used as input features to two classifiers which utilize annotations from
molecular networks and homologous proteins, respectively. In addition, ProSNet is inher-
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ently parallelized, which further promises scalability. When compared to the state-of-the-art
methods that only use homology data or molecular networks, ProSNet substantially improves
the function prediction performance on five major species.
3.2.2 Methods
As an overview, ProSNet first constructs a heterogeneous biological network by integrat-
ing homology data with molecular network data of multiple species. It then performs a
novel dimensionality reduction algorithm on this heterogeneous network to optimize a low-
dimensional vector representation for each protein. The vectors of two proteins will be
co-localized in the low-dimensional space if the proteins are close to each other in the het-
erogeneous biological network. A key computational contribution is that ProSNet obtains
low-dimensional vectors through a fast online learning algorithm instead of the batch learn-
ing algorithm used by previous work [31, 32]. In each iteration, ProSNet samples a path
from the heterogeneous network and optimizes low-dimensional vectors based on this path
instead of all pairs of nodes. Therefore, it can easily scale to large networks containing
hundreds of thousands or even millions of edges and nodes. After finding low-dimensional
vector representation for each node, ProSNet calculates an intra-species affinity score and
an inter-species affinity score by transfering annotations within the same species and across
different species, respectively. Finally, ProSNet predicts functions for a query protein by
averaging these scores and picking the function(s) with the highest score(s).
Runtime improvements through online learning
Like diffusion component analysis[31], the number of pairs of nodes 〈u, v〉 that are con-
nected by some path instances following at least one of the paths is O(|V |2) in the worst
case. This is too large for storage or processing when |V | is at the order of hundreds of
thousands. Therefore, sampling a subset of path instances according to their distribution
is the most feasible choice when optimizing, instead of going through every path instance
per iteration. Thus, our method is still very efficient for networks containing large num-
bers of edges. Based on Eq. (2.15), we can sample a path instance by sampling the nodes
on the heterogeneous path one by one. Once a path instance has been sampled, we use
gradient descent to update the parameters xu,xv,pr,qr, and µr based on Eq. (2.21). As
a result, our sampling-based framework becomes a stochastic gradient descent framework.
The derivations of these gradients are trivial and thus are omitted. Moreover, since stochas-
tic gradient descent can generally be parallelized without locks, we can further optimize
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via multi-threading. Decomposing a heterogeneous network with more than sixty thousand
nodes and ten million edges into a 500-dimensional vector space takes less than 30 minutes
on a 12-core 3.07GZ Intel Xeon CPU through this online learning framework.
Function prediction
After using the above framework to find the low-dimensional vector for each protein in
the HBN, ProSNet transfers annotations both within the same species and across different
species to predict for a query protein.
To transfer annotations within the same species, ProSNet first uses diffusion component
analysis [31] on the Gene Ontology graph [110] to find low-dimensional vector yi for each
functional label i. It then uses a transformation matrix W to project proteins from the
protein vector space to the function vector space, which allows us to match proteins to
functions based on geometric proximity. Let y
′
i be the projection of the protein vector xi:
y
′
i = xiW. (3.5)





A larger zij indicates that gene i is more likely to be annotated with function j. We follow
clusDCA[32] to find the optimal W.
Since proteins from different species are located in the same low-dimensional vector space,
ProSNet is able to use the annotations across different species as well. Instead of using the
annotations from all the other proteins, ProSNet only considers the k most similar proteins
based on the cosine similarity between their low-dimensional vectors. It then calculates the




cos(xi,xg) · 1(g ∈ Tj), (3.7)
where Bi is the set of k most similar proteins of i and Tj is the set of genes that are annotated
to function j in the training data.
After obtaining the intra-species affinity score z and inter-species affinity score s, ProSNet
normalizes them by z-scores. It predicts functions for a query protein by averaging these
two normalized affinity scores and picking the function(s) with the highest score(s)
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3.2.3 Experimental results
Construction of heterogeneous biological network for function prediction
To construct the heterogeneous biological network (HBN), we obtained six molecular
networks for each of five species, including human (Homo sapiens), mouse (Mus mus-
culus), yeast (Saccharomyces cerevisiae), fruit fly (Drosophila melanogaster), and worm
(Caenorhabditis elegans) from the STRING database v10 [98]. These six molecular networks
are built from heterogeneous data sources, including high-throughput interaction assays, cu-
rated protein-protein interaction databases, and conserved co-expression data. We excluded
text mining-based networks to avoid potential confounding. Each edge in the molecular
networks has been associated with a weight between 0 and 1 representing the confidence of
interaction. Next, we obtained protein-function annotations and the ontology of functional
labels from the GO Consortium [110]. We only used annotations that have experimental ev-
idence codes including EXP, IDA, IPI, IMP, IGI, and IEP. As a result, annotations that are
based on an in silico analysis of the gene sequence and/or other data are removed to avoid
potential leakage of labels. We built a directed acyclic graph of GO labels from all three
categories [biological process (BP), molecular function (MF) and cellular component (CC)]
based on “is a” and “part of ” relationships. This graph has 13,708 functions and 19,206
edges. We set all edge weights of protein-function links to 1 and all edge weights between
GO labels to 1. Finally, we extracted amino acid sequences of all proteins in our five-species
network from the STRING database and the Universal Protein Resource (Uniprot) [95].
To construct homology edges, we performed all-vs-all BLAST [92] and excluded edges with
E-value larger than 1e-8. We then used the negative logarithm of the E-values as the edge
weights and rescaled them into [0, 1]. We showed the statistics of our HBN in Tab. 3.2. For
simplicity, all edges are undirected. Note that we excluded the protein-function annotation
edges that are in the hold-out test set in the following experiments for rigorous comparisons.
Our heterogeneous network is similar to the example network in Fig. 2.1, except that our
network has five species and six different types of molecular networks.
Experimental setting
We used 3-fold cross-validation to evaluate the methods of interest. For a given species for
evaluation, we randomly split proteins of the species into three equal-size subsets. Each time,
the GO annotations of proteins in one subset were held out for testing, and the annotations
of the other two subsets were used for intra-species classification training. For inter-species
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Table 3.2: Statistics of our heterogeneous network
Human Mouse Yeast Fruit fly Worm
#proteins 16,544 16,649 6,307 11,261 13,469
#co-expression edges 1,319,562 1,406,572 628,014 2,466,234 2,774,840
#co-occurrence edges 28,334 29,472 5,328 17,962 14,678
#database edges 275,860 347,406 66,972 116,748 69,948
#experimental edges 492,548 672,326 439,956 380,046 298,684
#fusion edges 2,678 3,994 2,722 4,026 4,336
#neighborhood edges 78,440 77,962 91,220 69,934 49,890
#human homology edges 0 525,221 55,884 202,993 159,481
#mouse homology edges 525,221 0 52,916 188,729 151,408
#yeast homology edges 55,884 52,916 0 26,950 28,269
#fruit fly homology edges 202,993 188,729 26,950 0 75,831
#worm homology edges 159,481 151,408 28,269 75,831 0
#annotations 77,950 66,238 28,668 32,259 21,655
training, we used all experimental GO annotations from the other four species, ensuring no
leakage of label information in the training data. To evaluate the predictive performance,
we measured the extent to which the predicted ranked list was consistent with the ground
truth ranked list by computing the receiver operating characteristic curve (AUROC). We
used the macro-AUROC as the evaluation metric following previous work[106, 32]. The
macro-AUROC is calculated by separately averaging the area under the curves for each
label. We set the vector dimension d = 500, the number of nearest neighbors k = 2000, and
the negative sampling weight θ = 5 in our experiment. We observed that the performance
of our algorithm is quite stable with different d, k, and θ values. We included all edge types
in the predefined heterogeneous path set. Additionally, we added “transfer of annotation”
to the predefined heterogeneous path set (Fig. 2.1).
To show the improvement from integrating homology data with molecular networks of
multiple species, we compared our method with three existing state-of-the-art function pre-
diction methods: GeneMANIA[106], clusDCA[32], and BLAST[92]. GeneMANIA and clus-
DCA integrate protein molecular networks within a given species. Neither of them is able to
integrate information across different species. We used the latest released code and the sug-
gested parameter settings for these two methods. BLAST uses bit score to rank annotations
from significant hits by BLAST. We used the same datasets (i.e. annotations, proteins, and
networks) and the same evaluation scheme for every method we tested.
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Figure 3.5: Comparison of using different data sources for function prediction
Molecular network data and homology data are complementary in function prediction
We first studied whether information extracted from homology and from molecular net-
works are complementary. We compared the predictive performance of three different data
sources: 1) molecular networks, 2) homology, 3) both molecular network and homology (in-
tegrated). We used clusDCA to predict function annotations based on molecular networks.
We used BLAST to make predictions of function annotation based on homology. We summa-
rized how many functions can be accurately annotated (AUROC>0.9) by each data source
(Fig. 3.5). We notice that there are many functions that can only be accurately predicted
by homology or network. For example, on mouse MF with 3-10 labels, 9% of functions
(difference between yellow bar and green bar) can be accurately predicted only by homology
but not by network. In the same category, another 21% of functions (difference between blue
bar and green bar) can be accurately predicted only by network but not by homology. This
suggests that these two data sources are complementary, and integrating them can syner-
gistically improve the function prediction results. To this end, we integrated homology and
network data by simply taking average of the z-scores of predicted annotations from these
two data sources. We found that the predictive performance using both molecular network
data and homology data is significantly better than only using one in all categories on both
human and mouse. For example, on human MF with 101-300 labels, using both network
data and homology data accurately annotates 60% of functions, which is much higher than
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Figure 3.6: Comparison of different methods
4% of only using network data and 26% of only using homology data. Notably, we only use
the homology data from five species here. When including homology data from more species
in the future, homology data may further boost the function prediction performance.
ProSNet substantially improves function prediction performance
We performed large-scale function prediction on all five species to compare our method
to other state-of-the-art function prediction approaches. The results are summarized in Fig.
3.6 and Supplementary Fig. 1. It is clear that our approach achieved the best overall results
in all five species. When comparing with homology-based methods, we found that ProSNet
significantly outperforms BLAST on both sparsely annotated and densely annotated labels
(data not shown). For example, ProSNet achieves 0.8690 AUROC on human BP labels with
3-10 annotations, which is much higher than the 0.6326 AUROC by BLAST.
Furthermore, we compared ProSNet to existing state-of-the-art network-based methods,
including clusDCA and GeneMANIA, which only integrate molecular networks of single
species. We found that the overall performance of our approach is substantially higher than
that of both of these methods. For instance, in human, our method achieved 0.9211 AUROC
on MF labels with 3-10 annotations, which is much higher than 0.8673 by GeneMANIA and
0.8794 by clusDCA. In mouse, our method achieved 0.8523 AUROC on BP labels with 31-
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100 annotations, which is much higher than 0.8078 AUROC by GeneMANIA and 0.8299
AUROC by clusDCA.
To evaluate the integration of homology and network data, we developed a baseline ap-
proach that simply merges predictions made from homology data and sequence data, sepa-
rately. This additive approach takes the average z-scores of the annotation score of clusDCA
and BLAST to rank functional labels for each protein. We note that this baseline approach
outperformes both GeneMANIA and clusDCA, indicating that integrating homology with
molecular networks can substantially improve the function prediction performance. We then
compared this additive approach to our method. We found that ProSNet also outperforms
the additive approach. For instance, in human, our method achieves 0.9129 AUROC on MF
labels with 11-30 labels, which is higher than 0.8956 AUROC by the additive approach. The
improvement of our method in comparison to the additive approach demonstrates a bet-
ter data integration by constructing a heterogeneous network and finding low-dimensional
vector representations for each node in this network.
The improvement of ProSNet over existing network-based approaches is more pronounced
on sparsely annotated functions. Since very few proteins are annotated to these functions, it
is very easy to overfit any classification algorithm if we only use the data from a single species.
With the integrated heterogeneous biological network, ProSNet successfully transfers anno-
tations from other species to have a more robust and improved predictive performance on
sparsely annotated functions.
3.2.4 Conclusion
We have presented ProSNet, a novel protein function prediction method which seamlessly
integrates homology data and molecular network data. ProSNet constructs a heterogeneous
network to include molecular networks from all species and homology links across different
species. We have designed an efficient dimensionality reduction approach which only takes 30
minutes to decompose a heterogeneous network containing hundreds of thousands of proteins.
We have demonstrated that ProSNet outperforms state-of-the-art network-based approaches
and homology-based approaches on five major species. Furthermore, ProSNet has achieved
improved performance over an additive integration approach that simply adds predictions
from network and homology data. This result supports our hypothesis that constructing a
heterogeneous network and then finding low-dimensional vector representations for each node
in this network is a better data integration approach. In the future, we plan to study how to
annotate proteins of species that have very sparse molecular networks or even no molecular
network. In addition, we plan to pursue further improvement by integrating networks and
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homology data from a complete spectrum of reference species.
3.3 ANNOTATING GENE SETS BY INTEGRATING LITERATURE DATA AND
MOLECULAR NETWORKS
A large number of functionally related gene sets have been massively generated in high-
throughout experiments. Given a novel gene set, an immediate question to ask is the function
of this gene set. However, due to the limited coverage of known pathway and function collec-
tions, only a small proportion of these gene sets are found to be significantly overlapped with
existing functions. Consequently, extensive human efforts have been devoted to manually
search and summarize the function of these gene sets in the literature. In this work, I studied
the novel problem of gene set description generation. I took a network biology perspective
and mined millions of scientific research papers to automatically generate description of gene
sets. I evaluated our framework on both gene sets that have known function and novel gene
sets that are generated in high-throughput experiments. This work, along with the previous
introduced function prediction works, form a unified pipeline to comprehensively annotate
gene sets based on different data sources.
3.3.1 Introduction
With significant advances in ‘omics technologies, it has become increasingly routine to
identify functionally related sets of genes based on different biological patterns. For example,
a gene set may be computationally derived based on differential expression [111, 112], based
on associations to the same phenotypes [113, 114], or based on a high density of molecular
interactions among the genes [115, 116, 117, 118]. Because of their functional relationships,
these gene sets can often be interpreted as cellular pathways or protein complexes, enabling
a systems approach to studying human diseases beyond individual genes.
Given a gene set of interest, a critical task is to learn what is its overall function as a
pathway or complex in the cell. There are two major approaches to address this task. The
first approach is to search for significant overlap with known pathways in manually curated
databases such as the Gene Ontology (GO) [119] and the Kyoto Encyclopedia of Genes and
Genomes (KEGG) [120]. However, it is very likely that little or no overlap can be found due
to the limited coverage of these databases, especially when querying with gene sets related
to a rare disease.
The second approach is to search for scientific articles that describe each gene in the set,
and then summarize these articles to describe the aggregate function of the gene set. Man-
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ually performing this process requires substantial domain knowledge and does not scale to
large pathways. While automatic summarization of free text has been proposed by many
text-mining methods [121, 122], these methods can describe only one gene rather than a gene
set. In particular, automatic summarization for a gene set requires addressing several new
challenges. First, the increased number of free text articles introduces diverse and noisy an-
notations compared to individual genes. Second, the relationship between pathway functions
and gene interactions should be considered, since genes can perform very different functions
when participating in different biological processes. Third, literature contains many poten-
tial and diverse function annotations, only some of which are relevant. Thus researchers
need systematic approaches to filter, organize and display the most useful information in
literature to better understand the biological pathways represented by a gene set. Many
related approaches mine literature data to study the functions of a group of genes together.
CoCiter tests the significance of co-citation of a gene set either from a user-defined queried
gene sets or a known pathway [123]. Since the functions of this gene set are provided by
user, CoCiter is not able to automatically mine new functional annotations to describe the
gene set. Martini is a gene set comparison tool which assesses the similarity of two gene sets
by using keywords extracted from Medline abstracts [124]. Although gene sets are compared
using keywords, the functional description for each gene set is not explicitly generated.
Here we develop a novel approach to automatically mine functional annotations of path-
ways from a large corpus of literature supported by biological networks. Our approach has
two major advantages over previous text mining methods. First, it integrates semantic in-
formation derived from literature with biological information derived from experimental and
interactome data. In this framework, annotations and genes are linked through a comprehen-
sive similarity network. By propagating information in the network, an annotation can be
assigned to a gene even when the two were never mentioned together in the same literature.
Second, we adopt a new way to organize and visualize functional annotations using a data
structure called a Hierarchical Concept Ontology. This ontology reduces redundant informa-
tion and visual complexity to display the complex structure embedded in the network. We
evaluate our method on both manually-curated pathway annotations and gene sets derived
from computational tools. We observe substantial improvement in predicting the manually
curated annotations in comparison to a text-mining baseline (non-network) approach. We
further explore two case studies to demonstrate how our method can combine text mining,
molecular networks and advanced visualization to discover new pathways related to cancer.
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Figure 3.7: Diagram of our method
3.3.2 Methods
Our method consists of four major steps 3.7. First, it constructs a vocabulary of high
quality phrases (a sequence of one or more words) by processing a large corpus of PubMed
journal articles [125] using a software AutoPhrase [126]. Second, phrases are connected
within a weighted network based on their probability of co-occurrence within the same
articles. Third, our method builds a phrase-gene similarity network by joining the phrase-
phrase network with an existing gene-gene network derived from experimental data. Fourth,
phrases are ranked by how well they describe the function of a gene set. Finally, top-ranked
phrases are projected into a low-dimensional space and hierarchically clustered to create a
Concept Ontology.
Constructing a phrase-gene network
We construct a weighted network to quantify the functional similarities between both





where Pr(A) is the marginal probability that phrase A appears in any article and Pr(A,
B) is the probability that phrase A and phrase B co-occur in the same article. Intuitively,
two phrases receive a large edge weight if they co-occur together more often than expected
given their individual probabilities. In practice, non-informative phrases such as ‘cell lines’
and ‘system biology’ have many network neighbors with low edge weights; thus we retain
only the top 50 edges for each phrase. To calculate the edge weight between two genes,
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we integrate multiple heterogeneous data sources, including gene co-expression, protein-
protein interaction, protein-domain co-occurrence and genetic interaction. We perform this
integration in an unsupervised fashion using a network-fusion-based algorithmic framework
[127]. To calculate the edge weight between a phrase and a gene, the name of the gene is
considered as a phrase. In this way, the phrase-phrase and gene-gene networks are joined
into a single network consisting of both phrases and genes as nodes.
Ranking candidate annotations of a pathway
Based on connections in this initial phrase-gene network, we further identify non-obvious
links between phrases and genes through a random walk transformation of the network. An
association score between gene A and phrase B is defined as the probability of randomly
walking from A to B in the network, with restart probability = 0.5. Similarly, the association
score between a queried gene set (pathway) and a phrase is defined as the average association
score between the phrase and all genes in the set. We then rank pathways based on these
scores. To efficiently rank a large number of phrases in a reasonable time, we only consider
phrases that are within a distance of <3 to any of the genes in a queried pathway. Use of
this filter in practice did not result in any significant decrease in performance (as evaluated
below). Finally, we select all phrases with scores above a threshold as the candidate anno-
tations of the queried pathway. We will discuss how to empirically pick this threshold in the
below ‘Experimental results’ subsection.
Visualizing results as a Concept Ontology
The number of candidate annotations returned by the previous step can be very large,
especially for large pathways. In general, synonyms are connected by the strongest weights
because they are exchangeable in the literature. Phrases related to the same topic such as
‘tumor suppressor’ and ‘driver mutations’ will also be assigned strong weights but weaker
than synonyms. Such intuition encouraged us to organize the flat phrase networks into a
data-driven hierarchical ‘concept’ ontology [128, 129]. For this purpose we adopt a network
embedding approach [127] in which phrases are projected into a low-dimensional space and
the cosine of two phrase embedding vectors is used as their pairwise distance. Given this new
distance matrix, we then apply a network clustering approach, CLiXO [128], to transform the
flat phrase network into a data-driven ‘concept’ ontology, where leaf nodes are phrases and
internal nodes are clusters of similar phrases suggestive of higher order ‘concepts’. Low-level
concepts tend to be relatively concrete, because all phrases are strongly connected with each
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other, while high-level concepts tend to be more abstract, because phrases are more loosely
connected with each other. Similar to a manually curated ontology, we assign each concept
a name using a representative phrase having minimum distance with all the other phrases
in the same concept cluster. Cytoscape [130] is then applied to visualize the data-driven
Concept Ontology.
3.3.3 Experimental results
Dataset and experimental settings
We obtained 33,462,308 journal articles from PubMed published between 1994 to 2017.
For each article, we only used the abstract and title rather than the whole article. We
obtained 41,367 gene descriptions and gene name synonyms from NCBI [125]. The lengths
of descriptions ranged from 100 to 300 words. AutoPhrase [126] then identified 727,289
phrases from the text corpus combining both gene descriptions and journal articles.
To calculate gene similarities, we aggregated various types of molecular networks using
a Random Forest (RF) model trained to best recover the GO semantic distance between
gene pairs. The trained model can be viewed as a nonlinear weighting of different kinds of
features to reflect statistical pairwise correlations between two genes. The integrated data
sources include coexpression networks, protein-protein interaction networks and protein-
domain co-occurrences and genetics interactions, as follows. For co-expression networks,
we used 980 genome-wide datasets extracted from the Gene Expression Omnibus (GEO)
database [131]. We also used co-expression networks from the Genotype-Tissue Expression
(GTEx )[132] project in which both global and tissue-specific co-expression are considered.
In addition, we calculated a co-expression matrix on both the Human Protein Atlas and
the Cancer Cell Line Encyclopedia [133, 134]. For protein-protein interaction networks, we
included all interactions in InBioMap [135] and only physical interactions in BioGRID [136].
In addition, we included genetic interaction data inferred from radiation hybrid genotypes
[137] and domain co-occurrence data from InterPro [138] and PFAM [139].
Recovering curated names in GO
We examined the ability of our method to recover the names of known biological processes
and cellular components in GO, given only information about their sets of annotated genes.
For each GO term, we looked for its curated name among all candidate phrases ranked
according to their association scores to the genes in the term. Gene-term annotations were
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taken using experimental evidence codes (EXP, IDA, IPI, IMP, IGI, and IEP) but not in
silico codes (e.g. IEA) to avoid potential leakage of labels.
We found that for 40% of terms in the biological process branch of GO, the curated name
was among the top 50 candidates (Fig. 3.8a). Similarly, for 50% of terms in the cellular
component branch, the curated name was among the top 50 candidates (Fig. 3.8b). More
generally, we calculated the proportion of GO terms for which the curated name was among
the top K candidate names of the term. For comparison, we set up a baseline approach
in which a phrase is scored and ranked simply by the number of articles that mention this
phrase together with any of the genes in the gene set. This simple but intuitive baseline
mimics a search engine that ranks documents based on word frequency [140]. Our method
substantially outperformed this baseline approach in naming terms across all three branches
of GO (Fig. 3.8a-c). Here, for each term we only considered the curated name itself and
did not reward returning the names of ancestors or descendants. In practice, however, we
also observed the names of ancestors and descendants among the top ranked phrases (Fig.
S1-3).
Further examining these results, we observed that the rank of the curated name identified
by our method was positively correlated with the size of the gene set (Fig. 3.8d). That is,
our method predicted more accurately when the gene set was small. For sets with fewer
than 250 genes, our method found the correct curated term among the top 10 phrases the
majority of the time. When the gene set was larger than 750 genes, our method could
only detect the curated name among the top 75 phrases. An explanation for this result is
that large gene sets tend to cover broad or diverse functions and thus are more difficult to
summarize by a short phrase.
Next, we studied another critical problem: Given a ranking of phrases, how do we deter-
mine the threshold to select the most relevant phrases? To address this problem, for each
GO term, we compared the ranking of its curated name with its association score. As shown
in Figs. 3.9a-b, better rankings of curated names were generally tied to stronger association
scores. This implies that the association scores across different GO terms are comparable.
Therefore, we applied a universal threshold on the association score to determine final an-
notations for every GO term. We found that when the score is larger than -6 (log domain),
we could always find the curated name among top 40 ranked phrases, regardless of term size
(Fig. 3.9b). Therefore, we used -6 as our universal threshold to determine annotations.
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Figure 3.8: Comparison of our method and baseline on recovering term names of three
Gene Ontology categories: Biological Process (a), Cellular Component (b) and Molecular
Function (c). The fraction of terms for which the curated name was among the top K
candidate phrases. (d) The correspondence between the rank of term names and the sizes
of terms. The Y-axis shows the distribution of ranks of curated names with varying
sparsity levels shown in the X-axis.
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Figure 3.9: Selecting relevant phrases based on the association score. (a) For each GO
term, the association score of its curated name is plotted with the rank of this score among
all candidate phrases. (b) Zoom-in of panel (a) reveals that applying a threshold of -6 on
the association score guarantees that the curated name of a term is ranked among the top
40 candidate phrases.
Functional annotations for unknown cancer pathways
Encouraged by the ability of our method to recover the curated names of known pathways,
we set out to assign names to new gene sets inferred from molecular data. We analyzed a
total of 2,132 gene sets detected by the hierarchical clustering algorithm CLiXO [128] based
on a human gene similarity network with 19,035 genes and 181,156,095 edges. Of these,
we only considered those that did not significantly overlap with known pathways. In this
subsection, we chose two example gene sets which were suggested to be highly related to
cancer by our approach to demonstrate how our method can help to discover new biological
knowledge.
As a first case study, we examined a pathway consisting of eight strongly interacting genes:
NEDD4, PTEN, SLC11A2, SLC11A1, SFTPC, MT3, NDFIP1 and NDFIP2 (Fig. 3.10a).
To our knowledge, this pathway was previously unknown, as it has poor overlap with all
catalogued pathways in GO and KEGG (Jaccard Index 0.25). Our method identified 38
literature phrases associated with this set of genes (Fig. 3.10a). Although each of these
phrases might represent a distinct biological function, we found that some were highly related
to one another, forming a hairball-like subnetwork of gene-phrase linkages (Fig. 3.10a).
Thus, it would be very challenging for a human to summarize the overall functions of this
pathway. To address this challenge, we applied CLiXO to hierarchically organize these
phrases into a Concept Ontology. Visualization of this ontology revealed six major functions
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Figure 3.10: Discovery and characterization of a new pathway by our method. (a) The
pathway is defined by eight genes related by protein interactions, co-expression and protein
shared domains. These functions of these genes are collectively described by 38 phrases.
(b) Cancer types in which these genes are significant mutated in The Cancer Genome Atlas
(TCGA).
at multiple scales (Fig. 3.11). On a molecular level, this pathway has functions related to
‘ion transport’, ‘acetoacetate decarboxylase activity’ and ‘ubiquitin ligase’. On a cellular and
organismal level, it is involved in ‘epithelial cells’ and ‘lung disease’. These descriptions were
supported by direct associations between phrases and genes in multiple articles, such as ‘lung
disease’ and NEDD4 in Rotin et al. [139, 142] and ‘lung epithelial cell’ and PTEN in Mao
et al. [141], and by indirect associations learned through the random walk transformation.
As validation of these descriptions, we found that genes in this pathway were recurrently
mutated in lung squamous cell carcinoma (LUSC), a disease in epithelial cells [143], based on
MutSigCV scores [144] in The Cancer Genome Atlas (TCGA) [145]. All evidence suggested
that this is a novel functional pathway related to lung cancer.
As a second case study, we examined another pathway, consisting of eight genes FBXW7,
ARL2, FBXW11, FBXW2, BTRC, PWP2, COPA and FBXW10. These genes strongly in-
teracted with each other primarily through domain co-occurrence, suggesting their proteins
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Figure 3.11: Summarization of biological function by a Concept Ontology. The 38 phrases
describing the pathway were hierarchically clustered based on their semantic relations
using the CLiXO algorithm. These phrases were organized into six major concepts. We list
two of the journal articles, Mao et al.[141] and Rotin et al.[139, 142], contributing to the
concepts ‘lung disease’ and ‘epithelial cell’.
share similar 3D structures (Fig. 3.12a). This pathway was also previously unknown (Jac-
card Index 0.1 in GO and KEGG). Our method described its functions with 37 phrases,
which could be hierarchically organized into six major concepts (Fig. 3.13). An interesting
concept was ‘acute monoblastic leukemia’, suggesting this pathway was cancer-associated.
As shown in Fig. 3.13, validation for this pathway was achieved by tracing back the actual
literature referencing these genes and diseases simultaneously. One of the articles, Gel-
bard et al. [147], related FBXW7 to sinonasal carcinoma, a kind of head and neck cancer.
This is consistent with our finding that these genes were recurrently mutated in the HNSC
and UCEC patient cohorts in TCGA (Fig. 3.12b). These two examples demonstrate how
pathways can be automatically discovered and annotated by integrating years of biomedical
knowledge with ‘omics datasets.
3.3.4 Conclusion
In this work, we have developed a novel text mining and visualization tool for automated
pathway functional annotation. Our main idea is to integrate literature and molecular in-
teraction information into a large heterogeneous network and then use a random walk-based
approach to rank candidate pathway descriptions. In the final step, we use a Concept Ontol-
ogy to visualize annotations as a more informative alternative to a flat network of biomedical
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Figure 3.12: Discovery and characterization of another new pathway by our method. (a)
The pathway is defined by eight genes related by protein interactions, co-expression, and
protein shared domains. The functions of these genes are collectively described by 37
phrases set out around the periphery. (b) Cancer types in which these genes are
recurrently mutated in TCGA.
phrases. In this work our primary focus is to annotate gene set, however, our framework
can be well generalized to other applications. For instance, if the user provides a set of
drugs, targets and their corresponding interaction networks, our method should be able to
return the potential downstream and upstream pathways where these drugs might influence.
Another application is that we can replace gene set with a group of disease symptoms and
replace molecular network with symptom similarity network. Then our method might help
to define the potential pathways and genes that lead to such symptoms.
One of the major limitations of our work is that currently we can not accept users’ input
to specify a particular context. For example, the user might want to know the roles of
these genes in brain or the user only want to know the location information. Theoretically
speaking, these information is all included in our result, however, they might not rank
high enough to pass our filter. There are many interesting directions to explore in the
future. To name a few, we plan to automatically generate sentences instead of phrases
for new pathways. Sentences are more widely accepted and carry more information than
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Figure 3.13: Summarization of biological function by a Concept Ontology. The 37 phrases
describing the pathway were hierarchically clustered based on their semantic relations,
using the CLiXO algorithm. These phrases were organized into six major concepts. We list
two of the journal articles, Spinella et al.[146] and Gelbard et al.[147], from which the
concept ‘acute monoblastic leukemia’ was inferred.
phrases. Another direction is to improve our algorithm to move beyond the abstract and
title to scanning complete articles and even figures. A more challenging direction is to link
functional descriptions more deeply with molecular data. In our current method, the types
of interactions among genes do not influence the final functional annotations. However, in
practice, a rich protein-protein interactions and genetic interactions usually suggest a protein
complex.
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CHAPTER 4: KNOWLEDGE NETWORK ASSISTED DRUG DISCOVERY
In this Chapter, I will demonstrate how knowledge network can be used to accelerate
drug discovery. I will show how to use knowledge networks and the proposed network
embedding approaches to understand drug mechnisms of actions through identification of
drug targets and associated pathways. To identify drug associated pathways, I integrated
moleclar networks and pathways into a large hetergeneous network. I then applied the
proposed network embedding to project pathways and genes into the same low-dimensional
space. Experiment results showed that this heterogeneous network enables an improved
pathway identification performance. To identify drug targets, I applied the diffusion model
to yeast genetic interaction networks. Using network neighbors’ phenotypes can reduce noise
in the experimental data, thus improving target identification performance.
4.1 KNOWLEDGE NETWORK ASSISTED DRUG PATHWAY IDENTIFICATION
Basal gene expression levels have been shown to be predictive of cellular response to cy-
totoxic treatments. However, such analyses do not fully reveal complex genotype-phenotype
relationships, which are partly encoded in highly interconnected molecular networks. Bi-
ological pathways provide a complementary way of understanding drug response variation
among individuals. In this study, we integrate chemosensitivity data from a recent phar-
macogenomics study with basal gene expression data from the CCLE project and prior
knowledge of molecular networks to identify specific pathways mediating chemical response.
We develop a computational method called PACER, which ranks pathways for enrichment
in a given set of genes using a novel network embedding method. It examines known rela-
tionships among genes as encoded in a molecular network along with gene memberships of
all pathways to determine a vector representation of each gene and pathway in the same low-
dimensional vector space. The relevance of a pathway to the given gene set is then captured
by the similarity between the pathway vector and gene vectors. To apply this approach
to chemosensitivity data, we identify genes with basal expression levels in a panel of cell
lines that are correlated with cytotoxic response to a compound, and then rank pathways
for relevance to these response-correlated genes using PACER. Extensive evaluation of this
approach on benchmarks constructed from databases of compound target genes, compound
chemical structure, as well as large collections of drug response signatures demonstrates its
advantages in identifying compound-pathway associations, compared to existing statistical
methods of pathway enrichment analysis. The associations identified by PACER can serve as
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testable hypotheses about chemosensitivity pathways and help further study the mechanism
of action of specific cytotoxic drugs. More broadly, PACER represents a novel technique
of identifying enriched properties of any gene set of interest while also taking into account
networks of known gene-gene relationships and interactions.
4.1.1 Introduction
Large-scale cancer genomics projects, such as the Cancer Genome Atlas(Cancer Genome
Atlas Research [148], the Cancer Genome project [149], and the Cancer Cell Line Encyclope-
dia project [150], and cancer pharmacology projects such as the Genomics of Drug Sensitivity
in Cancer project [149] have generated a large volume of genomics and pharmacological pro-
filing data. As a result, there is an unprecedented opportunity to link pharmacological and
genomic data to identify therapeutic biomarkers [40, 39, 41]. In pursuit of this vision, sig-
nificant efforts have been invested in identifying the genetic basis of drug response variation
among individual patients. For instance, a recent study performed a comprehensive survey
of genes with basal expression levels in cancer cell lines that correlate with drug sensitivity,
revealing potential gene candidates for explaining mechanisms of action of various drugs [42].
While significant efforts have focused on specific genes that interact with compounds and
confer observed cellular phenotypes, there has been relatively little progress in studying the
synergistic effects of genes. These effects are key factors in comprehensively deciphering the
mechanisms of action of compounds and understanding complex phenotypes [151]. Similarly,
pathways, which comprise a set of interacting genes, have emerged as a useful construct for
gaining insights into cellular responses to compounds. Analysis at the pathway level not only
reduces the analytic complexity from tens of thousands of genes to just hundreds of pathways,
but also contains more explanatory power than a simple list of differentially expressed genes
[152]. Consequently, an important yet unsolved problem is the effective identification of
pathways mediating drug response variation. Although the associated pathways for certain
drugs have been studied experimentally [153, 154, 155], in vitro pathway analysis is costly
and inherently difficult, making it hard to scale to hundreds of compounds.
Fortunately, a growing compendium of genomic, proteomic, and pharmacologic data al-
lows us to develop scalable computational approaches to help solve this problem. Although
statistical significance tests and enrichment analyses can be naturally applied to compound-
pathway association identification (e.g., by testing the overlap between pathway members
and differentially expressed genes), these approaches fail to leverage well-established biolog-
ical relationships among genes [156, 157, 158, 159]. Even when analyzing individual genes,
molecular networks such as protein-protein interaction networks have been shown to play
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crucial roles in understanding the cellular drug response [160, 151, 161, 162, 163]. Therefore,
we propose to combine molecular networks with gene expression and drug response data for
pathway identification. However, integrating these heterogeneous data sources is statisti-
cally challenging. Moreover, networks are high-dimensional, incomplete, and noisy. Thus,
our algorithm needs to accurately and comprehensively identify pathways while exploiting
suboptimal networks.
Here we present PACER, a novel, network-assisted algorithm that identifies pathway as-
sociations for any gene set of interest. Additionally, we apply the algorithm to discover
chemosensitivity-related pathways. PACER first constructs a heterogeneous network that
includes pathways and genes, pathway membership information, and gene-gene relationships
from a molecular network such as protein-protein interaction network. It then applies a novel
dimensionality reduction algorithm to this heterogeneous network to obtain compact, low-
dimensional vectors for pathways and genes in the network. Pathways that are topologically
close to drug response-related genes in the network are co-localized with those genes in this
low-dimensional vector space. Hence, PACER ranks each pathway based on its proximity
in the low-dimensional space to genes that have basal expressions highly correlated with
drug response. We evaluated PACER’s ability to identify compound-pathway associations
with three ‘ground truth’ sets built from compound target data [42], compound structure
data [164], and LINCS differential expression data [165]. When comparing PACER to state-
of-the-art methods that ignore prior knowledge of interactions among genes, we observed
substantial improvement of the concordance with the chosen benchmarks. Even though we
developed PACER and tested its ability to identify compound-pathway associations, the
algorithm is applicable to any scenario in which one seeks to discover pathways related to a
pre-specified gene set of interest, while utilizing a given gene network.
4.1.2 Methods
Compound response data and gene expression data
We obtained a large-scale compound response screening dataset from Rees et al. [42],
which spans 481 chemical compounds and 842 human cancer cell lines encompassing 25
lineages. These 481 compounds were collected from different sources including clinical can-
didates, FDA-approved drugs and previous chemosensitivity profiling experiments. Area
under the drug response curve (AUC) was used by the authors of that study to measure cel-
lular response to individual compound. We also obtained gene expression profiles for these
cell lines from the Cancer Cell Line Encyclopedia (CCLE) project [134], profiled using the
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GeneChip Human Genome U133 Plus 2.0 Array. Since these expression measurements were
done in each cell line without any drug treatment, they are referred to as ‘basal’ expression
levels. In contrast, the expression profiling of a cell line was performed after treatment with
a drug in certain studies such as LINCS L1000 [165] and [166]. We obtained the SMILE
specification of each drug from PubChem [164] and then calculated the Tanimoto similarity
scores between all pairs of drugs based on their SMILE specifications.
STRING-based molecular network and NCI pathway collection
We obtained a collection of six human molecular networks from the STRING database
v9.1 [167]. These six networks include experimentally derived protein-protein interactions,
manually curated protein-protein interactions, protein-protein interactions transferred from
model organism based on orthology, and interactions computed from genomic features such
as fusion-fusion events, functional similarity and co-expression data. There are 16,662 genes
in the network. We used all the STRING channels except “text-mining” and used the
Bayesian integration method provided by STRING. Since our approach can deal with dif-
ferent edge weights, we did not set a threshold to remove low confidence edges. We referred
to this integrated network as the STRING-based molecular network. To test whether
genes that are highly correlated with many compounds tend to have higher degrees in the
network, we formed two groups of genes. One group contained genes that are correlated with
over 100 compounds, and the other group contained the remaining genes. We then used the
Wilcoxon signed-rank test to test whether the degrees of genes in these two groups were
from the same distribution. We obtained a collection of 223 cancer-related pathways from
the National Cancer Institute (NCI) pathway database. These manually curated pathways
include human signaling and regulatory pathways as well as key cellular processes [168].
The PACER Framework
PACER integrates pathway information with the STRING-based molecular network de-
scribed above by constructing a heterogeneous network of genes and pathways. An edge
exists between two genes if they are connected in the network. An edge exists between a
pathway and a gene if the gene belongs to the pathway. There are no direct pathway-pathway
edges in the heterogeneous network. PACER adopts diffusion component analysis (DCA),
a recently developed network representation algorithm to learn a low-dimensional vector for
each node in the network [59]. Because of its ability to handle noisy and missing edges in the
biological network, DCA has achieved state-of-the-art results in different tasks [59, 32]. Since
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compounds are not nodes in the constructed heterogeneous network, only genes and path-
ways are projected onto the low-dimensional space. After learning the low-dimensional rep-
resentations of all nodes (genes and pathways), DCA ranks pathways based on the weighted
cosine similarities between a pathway and the set of 250 genes most correlated with response
to a compound. We henceforth refer to this set of genes as “response-correlated genes”
(RCG) for the compound. These genes’ expression values are most significantly correlated
with chemosensitivity. We found that the performance of the PACER method is stable for
different choices (200, 250, and 300) for the number of RCGs considered in this step.
LINCS drug perturbation profiles
LINCS is a data repository of over 1.3 million genome-wide expression profiles of human
cell lines subjected to a variety of perturbation conditions, which include treatments with
more than 20 thousand unique compounds at various concentrations. Each perturbation
experiment is represented by a list of differentially expressed genes that are ranked based on z-
scores of perturbation expression relative to basal expression. For each gene, we first took the
difference between its expression in a perturbation condition and its expression in a control
condition (i.e., treatment with pure DMSO solvent). We then considered the differential
expression of the gene in multiple perturbation experiments involving that compound (i.e.,
different concentrations, time points, and cell lines). We used the maximum differential
expression to represent the compound’s effect on that gene’s expression. All genes were then
ranked by their differential expression on treatment with the compound, and the top 250
genes were treated as differentially expressed genes (DEGs) of the compound, provided their
z-score has an absolute value greater than 2.
Comparison with method of Huang et al.
We implemented the method of Huang et al. [156] ourselves using the exact same input
(i.e., chemosensitivity and gene expression data) as PACER. We first computed a gene’s
correlation to a drug by calculating the Pearson correlation coefficient between the gene’s
expression values and the drug response values across cell lines. Let the set of genes in
pathway p be denoted byGp, and their correlation values to a drug d by C(Gp, d). Conversely,
the set of genes not in pathway p is denoted as Gp, and their correlation values to d as
C(Gp, d). We then performed the Kruskal-Wallis H-test, following Huang et al., to test if
the medians of C(Gp, d) and C(Gp, d) were significantly different. We used the resulting
p-value to rank pathways for each drug.
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Figure 4.1: Global analysis of correlations between basal gene expression and compound
response. (A) Heatmap of the Pearson correlation coefficient between genes (expression)
and compounds (chemosensitivity, measured by AUC values). (B) Histogram of the
number of compounds associated with each gene. The y-axis shows the number of genes
associated with k compounds, where k is shown on the x-axis. (C) Histogram of the
number of genes associated with each compound. The y-axis shows the number of
compounds associated with k genes, where k is shown on the x-axis. (D) Histogram of the
number of compounds significantly associated with each pathway (Fishers exact test FDR
0.05). (E) Histogram of the number of pathways significantly associated with each
compound (Fishers exact test FDR 0.05).
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4.1.3 Experimental results
Global analysis of correlations between basal gene expression and compound response
Following the work of Rees et al. [42], we first examined correlations between the com-
pound sensitivity and basal gene expression profiles across hundreds of cell lines. We calcu-
lated Pearson correlation coefficients between each gene’s expression and the cellular response
(measured as the area under the curve or AUC) to each compound, across different cell lines
(Figure 4.1A). Compared to the IC50 and EC50 scores, AUC simultaneously captures the
efficacy and potency of a drug. Of the 8.7 million pairs of genes and compounds tested, we
found 294,789 to be significantly correlated (p-value < 0.0001 after Bonferroni correction,
corresponding to a Pearson correlation coefficient of 0.215.) Since the Rees et al. dataset
comprises measurements on 842 cell lines, each correlation was computed over 842 pairs of
values (drug response, gene expression). This is why even a modest-looking Pearson correla-
tion of 0.215 was deemed highly statistically significant. The key observation from this initial
analysis, also noted by Rees et al., is that basal gene expression levels are highly correlated
with cytotoxic response for large numbers of compound-gene pairs. Within these signifi-
cantly correlated pairs, 1,749 genes were correlated with over 100 compounds (Figure 4.1B,
Suppl. Table 1). We note that these key genes tend to be high-degree nodes in STRING-
based molecular network (Wilcoxon rank sum test p-value < 9.6e-14, see Methods). We also
found that some (10 of 481) compounds were significantly correlated (Pearson correlation
p-value < 0.0001 after Bonferroni correction) with more than 3,200 genes (Figure 4.1C).
Five of these ten compounds are chemotherapeutic agents (Suppl. Table 2). In contrast,
about 100 compounds were not significantly correlated with any genes; these compounds are
mostly probes that either lack FDA approval or are not clinically used. The large disparity
among the examined compounds in terms of the number of correlated genes reflects the di-
versity of these 481 small molecules. While many of them are chemotherapeutic, which can
affect the expression of a large number of genes, some compounds may be targeting specific
mutations, post-translational modifications, or protein expression. A closer examination re-
vealed that the compounds with the highest cytotoxicity had the fewest gene correlations
(i.e., fewest genes whose expression correlates with cytotoxic response were mostly those
with low cytotoxicity) (Suppl. Figure 1). This suggests that the strategy of identifying
compound-associated genes by correlating basal gene expression profiles with cytotoxicity
is likely to be more effective for more potent compounds, for which average response is
stronger. Note that the gene expression profiles used here are basal and not in response to
treatment with compound, hence it was not clear a priori that more effective compounds
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would have larger numbers of gene correlates. In summary, examination of individual genes’
correlations with chemical response confirmed previous reports [149, 169, 42] that basal gene
expression significantly correlates with cytotoxicity across cell lines, especially for effective
cytotoxic drugs.
Identifying compound-specific pathways via enrichment tests
The above evidence for correlations between basal gene expression and chemical response
raised the possibility that one might discover important biological pathways associated with
the response by a systems-level analysis of gene expression data. To explore this, we consid-
ered a collection of 223 cancer-related pathways from the National Cancer Institute (NCI)
pathway database[168] and used Fisher’s exact test to quantify the overlap between the set
of genes in a pathway p and RCGs. A significantly large overlap between the two sets in-
dicates an association between the pathway and the compound. We performed a multiple
hypothesis correction on all pathway association tests for each compound, using FDR 0.05.
The results of this baseline method for predicting pathway associations are shown in Figure
4.1D (distribution of the number of compounds that are significantly associated with each
pathway) and Figure 4.1E (distribution of the number of pathways significantly associated
with each compound). Both distributions revealed a long tail. For instance, while each
pathway was associated with an average of 18 compounds (of the 481 tested), there were 10
pathways that were associated with over 150 compounds (Suppl. Table 3). Likewise, while
each compound was associated with an average of eight pathways, there were 12 compounds
associated with over 25 pathways (Suppl. Table 4). We show the details of these long tails
in Suppl. Figure 2.
A new method for identifying pathways associated with chemical response, based on
network embedding
We observed above that key RCGs those correlated with many compounds tend to be
enriched in high degree nodes of the STRING-based molecular network. This suggests that
an analysis combining this network with pathway enrichment tests might provide additional
insights. We therefore developed a novel network-based method, called PACER, for scor-
ing compound-pathway associations. PACER (Figure 4.2A) first constructs a heterogeneous
network consisting of genes and pathways as nodes. In this network, gene-pathway edges
denote pathway memberships based on a compendium of pathways and gene-gene edges
from the STRING-based molecular network introduced above (also see Methods). PACER
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Figure 4.2: Identifying pathways associated with chemical response using PACER. (A)
Schematic description of PACER. (B) Heat map of associations between compounds and
pathways (PACER scores). Rows are pathways and columns are compounds. (C) Detailed
view of a subset of the red branch cluster of pathways, marked by C. (D) Detailed view of
a subnet of purple branch cluster of compounds, marked by a rectangle. (E) Comparative
evaluation of different methods for predicting compound-pathway associations. The ground
truth used here is the pathways that contain any known target gene of the compound. (F)
Comparison of PACER, Fishers exact test and Huang et al. on predicting compounds with
similar chemical structure. The y-axis shows the number of compounds with an AUROC
larger than k, where k is shown on the x-axis. Compound structure similarity is
determined by the Tanimoto similarity score calculated based on their SMILE
specifications. Prediction is made according to the Spearman correlation between the
pathway rankings of two compounds. (G) Number of compounds with significant overlap
(p < 0.05) between pathways from LINCS and pathways from PACER, from Huang et al.
2005 and from the baseline method (Fishers exact test) respectively, at different levels of
stringency in pathway prediction. Stringency refers to the FDR control used by the
baseline method in determining significant pathways. Both PACER and the Huang et al.
2005 method were used to predict the same number of (highest scoring) pathways as the
baseline method, for a fair comparison.
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then creates a low-dimensional vector representation for each gene and pathway node in the
heterogeneous network, reflecting the node’s position in this heterogeneous network. This
is done by the Diffusion Component Analysis (DCA) approach reported in previous work
[59, 32]. Nodes (i.e., pathways or genes) will have similar vector representations if they are
near each other in the network. For instance, two pathway nodes will have similar vector
representations if the pathways share genes and/or their genes are related by the STRING-
based molecular network. In a similar vein, two genes will have similar representations if
they belong to the same pathway(s) and/or exhibit the same network neighbors. A gene and
a pathway can also be compared in the low-dimensional space, and will be deemed similar if
the gene is in the pathway and/or the gene is related by network to other genes of the path-
way. DCA performs network-based embedding without utilizing gene expression or chemical
response data. Next, PACER identifies RCGs as a fixed number of genes the expression of
which shows the greatest correlation with chemical response to a specific compound. Finally,
it scores a pathway based on the average cosine similarity between the vector representation
of the pathway and those of the RCGs. A pathway can thus be found to be associated with
a compound if, in the network, the pathway genes are closely related to the compound’s
RCGs; this association can be discovered even if the pathway does not actually include the
RCGs. We note that scores assigned by PACER are not statistical significance scores and
are meant only to rank pathways for association with a given compound. Also, a negative
score assigned to a compound-pathway pair does not imply a negative correlation between
expression levels of pathway genes and chemosensitivity. Rather, it only implies a lack of
evidence for an association between the compound-pathway pair.
The PACER association scores for all combinations of 481 compounds and 223 NCI sig-
naling pathways are shown in Figure 4.2B. The pathways cluster into many distinct groups,
each with different compound association profiles. One group (cyan branches in the row
dendrogram), associated with more than half of the compounds, consists of pathways de-
scribing various integrin cell surface interactions (e.g., ‘Integrins in angiogenesis’ pathway,
‘Alpha 4 Beta1 integrin cell surface interactions’ pathway). These pathways are known
to play crucial roles in communications among cells in response to small molecules [170].
Notably, integrins are a major family of cell surface adhesion receptors, and are involved
in major pathways that contribute to cancer cell survival and resistance to chemotherapy
[171]. PACER found 329 of the 481 compounds to be associated with the “integrin family
cell surface interactions” pathway. Since PACER scores are not easily assigned statisti-
cal significance levels, we chose for each compound n pathways with the highest PACER
scores, where n is the number of statistically significant pathway associations (FDR ≤ 0.05)
found by the baseline method above for the same compound. We found literature support
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for some of these associations. For example, ruxolitinib, a JAK/STAT inhibitor, is associ-
ated with integrin pathways by PACER analysis. In a previous study, it was shown that
beta 4 integrin enhances activation of the transcription factor STAT3, which is a target of
ruxolitinib [172]. Furthermore, vorinostat, a member of a larger class of compounds that
inhibit histone deacetylases (HDACs), can induce integrin 51 expression and activate MET,
leading to resistance [173]. Figure 4.2C reveals another example of functionally related path-
ways being grouped together. The pathways ‘VEGFR1 specific signals’, ‘ErbB4 signaling
events’, ‘EGFR-dependent Endothelin signaling events’, ‘ErbB receptor signaling network’,
and ‘PDGF receptor signaling network’ form one group (red branches in row dendrogram),
and are associated with masitinib (PDGFRB inhibitor) and RAF265 (VEGFR2 inhibitor),
among other compounds (see Suppl. Table 5). Vascular endothelial growth factor recep-
tor (VEGFR inhibitor) and platelet-derived growth factor receptor (PDGFR inhibitor) are
both members of the family of 58 known tyrosine kinase receptors in humans [174]. Ty-
rosine kinases have various modulatory functions in growth factor signaling and several of
their inhibitors are known for their anti-tumor activity [175].
Figure 4.2B also shows compounds clustered into different groups based on their associa-
tions with pathways. We found that many compounds with similar structure were grouped
together. For example, teniposide and etoposide had a Tanimoto similarity score of 0.94 be-
tween their SMILE specifications, which was substantially higher than the average Tanimoto
similarity score of 0.3716 for all pairs of drugs. They were clustered together in the same
group (Figure 4.2D, also marked as a rectangle in Figure 4.2B), which had seven compounds.
This group is associated with a set of similar pathways, including ‘p53 pathway’, ‘Direct
p53 effectors’, ‘Signaling mediated by p38-alpha and p38-beta’, and ‘Signaling mediated by
p38-gamma and p38-delta’. We found support in the literature in favor of some of these as-
sociations. For example, a previous study reported that etoposide activates p38MAPK and
can be used as a new combined treatment approach when used with p38MAPK inhibitor
SB203580 [176]. To take another example, temsirolimus and tacrolimus, which are both
epipodophyllotoxins and inhibit topoisomerase II, have a Tanimoto similarity score of 0.82,
and are grouped closely in Figure 4.2B.
PACER improves pathway identification
We noted a substantial degree of complementarity between the top predictions of PACER
and those of the baseline method that uses Fisher’s exact test between RCGs and pathway
genes (see Suppl. Table 5). For instance, PACER found that PD153035, an ErbB2 inhibitor,
is associated with the ‘C-MYC pathway’, reflecting the fact that PD153035 is able to reduce
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Table 4.1: Compounds for which PACER predicted pathways with greatest precision.












c-Myc protein levels in breast tumor cells [177]. The baseline approach did not find this
association to be significant. Similarly, PACER reported that the ‘EGFR-dependent En-
dothelin signaling events’ pathway is associated with EGFR inhibitor gefitinib [178], while
the baseline method did not.
For a more systematic comparison between the two methods, we evaluated PACER based
on a database of known compound targets. We performed the evaluation under the as-
sumption that a pathway containing at least one known target is an associated pathway.
Huang et al. used and suggested this approach [156]. We used it here to evaluate PACER,
the baseline method, as well as a third method presented by Huang et al. [156] Although
this third method was proposed to detect association between pathways and drug clades, it
can directly detect pathway-compound associations. We implemented the method ourselves
(see Methods) and included it in our evaluations. We obtained the known targets for 246
compounds in our compound set from Rees et al. [42]. We then computed the AUROC
of pathway predictions made by PACER for each compound, and plotted this information
alongside analogous information for the baseline method and the method of Huang et al.
[156] As shown in Figure 4.2E, PACER identified pathways with higher AUROC compared to
the other two methods. For example, PACER identified pathways with an AUROC greater
than 0.75 for 22 different compounds, while the baseline method achieved this level of AU-
ROC for only 7 compounds. Table 4.1 shows the 10 compounds for which PACER achieved
highest AUROC. We present a closer examination of PACER predictions for one of these
compounds:‘nsc23766’ (0.84 AUROC) in Table 4.2. This table also shows the complemen-
tarity between PACER predictions and those of the baseline method.
We note that the AUROC values reported here are likely to be underestimates, as there is
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Fanconi anemia pathway NO 0.2670
CXCR4-mediated signaling events YES 1
TCR signaling in naive CD4+ T cells YES 1
IL2 signaling events mediated by PI3K YES 1
ATR signaling pathway NO 1
TCR signaling in naive CD8+ T cells YES 1
Class I PI3K signaling events NO 1
p53 pathway YES 0.3185
BARD1 signaling events NO 1
EPO signaling pathway NO 1
literature evidence for some of the reported pathways being associated with the compound,
even though the pathway does not include a known target (and is thus considered a false
positive in our AUROC estimate). The Rac1-specific inhibitor nsc23766 was identified by
PACER as being associated with several pathways that include a known target (Table 4.2),
as well as some pathways that do not but whose association is supported by literature
evidence. For example, the pathway ‘Beta5 beta6 beta7 and beta8 integrin cell surface
interactions’ was predicted as being associated with this compound, and even though the
latter’s known target is not in this pathway, various lines of evidence support the association.
A study of cholangiocarcinoma found beta6 integrin to promote invasiveness by activating
Rac1, and that the compound nsc23766 is able to suppress this invasiveness [179] and can be
used to identify poor prognostic HER2 amplified breast cancer patients [180]. Beta8 integrin
influences Rac1 levels to promote cell invasiveness in glioblastoma [181]. Also, Beta8 integrin
is reported to activate Rac1 signaling in endometrial epithelial cells [182]. In addition,
ncs23766 was predicted to be associated with ‘a4b7 Integrin signaling’. While this pathway
does not directly include the compound’s target, Rac1 was previously shown to induce
a4b7-mediated T cell adhesion to MAdCAM-1 [183], supporting the predicted association.
Furthermore, ‘Plexin-D1 Signaling pathway’ was found by PACER to be associated with
ncs23766. Plexin-D1 is a receptor for SEMA4A which inhibits Rac activation [184]. Thus,
the anecdotal observations made above suggest that compound-pathway predictions made
by PACER may sometimes be worth pursuing even if the compound’s target is not included
in the pathway.
We further evaluated PACER based on the identified pathways for compounds with similar
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chemical structures. We performed this evaluation under the assumption that compounds
with similar chemical structures tend to be associated with the same pathways. To this end,
we calculated the Tanimoto similarity between each pair of compounds according to their
SMILE specifications. We regarded two compounds as having similar chemical structures if
their Tanimoto similarity is larger than 0.8. This threshold was used in previous work to
indicate high Tanimoto similarity [185]. For a given compound, we used PACER to rank
other compounds according to the Spearman correlation coefficient between their rankings
of pathways, and asked if this ranking was predictive of chemical structure similarity. For
each compound, an AUROC score was computed to measure this predictive ability. We
repeated this evaluation with the three different methods of ranking pathways for a com-
pound: PACER, the baseline method, and the method of Huang et al. Figure 4.2F shows
the number of compounds for which the AUROC is above a specified threshold, for each
of the three methods. We found that PACER achieves better performance in identifying
compounds with similar chemical structure based on similarity of pathway ranking. For
example, 21 (of 42) compounds yielded an AUROC greater than 0.8 when using PACER,
compared to 10 compounds meeting the same criterion when using the baseline method.
As compounds with similar chemical structure tend to be functionally similar, our results
demonstrate that PACER can be used to identify similar compounds by integrating prior
network information into chemosensitivity data.
We also compared the associations predicted by the three methods to those identified
from an external data set. To this end, we mined the Library of Integrated Network-Based
Cellular Signatures (LINCS) L1000 data[165], which reports genes differentially expressed
upon treatment of various cell lines with a compound. For each compound in our analysis
that is also included as a perturbagen in the L1000 compendium, we established a LINCS-
based benchmark of significantly associated pathways. This was based on a Fisher’s exact
test (p-value ≤ 0.05) between pathway genes and the most differentially expressed genes
from treatments with the same compound (see Methods). We required this criterion to be
met in at least one of the cell lines for which data was available from LINCS. We then
assessed the concordance between this set of LINCS-based compound-pathway associations
and those predicted by either method presented above. We recognize that this is not an ideal
benchmark: LINCS data points to genes (and, indirectly, to pathways) that are differentially
expressed in response to treatment, while PACER and the compared methods base their
pathway predictions on genes that have basal expression levels across cell lines that correlate
with chemical response. At the same time, we expect the pathways affected by chemical
treatment to also be, to an extent, involved in interpersonal variation of chemosensitivity,
making this a suitable evaluation procedure. This was inspired by similar observations
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in cancer biology: genes and pathways disrupted in cancer tissues overlap with genes and
pathways whose mutation status in germline non-tumor samples is informative about disease
susceptibility and progression.
To test whether the significant pathways identified from LINCS data agree with the path-
ways predicted by one of the methods being evaluated (based on chemical response variation
in CCLE cell lines), we counted the compounds for which the two sets of predicted path-
ways overlapped significantly (Fisher’s exact test p-value ≤ 0.05). As shown in Figure 4.2G,
the PACER approach predicts pathways concordant with the corresponding LINCS-based
benchmark for more compounds, compared to the baseline method and that of Huang et
al.[156] For instance, when the baseline method used an FDR threshold of 10% to desig-
nate significant pathway associations for each drug, and the PACER method predicted the
same number of pathways, the latter’s predictions were concordant with the LINCS-based
benchmark for 110 of the 481 compounds, a nearly two-fold improvement over the baseline
method’s predictions. Our evaluations actually provide evidence for the above-mentioned
possibility that pathways predictive of drug sensitivity overlap with genes that mediate drug
response. In fact, we found 86 compounds for which the pathways identified from basal ex-
pression correlations and the pathways identified from LINCS signatures overlap with FDR
< 5%.
After observing the substantial improvement of PACER, we then investigated whether
the performance of PACER is stable when only using experimental derived protein-protein
interactions as input. In our current work, we used different types of STRING channels
except “text-mining”. One may have the concern that some of these channels (e.g., the
“databases” channel) contain direct information about the pathways we want to prioritize
in this paper. However, we believe that it is appropriate to use all available information,
including this channel, in our method for the following reasons. (1) Our method is completely
unsupervised. Any existing resources can therefore be legitimately used by our method
for pathway identification. (2) The goal is to rank pathways for each drug. The pathway
information encoded in STRING database is not drug-specific and thus should not introduce
bias into our results. (3) The “databases” channel can provide additional information that
other molecular networks may not have. It improves the quality of the integrated network
by using the information from “databases” interactions. For these reasons, we believe that
using the “databases” channel is appropriate and decided to use the results that contain the
“database” channel in Figure 4.2E,F,G. However, we also report the results of only using
“experimental” channel in the supplementary. We found that the performance of PACER, as
per the three evaluations presented above, was stable when only using experimental derived
protein-protein interactions as input (Suppl. Figure 4-6). We further demonstrated that the
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result of our method is robust to different numbers of top response-correlated genes used
in PACER, as shown in Suppl. Figures 7-9. We compared different values for k in the top
k genes chosen by PACER. We found that for two of the three evaluation schemes, results
were comparable when using k=100, 150, 200, 250 and 300. For the third evaluation scheme,
results were comparable when using k=200, 250, and 300. This demonstrates the stability
of the algorithm’s performance to different but reasonable values of k in its choice of top k
response-correlated genes.
4.1.4 Conclusion
We have shown that embedding prior knowledge in a gene network can more accurately
identify compound-pathway. Our new method, called PACER, identified many compound-
pathway associations that are supported by known compound targets as well as literature
evidence. Due to its unique ability to incorporate any suitable compendium of gene inter-
actions, our approach may provide complementary insights into drug mechanisms of action.
Historically, pathways associated with a particular gene set are identified by using popular
statistical methods such as Gene Set Enrichment Analysis [186], Fisher’s exact test or the
Binomial test (Reactome [187]). These tools test the overlap between differentially expressed
genes and pathway members. They may also be applied to the set of drug-response-correlated
genes (RCGs) analyzed here. Ingenuity Pathway Analysis [188] is another related tool,
which utilizes information about causal interactions between pathway members. Our study
is similar to the above tools in that PACER also seeks to find pathways implicated by a
gene set. However, our approach differs from these existing tools in that known molecular
interactions (e.g., PPI) among different genes are taken into consideration. Thus, a gene set,
be it the RCGs of a compound or the members of a pathway, is not treated merely as the
sum of its parts, but also includes the relationships among those parts. Since the dominant
theme in existing approaches is assessment of overlaps between two gene sets (MSigDB,
DAVID, and Reactome adopt variations on this theme), our extensive comparisons between
PACER and the baseline method of Fisher’s exact test shed light on the relative merits of the
new approach. A related line of work aims to identify differentially expressed subnetworks
in a given interaction network, e.g., KeyPathwayMiner [189], but these studies are only
superficially relevant to our work since we aim to prioritize existing pathways instead of
finding new pathways.
We consider two potential reasons for the strong performance of PACER. First, it is widely
appreciated that a chemical compound not only affects individual genes, but also combina-
tions of genes in molecular networks corresponding to core processes, such as cell proliferation
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and apoptosis. Our method postulates that even if the RCGs and a pathway may only have
a few genes in common, they may be close to each other in the network. Although current
compound pathway maps are incomplete, much relevant information is available in public
databases of human molecular networks. While traditional pathway enrichment analysis
methods like Fisher’s exact test identify pathways according to the number of shared genes,
PACER prioritizes pathways based on their proximities to RCGs in molecular networks.
Second, manually curated pathways may have arbitrary boundaries due to the need to cap-
ture knowledge at different levels of detail. Consequently, identifying drug related pathways
might be hindered by pathway boundaries. By leveraging the prior knowledge in molecular
networks, PACER is more robust to pathways with different boundaries, thus improving the
sensitivity of detecting compound-pathway associations.
We see many opportunities to improve upon the basic concept of PACER in future work.
First, although the current PACER framework was developed in an unsupervised fashion, the
scores assigned to each pathway for the given gene set can be used as the feature and plugged
into off-the-shelf machine learning classifiers for compound-pathway association identifica-
tion. Second, although this study focused on chemosensitivity response, the PACER method
is broadly applicable to testing the association between two sets of genes according to their
proximity in the network. Finally, although we use gene expression data as the molecular
profile of each cell line, it might be interesting to test our method based on other molecular
data such as somatic mutations and copy number alterations.
4.2 NETWORK-ASSISTED DRUG TARGET IDENTIFICATION
Chemical genomic screens have recently emerged as a systematic approach to drug dis-
covery on a genome-wide scale. Drug target identification and elucidation of the mech-
anism of action (MoA) of hits from these noisy high-throughput screens remain difficult.
Here, I present GIT (Genetic Interaction Network-Assisted Target Identification), a net-
work analysis method for drug target identification in haploinsufficiency profiling (HIP) and
homozygous profiling (HOP) screens. With the drug-induced phenotypic fitness defect of
the deletion of a gene, GIT also incorporates the fitness defects of the gene’s neighbors
in the genetic interaction network. On three genome-scale yeast chemical genomic screens,
GIT substantially outperforms previous scoring methods on target identification on HIP and
HOP assays, respectively. Finally, I showed that by combining HIP and HOP assays, GIT
further boosts target identification and reveals potential drug’s mechanism of action.
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4.2.1 Introduction
Chemical genomic screens have been extensively used to discover functional interactions
between genes and small molecular compounds in vivo [190, 191, 192, 193, 194, 195, 196, 197].
Due to its short generation time, inexpensive cultivation, and facile genetics, the budding
yeast S. cerevisiae has been widely used as a platform for chemical genomic screens to de-
cipher proteins and pathways targeted by small molecular compounds [198, 199, 200]. In
comparison to other approaches [201, 202, 203, 204], yeast chemical genomic screens pro-
vide comprehensive and systematic genome-wide measurements of a complete set of deletion
strains. When the target protein(s)’s functions are conserved throughout evolution, results
of chemical genomic screens in yeast can be readily transferred to other species, including
human [205, 206, 207]. There are two types of yeast chemical genomics assays: haploinsuf-
ficiency profiling (HIP) and homozygous profiling (HOP). A HIP assay consists of a set of
heterozygous deletion diploid strains that are grown in the presence of a compound. De-
creasing gene dosage of a drug target from two copies to one copy will result in increased
drug sensitivity, or drug-induced haploinsufficiency [208]. Under normal condition, one copy
of gene is adequate for the normal growth for diploid yeast. Haploinsufficiency can happen
when a drug is added into the strain. Consequently, HIP experiments are designed to iden-
tify the relationship between gene haploinsufficiency and compounds. In contrast, a HOP
assay measures drug sensitivities of strains with complete deletion of non-essential genes in
either haploid or diploid strains. Because of the complete deletion, HOP assays identify
genes that act to buffer the drug target pathway. The fitness defect score (FD-score) is
widely used to predict drug targets by comparing the perturbed growth rates to those of a
set of control strains [198, 199].
Recently, a large-scale Synthetic Genetic Analysis (SGA) study [209] showed that target’s
genetic interaction profiles are highly correlated with the outcomes of chemical genomic
screens, suggesting the possibility of combining genetic interaction profiles with chemical ge-
nomic screens for drug target identification [210, 211, 212]. A genetic interaction is measured
as the difference between the experimentally measured double-mutant phenotype and the
expected double-mutant phenotype [213]. A negative genetic interaction occurs when two
genes have similar functions that compensate each others absence to support cell viability
[214, 215, 216]. In contrast, a positive genetic interaction occurs when a mutation in one
gene rescues the fitness defect associated with a mutation in another gene [217, 218, 219].
Intuitively, a gene’s genetic interaction neighbors are also modulated if the gene is tar-
geted and perturbed by a compound. Hence, we can use genetic interaction neighbors’
FD-scores to assist the inference of drug targets on chemical genomic screens. To the best
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of our knowledge, the only previous attempt to combine chemical genomic screens with ge-
netic interaction profiles is by computing the Pearson correlation coefficient between their
outcomes[212]. A higher and positive Pearson correlation coefficient indicates a potential
compound-target interaction because genetic perturbation is inherently similar to chemical
perturbation. However, this approach often works poorly because the Pearson correlation
coefficient is sensitive to the noise in high-throughput chemical genomic screens and SGA
profiles. Moreover, these existing methods ignore the inherent differences between HIP and
HOP assays. Since HIP and HOP assays are complementary, combining HIP and HOP
should further improve target identification and enhance our understanding of compounds’
mechanisms of action (MoA) in a comprehensive way.
We introduce GIT, a novel Genetic Interaction Network-Assisted Target Identification
scoring method for HIP-HOP screens. Due to the inherent similarity between genetic pertur-
bation and chemical perturbation, it is possible to use genetic interaction neighbors’ chemical
genomic profiles to assist drug target inference. Therefore, we adopt a network biology per-
spective to detect drug targets by its neighbors. We first constructed a weighted, signed
genetic interaction network from SGA profiles. For HIP assays, GIT supplements a gene’s
FD-score by the FD-scores of its neighboring genes in the genetic interaction network. If
the FD-scores of its positive genetic interaction neighbors are high while the FD-scores of
its negative genetic interaction neighbors are low, the gene is more likely to be a target.
For HOP assays, GIT incorporates the FD-scores of long-range two-hop neighbors to iden-
tify drug targets, since HOP is more likely to prioritize genes that buffer the drug target
pathway rather than the direct targets. By combining HIP and HOP assays using GIT,
we observed further improvement in target identification. Extensive experiments on three
genome-wide chemical genomic screens demonstrated that GIT substantially improves tar-
get identification in comparison with existing scoring methods. We also identified many
novel compound-target interactions that are currently not in any curated database but are
supported by literature. In addition to target identification, we further demonstrated that




The fitness defect score (FD-score) is the log-ratio of the growth defect of a deletion strain
in response to a compound treatment, relative to its growth under control conditions. For
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where ric is the growth defect of deletion strain i in the presence of compound c, and ri is
the average growth defect of deletion strain i measured under multiple control conditions
without any compound treatment. FD-score reflects the sensitivity of a gene deletion strain
to a compound treatment. Specifically, a negative FDic score means the growth fitness of the
strain i in the presence of the chemical c should be weaker than that of the control without
treatment. Therefore, a low, negative FD-score indicates a putative interaction between the
deleted gene and the compound.
The FD-score does not consider epistasis or interactions among genes. However, recent
studies indicate that the phenotype of a particular strain can be caused by the deletion of
a genetic modifier of a neighboring gene that is responsible for the phenotype [220, 221,
222, 223, 198]. Therefore, it is necessary to consider a gene’s neighboring genes for target
identification.
Genetic interaction network
We first obtained genetic interaction profiles of 5.4 million gene-gene pairs in yeast from
a recent genome-scale Synthetic Genetic Array (SGA) study [209]. We then constructed a
signed, weighted genetic interaction network based on these profiles. The edge weight gij
between gene i and gene j in the genetic interaction network is defined as
gij = fij − fifj, (4.2)
where fij is the double-mutant growth fitness, and fi is the single-mutant growth fitness
of gene i. A negative genetic interaction refers to a more severe growth fitness observed
than expected, with an extreme case being synthetic lethality, whereas a positive genetic
interaction refers to double mutants with a less severe growth fitness than expected [224, 24].
Network-assisted target identification in HIP assays
To identify drug targets in HIP assays, we introduce the GITHIP-score, which combines
a gene’s FD-score and the FD-scores of its neighboring genes in the genetic interaction
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network. For gene i and compound c, we define the GITHIP-score as
GITHIPic = FDic −
∑
j
FDjc · gij. (4.3)
The GITHIP-score considers two types of information of gene i: the FD-score of gene i and
the FD-scores of gene i’s genetic interaction neighbors (Fig. 4.3).
To account for different signs and strengths of genetic interactions, we compute a linear
combination of the FD-scores of neighboring genes according to their genetic interaction
edge weights to gene i. When gene i and gene j are a negative genetic interaction pair
(gij < 0) and gene i is the target of compound c, it is very likely that we also observe a
negative FDjc value. This is because the deletion of one copy of gene j will make gene i
more essential to the cell growth, according to the SGA assays. Likewise, if gene i and gene
j are a positive genetic interaction pair (gij > 0) and gene i is the target of compound c,
it is very likely that we observe a positive FDjc value. This is because the deletion of one
copy of gene j will make gene i less essential to the cell growth. Therefore, we designed the
GIT score to integrate the information from the genetic interaction neighbors to increase
the signal-to-noise ratio, thus improving the sensitivity of the target identification. A low
GITHIP-score indicates a potential compound-target interaction.
For target that cannot be accurately identified by the FD-score because of the noise in
chemical genomic screens or neighboring gene effect [220], the GITHIP-score corrects the
target’s FD-score according to the FD-scores of its genetic interaction neighbors. Previous
study proposed to identify essential genes in human cancer cell lines according to the ex-
pression profile of genetic interaction neighbors [225]. Specifically, one gene becomes more
essential if its negative genetic interaction neighbors are inactive and its positive genetic
interaction neighbors are active [226]. In this paper, we studied more direct phenotypic
growth fitness from chemical genomics assays, instead of gene expression data. Accordingly,
the GITHIP-score can also be viewed as a conditional essentiality score since it captures the
growth fitness of genetic interaction neighbors.
Network-assisted target identification in HOP assays
Compared to HIP, HOP assays delete both copies of non-essential genes in either haploid
or diploid strains. Therefore, the FD-score in HOP assays prioritizes genes that buffer the
drug target pathway. In contrast to existing studies [212, 198, 199, 200], which apply the
same scoring methods for HIP and HOP assays, we introduce a different network-assisted
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Figure 4.3: Illustration of how GIT identifies drug targets in HIP assays. Red
(Blue) nodes indicate genes with high (low) FD-scores. Red (Blue) lines indicates positive
(negative) genetic interactions. Yellow node indicates drug target. GIT supplements a
gene’s FD-score by the FD-scores of its neighboring genes in the genetic interaction
network. GIT identifies a gene as the target if the gene’s positive genetic interaction
neighbors have high FD-scores and the gene’s negative genetic interaction neighbors have
low FD-scores.
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approach for HOP assays to tackle the inherent difference between HIP and HOP assays.
Since genes with low FD-scores in the HOP assay are often close to or located in the drug
target pathway, we extend our framework to consider the FD-scores of long-range two-hop
genetic interaction neighbors.
To utilize long-range two-hop genetic interaction neighbors’ FD-scores, we first calculate
the first-order GIT-score of each gene. We define the first-order GIT-score GIT1stic of gene i
in the presence of compound c as
GIT1stic = FDic −
∑
j
FDjc · gij. (4.4)
We then use the first-order GIT-score to calculate the GITHOP-score for target identifica-
tion in HOP assays.
GITHOPic = FDic −
∑
j
GIT1stjc · gij. (4.5)
The GITHOP-score considers two types of information for each gene: the FD-score of the gene
itself and the first-order GIT-scores of the gene’s genetic interaction neighbors (Fig 4.4). A
low GITHOP-score indicates a potential compound-target interaction.
While genes that act to buffer the drug target pathway may not be the one-hop neighbors
of the target, the GITHOP-score takes into account indirect neighboring genes in the genetic
interaction network. Specifically, if the FD-scores of positively (negatively) weighted two-hop
neighbors are high (low), the corresponding one-hop neighbors will have a significantly low
GIT1st-scores. On the other hand, if the FD-scores of positively (negatively) weighted two-
hop neighbors are low (high), the corresponding one-hop neighbors will have a significantly
high GIT1st-scores. By correcting a gene’s FD-score according to the GIT1st-scores of the
gene’s genetic interaction neighbors, the GITHOP-score explicitly considers the FD-scores of
two-hop neighbors, which capture the drug target pathway buffer effect in the HOP assay.
GITHOP-scores can be viewed as the second-order GIT-score. It can be calculated by
iteratively multiplying the FD-score vector with the genetic interaction network matrix.
Although this scoring framework can be naturally extended to kth-order, we did not observe
substantial improvement for k > 2 in our experiments.
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Figure 4.4: Illustration of how GIT identifies drug targets in HOP assays. Red
(Blue) nodes indicate genes with high (low) FD-scores. Red (Blue) lines indicate positive
(negative) genetic interactions. Yellow node indicates drug target. GIT supplements a
gene’s FD-score by the FD-scores of its long-range two-hop neighbors in the genetic
interaction network. These long-range two-hop neighbors capture the drug target pathway
buffer effect in HOP assays.
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ρ-score
In addition to the FD-score, we compared our GIT-score with the ρ-score, which combines
genetic interaction profiles with chemical genomic screens by computing the Pearson corre-
lation coefficient between their outcomes[212]. ρ-score is proposed to leverage the inherent
similarity between genetic perturbation and chemical perturbation. Both of them profiles
the relative growth fitness when a gene i is knockdown by mutation or chemical compound.
Thus if the genetic interaction profile of a gene i is positively correlated to the FD-score
profile of a compound c, it means that the effect of mutating this gene i is similar to adding
a compound c.
For gene i and compound c, the ρ-score is defined as
ρic =
∑





where ngh(i) denotes the genetic interaction neighbors of gene i. When calculating ρic,
we excluded pairs of k and c if FDkc is missing a value. A high, positive ρ-score indicates a
potential compound-target interaction.
4.2.3 Datasets
STITCH compound-target interactions and genetic interaction profiles
We obtained known compound-target interactions from the STITCH 4 database [227] as
a benchmark to evaluate the performance of different target identification scoring methods.
These compound-target interactions are built from heterogeneous data sources, including
experiments, expert-curated databases, and literature mining. Each interaction has a com-
bined score (between 0 and 1) representing the confidence. We excluded low-confidence
interactions (combined score < 0.4), as suggested by the STITCH 4 database. We further
excluded interactions predicted solely from putative homologs from other species. After fil-
tering compounds that are not in any of the collected chemical genomics screens, we obtained
1472 compound-target interactions. We obtained genetic interaction profiles of 5.4 million




We obtained three yeast HIP-HOP chemical genomic screens from [198, 199, 200]. For
evaluation purposes, we only included compounds that had at least one STITCH compound-
target interaction. The first screen from Hoepfner et al. 2014 has 4,146 and 4,921 deletion
strains grown under 71 and 73 compound treatment conditions for heterozygous and homozy-
gous deletion collections, respectively. The second screen from Lee et al. 2014 has 1,095
and 4,810 deletion strains grown under 382 compound treatment conditions for heterozygous
and homozygous deletion collections, respectively. The third screen from Hillenmeyer et al.
2008 has 5,307 and 4,810 deletion strains grown under 333 and 162 compound treatment
conditions for heterozygous and homozygous deletion collections, respectively.
Experimental settings
We evaluated the performance of each scoring method based on two criteria: 1) the number
of compound-target interactions that can be identified in the top k genes and 2) the number
of compounds, at least one target of which can be identified in the top k genes.
For each criteria, we plotted a curve which describes the number of identified compound-
target interactions (drugs for second criteria) against the rank of gene for each scoring
method. The y-axis shows the number of compound-target interactions (drugs for second
criteria) identified in the top k genes, where k is shown on the x-axis. We first calculated
the area under the curve (AUC) of each scoring method.





where the AUCFD−score is the AUC of the FD-score and the AUCX is the AUC of the scoring
method X. If the nAUC is larger than 1, then the corresponding scoring method is better
than the FD-score method.
We denoted the nAUC obtained from the first criteria as nAUCt and the nAUC obtained
from the second criteria as nAUCd. Since one drug may have multiple targets, nAUCt is
more suitable for evaluation. Therefore, nAUCt is the primary metric used for evaluation in
this paper.
When calculating the GITHIP-score and the GITHOP-score, we only considered the top q
positive genetic interaction neighbors with highest weights and the top q negative genetic
interaction neighbors with highest absolute weights for each gene in the network. We set q
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Figure 4.5: Comparison of GIT with other scoring methods in terms of nAUCt in HIP
assays (A, B, C) and HOP assays (D, E, F) on three chemical genomic screens. The y-axis
shows the number of compound-target interactions identified in the top k genes, where k is
shown on the x-axis.
to 100 in all three screens.
4.2.4 Experimental results
GIT substantially improves target identification in HIP assays
To evaluate GIT in HIP assays, we performed large-scale target identification on three
chemical genomic screens. The results are summarized in Fig 4.5. It is clear that our
GITHIP-score substantially outperforms other scoring methods on all three screens. For
example, on Hoepfner et al. 2014 screen, GIT achieves 1.270 nAUCt, which is much higher
than 1.000 nAUCt of the FD-score. On Hillenmeyer et al. 2008 screen, GIT identifies 89
compound-target interactions in the top 150 genes, which is again substantially higher than
the 75 compound-target interactions identified by the FD-score. Similar improvement was
observed in terms of nAUCd on all three screens.
To further understand how the GITHIP-score achieves improved performance, we listed
compound-target interactions that are ranked higher by the GITHIP-score than by the FD-
score in Table 4.3. For instance, the FD-score failed to identify the interaction between
HSP90 and geldanamycin because of the large FD-score (2.01) of HSP90 in the presence of
geldanamycin. In contrast, our GITHIP-score successfully identified HSP90 as the target of
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geldanamycin by considering relevant HSP90’s negative genetic interaction neighbors (e.g.,
SGT1 with FD-score -8.77) and its positive genetic interaction neighbors (e.g., NSE3 with
FD-score 0.68).
Table 4.3: Top compound-target interactions identified by GIT in HIP assays.
We listed examples of compound-target interactions that are ranked higher by the
GITHIP-score than by the FD-score. We showed compound-target interactions that are






5-fluorouracil GLT1 78 140
5-fluorouracil DFR1 31 760
Curcumin STT1 20 94
Cycloheximide GSP1 64 513
Fenpropimorph ERG11 33 5,567
Fenpropimorph ERG2 26 56
Geldanamycin HSP90 69 5,731
Hydrochloric Acid END7 14 17
Hydroxyurea SGS1 13 406
Latrunculin A END7 13 56
Latrunculin A PSL7 85 125
Methotrexate DFR1 1 4
Radicicol TOP3 79 961
Rapamycin STT1 96 853
Rapamycin TOR2 2 3
Rapamycin LST8 4 30
Triclosan OAR1 62 224
We further compared the GITHIP-score with the ρ-score, which combines SGA profiles
with chemical genomic screens via the Pearson correlation coefficient. We found that GIT
substantially outperforms the ρ-score on all three chemical genomic screens. For instance,
GIT achieves 1.270 nAUCt on Hoepfner et al. 2014 screen, which is much higher than 0.919
nAUCt of the ρ-score. Same as the observation in the previous work [212], the ρ-score
performs consistently worse than the FD-score, possibly due to the fact that the Pearson
correlation coefficient is sensitive to the noise in high-throughput chemical genomic screens
and SGA profiles.
Finally, we examined whether other molecular networks also enable good target identifi-
cation performance. Since previous work [228] has used protein-protein interaction network
to identify essential genes in CRISPR screens, we hope to test if protein interaction network
can also achieve good performance when is used to identify drug targets. Therefore, we com-
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pared the performance between protein interaction network and genetic interaction network
on chemical genomics screens. We first obtained a physical interaction network (PI) of yeast
proteins from BioGRID V3.4 [4]. There are no sign but only weighted edges in the obtained
physical interaction network. We then used Eq. 4.3 to calculate the GITHIP-score(PI) based
on this physical interaction network, where gij is the weight between gene i and gene j in
the physical interaction network. We found that the GITHIP-score has better performance
than the GITHIP-score(PI). Since the physical interaction network is unsigned, the GITHIP-
score(PI) inevitably prioritizes hubs which have a large number of neighbors. In contrast,
by considering both negatively weighted edges and positively weighted edges in the genetic
interaction network, our GITHIP-score is not biased towards hubs and thus substantially
enhances target identification performance.
GIT substantially improves target identification in HOP assays
We next performed large-scale target identification on three chemical genomic screens to
evaluate GIT in HOP assays. The results are summarized in Fig 4.5. It is clear that our
GITHOP-score achieves the best target identification performance on all three chemical ge-
nomic screens. For instance, the GITHOP-score achieves 1.355 nAUCt on Lee et al. 2014
which is substantially higher than 1.000 nAUCt of the FD-score. We listed compound-target
interactions that are ranked higher by the GITHOP-score than by the FD-score in Table 4.4.
For instance, the FD-score fails to identify YSR2 as the target of sphingosine because of
the close to zero FD-score (-0.017) of YSR2 in the presence of sphingosine. In contrast, the
GITHOP-score successfully identifies the interaction between YSR2 and sphingosine, mainly
due to the high GIT1st-scores of YSR2’s positive genetic interaction neighbors (e.g., CSF1
with the GIT1st-score 1.60) and the low GIT1st-scores of YSR2’s negative genetic interac-
tion neighbors (e.g., VBM2 with the GIT1st-score -3.00). The substantial improvement of
GIT over the FD-score demonstrates the promising of utilizing two-hop genetic interaction
neighbors’ FD-scores to identify targets in HOP assays.
It is crucial to understand whether it is necessary to apply different scoring methods to
the HIP assay and the HOP assay. To this end, we calculated the GITHIP-score in the HOP
assay based on Eq. 4.3, where FDic (FDjc) is the FD-score of the HOP assay rather than
the HIP assay. Consequently, the GITHIP-score in the HOP assay corrects a gene’s FD-score
only according to the FD-scores of its one-hop neighbors. Although the GITHIP-score in
HOP assays achieves better performance in comparison to the FD-score and the ρ-score, we
noticed that it is consistently worse than the GITHOP-score on all three screens, suggesting
the necessity of utilizing the FD-scores of two-hop neighbors to capture the drug target
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Table 4.4: Top compound-target interactions identified by GIT in HOP assays.
We listed examples of compound-target interactions that are ranked higher by the
GITHOP-score than by the FD-score. We showed compound-target interactions that are






Caffeine TOR1 4 111
Camptothecin RAD51 39 349
Fenpropimorph ERG11 27 2,414
Fluconazole ERG11 85 2,412
Hydrochloric Acid GET3 79 278
Hydroxyurea RAD51 20 1,751
Hydroxyurea RAD52 82 1,396
Nocodazole YOR29-09 62 393
Nocodazole KAR9 26 256
Sphingosine YSR2 2 1,981
Staurosporin STT1 11 2,261
pathway buffer effect in the HOP assay.
We further investigated whether two-hop neighbors also enable better performance in HIP
assays. We calculated the GITHOP-score in HIP assays by using the FD-score of HIP assays
in Eq. 4.4 and Eq. 4.5. Different from HOP assays, the GITHOP-score does not obtain
substantial improvement in comparison to the GITHIP-score in HIP assays, reflecting the
inherent differences between the HIP assay and the HOP assay.
Finally, we examined whether using the physical interaction network enables good target
identification performance in HOP assays. We used Eq. 4.4 and Eq. 4.5 to calculate the
GITHOP-score(PI) based on the obtained physical interaction network, where gij is the edge
weight between gene i and gene j in the physical interaction network. We compared the
GITHOP-score(PI) with the GITHOP-score in HOP assays. Similar to our observation in HIP
assays, we found that using the genetic interaction network has an overall better performance
than using the physical interaction network in HOP assays.
Combining the HIP assay with the HOP assay further improves target identification
Since the HIP assay and the HOP assay are inherently different, we then studied whether
these two assays can be combined for improving target identification. We noticed that either
using the GITHIP-score from the HIP assay or using the GITHOP-score from the HOP assay
identifies compound-target interactions that are not identified by the other. For example, in
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Figure 4.6: Comparison of GIT with other scoring methods in terms of nAUCt on two
chemical genomic screens. The y-axis shows the number of compound-target interactions
identified in the top k genes, where k is shown on the x-axis. The GITHIP-score is
calculated by using the FD-score from the HIP assay. The GITHOP-score is calculated by
using the FD-score from the HOP assay. To calculate nAUCt, we divided the AUC of each
method by the AUC of the GITHIP-score.
the Hoepfner et al. 2014 screen, the GITHOP-score identifies 11 compound-target interactions
that are not discovered by the GITHIP-score. Since the HIP assay and the HOP assay
are complementary, we sought to combine them in order to further enhance the target
identification performance.
We proposed a combined scoring method which takes the average of the z-score by the
GITHIP-score from the HIP assay and the z-score by the GITHOP-score from the HOP assay.
Averaging these two scores can be viewed as boosting two weaker scoring methods to create
a more robust and better scoring method. We denote this score as the GIT-score. Since Lee
et al. 2014 only measures the FD-scores of the heterozygous strains of essential genes and
the homozygous strains of nonessential genes, there is no overlapping genes between the HIP
assay and the HOP assay in this screen. Therefore, we evaluated the GIT-score on the other
two chemical genomic screens. We observed that the combined GIT-score is substantially
better than both the GITHIP-score and the GITHOP-score (Fig 4.6). For example, the GIT-
score achieves 1.802 nAUCt, which is much higher than 1.284 nAUCt of the GIT
HOP-score
and 1.000 nAUCt of the GIT
HIP-score on the Hoepfner et al. 2014 screen.
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Statistical assessment of using genetic interaction network in GIT
Since drug targets are likely to be enriched with high-degree nodes in the network [229],
the improvement of GIT may be caused by its ability to prioritize these high-degree nodes
instead of utilizing neighboring gene’s FD-scores. We then examined whether the improve-
ment of GIT comes from prioritizing high degree nodes. We first constructed a large set of
random networks according to the following procedure. For each node, we replaced each of
its neighbors to another random node in the network while keeping the same edge weight
and sign. Hence, each node in the new random networks has the same number of positive
weighted neighbors and negative weighted neighbors as in the original genetic interaction
network. We then used these networks to calculate the GIT-score, where gij is the edge
weight between gene i and gene j. We calculated an empirical p-value according to the
number of random networks that have better performance than the genetic interaction net-
work when used to identify targets. Since each node in the new random networks have the
same degree as it does in the original genetic interaction network, this empirical p-value tests
whether the improvement of GIT is achieved by identifying high-degree nodes. We obtained
significant empirical p-values on both screens (empirical p-value < 0.009 on Hoepfner et al.
2014; empirical p-value < 0.018 on Hillenmeyer et al. 2008). Therefore, we found that GIT
on these random networks is significantly worse compared to GIT on the original GI network.
This demonstrates that the improvement comes from correcting each genes FD-score with
its neighbors FD-scores rather than the network topology only.
GIT elucidates established mechanism of action of compound
To understand how GIT achieves the substantial improvement, we studied how GIT-score
elucidates the compound’s MoA. We examined caffeine, which is a distinct, small molecular
inhibitor of TOR complex [230, 231]. We analyzed GIT’s performance based on the Hoepfner
et al. 2014 chemical genomic screen, which is the most recent screen among all three screens.
We first noticed that the FD-scores of TOR1 in the HIP assay and the HOP assay are 0.079
and -1.827 in the presence of caffeine, respectively. Consequently, the FD-score fails to
identify TOR1 as the very top target candidate. In contrast, our GIT-score successfully
identifies TOR1 as the target of caffeine, mainly due to the high FD-scores of its positive
genetic interaction neighbors SAC7 and UGP. The high FD-scores of SAC7 (1.75) and UGP
(2.38) indicate that their positive genetic interaction neighbor TOR1 is inhibited by caffeine.
Moreover, most of TOR1’s negative genetic interaction neighbors have substantially low FD-
scores (e.g., GTR1 has -4.52 FD-score). We show the genetic interaction neighbors of TOR1
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Figure 4.7: GIT elucidates MoA of caffeine. Green lines indicate positive genetic
interactions. Red lines indicate negative genetic interactions. Red nodes (e.g., GTR1) are
genes with low FD-scores in the HIP assay and the HOP assay. Green nodes (e.g., SAC7)
are genes with high FD-scores in the HIP assay and the HOP assay. TOR1 and TOR2 are
established targets of caffeine. The GIT-score successfully identifies their interactions with
caffeine by using neighboring genes’ FD-scores. TOR1 complex, TOR2 complex, and GSE
complex are identified as crucial cellular components that interact with caffeine.
in Fig 4.7. We can see that TOR1’s negative genetic interaction neighbors have low FD-
scores, whereas its positive genetic interaction neighbors have high FD-scores. Even though
TOR1 does not have a substantially low FD-score, GIT still accurately identifies TOR1 as
the target of caffeine by correcting TOR1’s FD-score according to its genetic interaction
neighbors’ FD-scores.
Notably, the GIT-score also identifies TOR2 as a target of caffeine. Although the GIT-
score ranks TOR2 lower than TOR1, it ranks TOR2 higher than the FD-score does. We
noticed that it is difficult to identify TOR2 only according to one-hop genetic interaction
neighbors’ FD-scores. Both TOR1 and AVO1 have close to zero FD-scores. GTR1 has
a substantially low FD-score, but the genetic interaction edge weight between GTR1 and
TOR2 is much lower than the one between GTR1 and TOR1. Nevertheless, the GIT-score
still identifies TOR2 as a target of caffeine through the GIT1st-scores of TOR2’s genetic
interaction neighbors (e.g, GTR1, TOR1 and AVO1).
Fig 4.7 not only elucidates how the GIT-score identifies the targets of caffeine, but also
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reveals the underlying MoA of caffeine. We can see that there are three major functional
complexes that interact with caffeine. Both the TOR1 complex and the TOR2 complex are
established cellular components that are affected by caffeine [230, 231]. GSE complex, along
with PIB2 and YCL062W, are all associated with vacuolar membranes which play important
roles in the TOR2 complex [232].
GIT discovers novel compound-target interactions
We then investigated whether those novel compound-target interactions that are discov-
ered by the GIT-score can be supported by existing literature. The output of GIT is a
score for each compound-gene pairs. The top ranking genes are the potential targets of each
drug. According to the average number of targets of each compound, we proposed to use
an empirical p-value 0.001 as the cut-off values of significant compound-target interactions.
Here, for each compound, we examined the top five genes that were predicted to be poten-
tial targets by the GIT-score. We listed the novel compound-target interactions that are
supported by literature in Table 4.5. To show the advantage of using the genetic interaction
network, we only listed targets that cannot be identified by the FD-score. For example,
the GIT-score successfully identifies the interaction between 5-fluorouracil and SSF1. This
interaction is verified by a haploid yeast knockout strains screen [233]. In contrast to the
FD-score which fails to identify SSF1, the GIT-score identifies this interaction according to
the high FD-scores of SSF1’s positive genetic interaction neighbors (YLR407W, TSL26) and
the low FD-scores of SSF1’s negative genetic interaction neighbors (RRP6, YMR268W-A).
The GIT-score also identifies POL32 as the target of camptothecin, which is verified by a
recent cross-species chemical genomics profiling [234]. Again, the FD-score of POL32 in the
presence of camptothecin is not significantly low (-0.38 in the HIP assay and -1.38 in the
HOP assay). The GIT-score identifies POL32’s interaction with camptothecin through the
high FD-scores of its positive genetic interaction neighbors (VPS39, BTS1 and RPL13A)
and the low FD-scores of its negative genetic interaction neighbors (YCL060C, XRS1 and
RTT110).
GIT groups genes into co-functional gene complexes
In addition to understanding of compound’s MoA, we studied whether the GIT-score can
be used to identify co-functional gene complexes. We used k-means to cluster yeast genes into
100 different clusters based on their GIT-scores in the presence of different compounds. For
each cluster, we used Fishers exact test to test whether it was enriched with the annotated
81
Table 4.5: Novel compound-target interactions identified by GIT. We listed
compound-target interactions that are identified by the GIT-score but are currently not in
any curated database. All these interactions are supported by literature.
Compound Target PMID
5-fluorouracil SSF1 18314501
Bafilomycin A1 DOR1 22470510
Caffeine SLT26 16729036, 16738548
Camptothecin POL32 21179023
Curcumin SEC37 21908599
genes of at least one Gene Ontology term. We obtained Gene Ontology annotations from
BioGRID V3.4 [4]. We compared the clustering performance of using the GIT-score with
using the FD-score from the HIP assay and using the FD-score from the HOP assay on
three Gene Ontology categories in Fig 4.8. We can see that the GIT-score discovers more
established complexes than the FD-score. For example, 93 of the 100 clusters identified
by the GIT-score are significantly enriched with at least one cellular component function
by using a false discovery rate of 0.005. In contrast, the FD-score from the HOP(HIP)
assay only identifies 75(65) clusters that are significantly enriched with at least one cellular
component function. In addition, the GIT-score also exclusively identifies many important
cellular component complexes such as pore complex, chromosome, centromeric region, and
microtubule.
4.2.5 Conclusion
Here we have reported the discovery that, through the use of prior knowledge captured in
the genetic interaction network, compound-target interactions can be identified more accu-
rately on chemical genomic screens. Our method identifies many compound-target interac-
tions that comprise existing curated database as well as novel compound-target interactions
that are supported by literature evidence. Due to its ability in modeling the genetic in-
teraction among genes, we can better understand the mechanism of action of compounds,
which may provide new insight into drug discovery and drug repositioning. Historically,
genetic interaction profiles have been integrated with chemical genomic screens to identify
compound-target interactions via the Pearson correlation coefficient [212] due to the inherent
similarity between genetic perturbation and chemical perturbation. Our study is different
from these previous works in that different local network topology features are taken into
consideration in HIP and HOP assays. To the best of our knowledge, this is the first time
that HIP and HOP assays are used differently to decipher compound-target interactions.
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Figure 4.8: GIT identifies co-functional gene complexes. The y-axis shows the
number of co-functional gene complexes that can be identified by the GIT-score, the
FD-score from the HIP assay, and the FD-score from the HOP assay by using false
discovery rate r, where r is shown in the x-axis. (A) shows the biological process category.
(B) shows the cellular component category.
One might consider at least three potential reasons for the good performance of GIT. First,
existing high-throughput chemical genomic screens might be noisy. GIT is more robust to
the noise by using genetic interaction neighbors’ FD-scores to assist the inference of drug
targets. Second, HOP assay and HIP assay are fundamentally different biological assays, thus
prioritizing different sets of genes. We use direct neighbors’ FD-scores to identify compound-
target interactions in the HIP assay, whereas we consider two-hop neighbors’ FD-scores to
capture the drug target pathway buffer effect in the HOP assay. Moreover, combining
predictions from the HIP assay and the HOP assay further makes GIT more robust. Finally,
the genetic interaction network reflects the consequence of perturbing gene function and
uncovers broader relationships between diverse functional modules, thus provides functional
information that is largely invisible to physical interactions.
One interesting observation is that GIT achieves a substantial improvement in comparison
to the ρ-score. Both the ρ-score and the GIT-score use genetic interactions to assist target
identification. However, the ρ-score prioritizes genes according to the Pearson correlation
between one genes chemical genomic profile and its genetic interaction profile. Consequently,
it is sensitive to the noise in SGA and chemical genomic screens. In contrast, GIT scores
a gene according to the dot product between its neighbors FD scores and their genetic in-
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teraction edge weights, making it more robust to the noise. More importantly, in HOP
assays, unlike the ρ-score which only considers one genes one-hop genetic interaction neigh-
bors, we also consider its two-hop genetic interaction neighbors. Our observation that the
GITHOP-score (two-hop) has much better performance than the GITHIP-score (one-hop) and
the ρ-score (one-hop) in HOP assays demonstrates the promising of considering two-hop
genetic interaction neighbors in the HOP assay.
Finally, we see many opportunities to improve upon the basic concept of GIT in future
work. First, although the current GIT framework is developed in an unsupervised fashion,
the GIT-score can be used as the feature and plugged into off-the-shelf machine learning
classifier for compound target identification on chemical genomic screens. Second, although
this study focused on yeast chemical genomic assays, the GIT method is broadly applicable
to any drug perturbation screens on other species [166]. Finally, current genetic interaction
network is still noisy, whereas GIT can be potentially used to predict the genetic interaction
given the compound-target interaction. For example, one gene with a low FD-score might
have a negative genetic interaction with the drug target. In comparison to model organisms
such as yeast and worm, high-throughput measuring genetic interactions in human is inher-
ently difficult due to the lower efficiency of genetic engineering and the absence of resources
like the yeast knockout collection. With available large-scale drug perturbation screens [166]
in human, GIT offers the intriguing opportunity to explore genetic interactions in human.
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CHAPTER 5: KNOWLEDGE NETWORK ASSISTED CLINICAL
DECISION MAKING
In this Chapter, I will show how knowledge networks can be used to support clinical
decision making. I will first propose a novel topic model which is developed to construct
knowledge networks from noisy text data. I will then introduce how we use a medical knowl-
edge graph to support clinical decision making by analyzing large-scale electronic medical
records. Using our network embedding approach, we obtain promising results in many impor-
tant clinical decision support tasks, including patient categorization, patient visualization,
and survival prediction.
5.1 CONSTRUCTING A SYMPTOM, DISEASE, AND DRUG NETWORK FROM
CLINICAL DATA
Recently, electronic medical records (EMRs) have been widely adopted in United States.
These EMRs contain invaluable clinical notes that record medical events. However, these free
text notes pose ineligible challenges for data mining algorithms to understand and mine these
unstructured datasets. Instead of evaluating our approach on western medicine electronic
medical record collection, I evaluated my approach on a large traditional Chinese medicine
(TCM) medical record collection. I chose to study this dataset because mining TCM data is
more challenging as each patient is often prescribed with more than 10 drugs, thus making
it difficult to identify the drug symptom relations properly. Consequently, if we can discover
symptoms, disease, and drug relations on this dataset, our method would be likely to work
well for EMR datasets in other domains.
Traditional Chinese medicine (TCM), a style of medicine widely used in China for thou-
sands of years, has been used as a complementary and alternative medicine (CAM) [235] and
is especially effective for certain diseases such as stomach ailments [236]. According to the
2007 National Health Interview Survey (NHIS) [237], which included a comprehensive survey
on the use of complementary health approaches by Americans, an estimated 3.1 million U.S.
adults had used TCM treatment in the previous year. Traditional Chinese medicine has also
been widely used in Australia, which has an estimated 2.1 million active TCM practitioners
each year [238].
In TCM clinical notes, doctors record symptoms that they observe in their patients. The
symptoms are captured and described in information entities such as “night sweats” and
“night fevers.” The doctors then prescribe herbs, which is the corresponding drugs in TCM,
based on the patient’s disease profile. This personalized medical process is then detailed in
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Figure 5.1: A toy example of symptom separation in a medical record. The latent
associations are not explicitly stated in the record.
the patient’s medical record. Unlike modern medicine, TCM is flexible with prescriptions,
assigning multiple ingredients accordingly to treat a particular patient’s symptoms. Learning
how TCM doctors analyze symptoms and arrive at prescriptions can greatly increase our
knowledge of medicine.
Unfortunately, due to the empirical nature of TCM, key knowledge about disease diag-
noses based on TCM-specific symptoms and herb prescriptions is not well-documented. This
creates a significant challenge to retain, share, and inherit knowledge of TCM [239]. This
challenge is exacerbated by the fact that patients often have comorbid medical conditions
and symptoms, which introduces a host of complex, intricately connected factors [240]. In
general, medical data is considered to be one of the most difficult domains for data mining
[241]. Moreover, because of the personalized treatment principle in TCM, prescribed herbs
and observed symptoms are often mixed together in a patient’s medical record. Conse-
quently, for patients with multiple diseases, it is difficult to associate each disease with the
prescribed herbs and observed symptoms. We refer to this challenge as the mixed pre-
scription challenge. Though we focus on TCM medical record data in this paper, mixed
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prescription is also a fundamental challenge in western medicine record analysis when a pa-
tient is prescribed a combination of drugs to simultaneously treat several diseases. We show
an example of a mixture in which six symptoms are associated with three different diseases
(Figure 5.1).
Fortunately, these challenges can be addressed by analyzing large-scale TCM clinical pa-
tient data. With this vision, the National Data Center of Traditional Chinese Medicine
in Beijing, China has been collecting TCM electronic medical records (EMRs) since 2007,
integrating them into a clinical data warehouse [242]. The data warehouse has curated
over 300,000 clinical cases and will continue to acquire patient records from six hospitals
in subsequent years. Each hospital has received roughly 3,000,000 patient visits annually
for a decade. This data provides an unprecedented opportunity to apply powerful mining
algorithms to discover useful knowledge. Indeed, several interesting studies have already
succeeded in detecting herb combinations for disease treatment [243], latent symptom phe-
notype regularities [244], and symptom-herb relationships [245].
In pursuit of this vision, we analyze large-scale datasets obtained from the TCM Data
Center. We propose a novel probabilistic model proTCM to jointly analyze symptoms,
diseases, and herbs and to discover patterns that reveal knowledge about the following:
1. Typical symptom groups associated with disease conditions. This knowledge can help
doctors diagnose diseases.
2. Typical herb groups associated with disease conditions. This knowledge can help doctors
prescribe herbs.
3. Correlations among symptom groups and herb groups. This knowledge can facilitate
personalized prescriptions and reveal new insights into herb effectiveness.
Generative probabilistic models can model an entire dataset as a whole, which optimizes
pattern discovery by using all of the available data. Such models have already been suc-
cessfully used for text mining [246] and TCM data analysis [247, 248]. However, previous
works did not model the asymmetric causal relations among symptoms, diseases, and herbs;
the relations were instead inaccurately considered to be symmetric. In this paper, we pro-
pose a new probabilistic model that can represent the causal relations asymmetrically to
enable more accurate discovery of medical knowledge. In particular, we are interested in
disease-specific knowledge. We first introduce a new pattern, which we call a disease profile.
It consists of three elements: a disease, a multinomial distribution over symptoms for the
disease, and a multinomial distribution over herbs for the disease. For example, the disease
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profile for chronic gastritis shows that its most common symptoms are “bloating” and “epi-
gastric pain and chills,” and its most frequently prescribed herbs are “stir-fried immature
bitter orange in bran” and “crow-dipper.” To discover disease profiles from our dataset, we
propose a generative probabilistic model with the profiles as model parameters. We can ob-
tain maximum likelihood estimates for these profile parameters, which can be interpreted as
knowledge discovered from the data. These profiles are not only meaningful by themselves,
but are also useful as references to TCM practitioners for recommending prescriptions.
5.1.1 Methods
Specifically, the disease information implicitly provides important connections between
symptoms and herbs, effectively reducing the space complexity of all possible matchings.
Moreover, explicit incorporation of diseases into the mining process also enables direct dis-
covery of symptom-disease and herb-disease associations. Both types of associations have
important clinical applications, with the former aiding diagnosis and the latter aiding herb
prescription in real-world clinical settings.
To mine these associations, we define our computational problem as follows: the input
consists of a set of tripes (S,D,H), where S is a subset of all possible symptoms, D is a
subset of all possible diseases, and H is a subset of all possible herbs. The output consists of
a set of r disease profiles
{
p1, p2, . . . , pr
}
. Each profile corresponds to a disease d ∈ D, and
is characterized by two distributions. One distribution is over symptoms, Pr(s|d), s ∈ S,
reflecting the typical symptoms of disease d. The other is over herbs, Pr(h|d), h ∈ H,
capturing the typical herbs prescribed to treat disease d.
In a medical record, a single patient possesses a set of symptoms, to which a physician
attributes to a set of diseases. However, within the patient record, it is unknown whether a
given symptom s ∈ S is related to some assigned disease di ∈ D or another assigned disease
dj ∈ D (Figure 5.1). Furthermore, a patient record contains a set of prescribed herbs. The
disease that each herb is meant to treat is also unknown. This challenge of symptom and
herb separation occurs very frequently in our dataset, in which each record has an average
of 15 symptoms and 20 herbs. As a result, separating symptoms and herbs is necessary to
optimally deduce their corresponding diseases and thus prescribe the appropriate treatments
to the patient. Here, we propose to solve the challenge of symptom and herb separation by
using an unsupervised generative probabilistic model. The proposed probabilistic model
mimics these causal relations: Pr(s|d) models the symptoms of a disease d, while Pr(h|d)
models the prescribed herbs. Using a distribution to represent the causal relations captures
uncertainty, which is inevitable given the lack of documented, precise medical knowledge in
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TCM. There are at least two simplifications of these models, dependent upon the assumptions
that we make.
1. Multinomial model. In this model, we assume that the symptoms “compete” with each
other. If one symptom has an increased probability of appearing, then it decreases the
probability of appearance of other symptoms. This assumption allows us to infer which
symptom is most likely to appear, giving us two constraints:
∑
s∈S Pr(s|d) = 1 and∑
h∈H Pr(h|d) = 1. From the perspective of a generative model, we assume that the
observed symptoms are generated by sampling symptoms using Pr(s|d). Similarly, the
observed herbs are sampled using Pr(h|d).
2. Multi-Bernoulli model. In this model, we assume that symptoms independently appear.
Under this assumption, we have two constraints: Pr(s = 0|d) + Pr(s = 1|d) = 1 and
Pr(h = 0|d) + Pr(h = 1|d) = 1. Each symptom is generated independently from its
symptom distribution. In other words, we flip a biased coin with probability Pr(s|d) to
determine whether symptom s appears with disease d. Herbs are generated in the same
way, but with Pr(h|d).
Here, we focus on the multinomial model in the hopes of discovering the most prominent
symptoms and herbs for each disease, leaving the exploration of the multi-Bernoulli model
as future work. We now give a more detailed description of the multinomial model.
Intuitively, we model how symptoms and herbs of a patient record are generated from
their corresponding set of diseases by using the conditional distribution Pr(s, h|d). In order
to characterize this generative model, we introduce another distribution over diseases for
patient record t, Pr(d|t). Pr(d|t) decides the primary disease responsible for generating a
specific set of symptoms and prescriptions.
To generate a set of symptoms S =
{
s1, . . . , sn
}
, we generate each symptom si ∈ S
independently. We first sample a disease with probability Pr(d|t), and then sample from its
corresponding symptom model Pr(s|d). We repeat this process n times to generate the n
symptoms. The herbs
{
h1, . . . , hm
}
are generated in a similar way, using Pr(h|d) instead of
Pr(s|d).
The probability of patient t having symptom s and being prescribed herb h with disease
diagnoses Dt =
{






Pr(d|t) Pr(s|d) Pr(h|d) (5.1)
If we view symptoms and herbs as “words,” our proposed model is similar to basic topic
models such as PLSA [246], which has been successfully applied to the task of discovering
89
word clusters from noisy text collections. However, an important difference is that in PLSA,
each word w ∈ W in document d ∈ D belongs to an underlying cluster (topic). In contrast,
we assume that all of the clusters (diseases) are observed. This assumption not only applies
to real clinical situations, but also restricts the model and allows us to directly learn disease-
specific knowledge. In effect, we are imposing an infinitely strong prior on latent topics such
that they are strictly tied to certain diseases.
A previous model for a similar dataset assumed latent associations between symptoms
and herbs [249]. As a result of this limitation, the learned associations are not ensured to be
aligned with particular diseases, despite using diagnosis information. We hypothesize that
our model can discover more accurate disease-specific knowledge than this older, related
model. The results of our experiments confirm this hypothesis.
Because common symptoms and herbs frequently co-occur with many different diseases,
they are not discriminative enough to accurately infer a specific disease. To alleviate this
problem, we further define a background cluster Pr(θB|t). The background cluster helps
generate these noisy symptoms and herbs, allowing the final disease cluster to be more







+ Pr(θB|t) Pr(s|θB) Pr(h|θB)
(5.2)
where Pr(s|θB) and Pr(h|θB) are the background multinomial distributions over symptoms
and herbs, respectively.
By fitting this mixture model to patient records, we can find the multinomial distributions
that best explain our data. These distributions are associated with the symptoms and
herbs that correspond the most to each disease. Under the definition of Pr(s, h, t), the
log-likelihood function of the patient record collection M is:







I(t, s, h)× log Pr(s, h|t) (5.3)
where I(t, s, h) = 1 if patient t has symptom s and was prescribed herb h, 0 otherwise. Our
model has the following parameters: Pr(d|t), Pr(s|d), Pr(h|d), Pr(θB), Pr(θB|t), Pr(s|θB),
and Pr(h|θB). We use an expectation-maximization (EM) algorithm to perform maximum
likelihood estimation of this latent variable model. The EM algorithm alternately performs
an expectation (E) step and a maximization (M) step, and is guaranteed to converge [250].
It attempts to find the optimal parameters to explain the model. Because the parameter
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estimation for the background cluster and herb distributions is similar to that of a symptom
distribution, we only give the update formula for a symptom distribution. In the E step, we
compute the posterior probabilities for Pr(d|s, h, t).
Pr(d|s, h, t) ∝ P n(d)P n(t|d)P n(s|d)P n(h|d) (5.4)
In the M step, we re-estimate the parameters based on the posterior probabilities obtained
in the E step.
5.1.2 Clinical Decision Support Applications
Note that our model is completely unsupervised, so it requires neither human annotation
nor prior knowledge. After estimating the model parameters from the patient record, we can
use the resulting symptom and herb distributions for TCM clinical decision support. We
outline three possible applications in the following subsections.
1. Mining Disease-Specific Symptoms and Herbs Mining TCM symptoms and herbs can help
doctors diagnose diseases as well as reveal when certain herbs are prescribed. In our model,
Pr(s|d) and Pr(h|d) provide distributions over all symptoms and herbs, respectively. Dis-
tributions with the highest probabilities are the most relevant to disease d.
2. Symptom-Herb Relationship Discovery Besides mining symptoms and herbs of a given
disease, our model can discover highly correlated symptoms and herbs. Here, we define





Thus, if symptom s and herb h co-occur frequently in many disease multinomial distribu-
tions, they will have a high correlation score. These symptom-herb relationships can help
doctors understand the precise usages of each herb.
3. Disease and Treatment Prediction Our model can be extended to build intelligent systems
that can predict a patient’s disease based on his or her symptoms. Assuming that all
diseases are equally likely to occur, the probability of a patient with symptoms
{
s1, . . . , sn
}
having disease d is computed as:
Pr(d|
{
s1, . . . , sn
}
) ∝ Pr(s1|d) . . .Pr(sn|d) Pr(d) (5.6)
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Similarly, we can build an intelligent prediction system to recommend herbs to a patient
based on his or her symptoms. The probability of a patient with symptoms
{
s1, . . . , sn
}
receiving effective treatment by using herb h is computed as:
Pr(h|
{





Pr(s1|d) . . .Pr(sn|d) Pr(h|d) Pr(d) (5.7)
5.1.3 Experimental Results
The main goal of our experiments is to examine whether the proposed model can indeed
extract useful knowledge from patient records. While we hypothesize that our method can
successfully mine a large number of patient records obtained from multiple physicians, direct
experimentation with such a mixed dataset would make it difficult to choose the most suitable
physician to assess the data mining results. This is because different physicians tend to have
varying opinions due to the differences in their training and experiences. Thus, we decided
to evaluate the proposed model on two real-world medical record collections, each of which
was obtained from a single physician.
1. Digestive disorder EMR. In this dataset, we collected 10,907 anonymous electronic med-
ical records provided by a TCM physician who specializes in digestive disorders. We
normalized the symptom and herb terms to obtain 9,530 records with 3,000 symptoms,
97 diseases, and 652 herbs. All disease terminology in this dataset all have analogs in
western medicine (i.e., hypertension, chronic gastritis, and constipation).
2. Lung cancer EMR. In this dataset, we collected 187 anonymous electronic medical records
provided by a TCM physician who specializes in lung cancer. We normalized the symptom
and herb terms to obtain 187 records with 12 symptoms, 12 syndromes, and 318 herbs.
This dataset contains only TCM syndromes and no western medicine diseases besides the
initial cancer diagnosis. We treated these 12 syndromes collectively as the disease profile
in our model and aimed at mining the associated herbs and symptoms accordingly.
We compare our model with with the closely related, previously proposed symmetric gener-
ative model [249].
proTCM substantially improves symptom-herb relationship prediction
To quantitatively evaluate our model, we collected a set of symptom-herb relationship
annotations manually curated by TCM experts. These annotations contain 27,285 symptom-
92
Figure 5.2: Comparison of our method and frequent pattern mining for identifying
symptom-herb relationships
herb relationships. The symptoms and herbs of only 1,624 of these relationships appear in
our dataset. Consequently, we evaluate how our method can accurately identify this subset
of 1,624 relationships.
We use AUROC, one of the most widely used metrics, to evaluate our method. We compare
our method with frequent pattern mining (FPM), which is extensively used in pattern mining
[251]. FPM ranks symptom-herb pairs by their frequencies in the collection. Consequently,
it identifies frequently co-occurring symptom-herb pairs. However, FPM fails to identify
symptom-herb pairs that do not frequently co-occur in the medical records. Moreover, FPM
biases towards highly frequent herbs (or symptoms) as they often co-occur with many other
symptoms (or herbs) in the medical record. In contrast to FPM, our method infers the
associated herbs (or symptoms) among a mixed of herbs (or symptoms) by simultaneously
modeling the patient record of all patients. It can also discover symptom-herb pairs that do
not frequently co-occur in the dataset.
Our method significantly outperforms FPM with a p-value < 4.45 × 10−8 (Figure 5.2).
Our method achieves an AUROC of 0.7721, which is much higher than FPM’s AUROC of
0.6938. Notably, we found that FPM does not make accurate predictions when the false
positive rate exceeds 0.2. This is because FPM requires an herb and a symptom to appear
in the same transaction to constitute an symptom-herb relationship, a restriction that does
not affect our model.
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Table 5.1: Comparison between our model and frequent pattern mining in treatment
prediction and disease prediction
Treatment prediction Disease prediction
F1 Precision Recall F1 Precision Recall
proTCM 0.2504 0.1518 0.738 0.5813 0.7281 0.6084
FPM 0.2456 0.1489 0.7250 0.5266 0.7277 0.5130
proTCM improves disease and treatment prediction
Our model can be further extended to build an intelligent system that can predict diseases
and recommend herbs as references for physicians or patients. To examine the potential of
this direction, we use two-thirds of the patient record collection as training data and the
remaining one-third as test data. The test set and training set are disjoint. This simulates
a realistic scenario in which the system learns from the patient record history to provide
support for the treatment of new patients.
We employ three standard metrics commonly used to evaluate prediction tasks: F1 score,
precision, and recall. We take the macro-average of these three metrics (Table 5.1). We note
that disease prediction based on symptoms achieves a reasonably high F1 score, precision,
and recall (0.58, 0.73, and 0.61, respectively). Herb prediction, based on symptoms and
diseases, achieves a relatively low F1 score, a much worse precision, but a very high recall
(0.25, 0.15, and 0.74, respectively). This suggests that the system can recover the herbs that
the physician actually prescribed to a patient, while also recommending many herbs that
were not prescribed.
We compare our method with frequent pattern mining (FPM), which is one of the most
widely used approaches in pattern mining (Table 5.1). We see that our method outperforms
the frequent pattern mining method on all metrics for both disease prediction and herb
prediction.
proTCM recommends quality herb prescriptions for TCM syndromes
The concept of syndromes is unique to the field of TCM. Syndromes are high-level ab-
stractions of health conditions and are not specifically associated with any single organism or
disease. For example, the moisture syndrome is used to describe patients who have arthralgia
and weakness due to a dysfunctional spleen. These TCM syndromes are often diagnosed by
the comprehensive analysis of a patient’s overall condition and thus cannot be determined
solely by laboratory tests.
Syndromes serve as an alternative method of categorizing patients, and have been used as
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the principle element in TCM diagnosis. However, current understanding of syndromes is
incomplete and inconsistent among different TCM physicians. Here, we take a data-driven
perspective to prescription recommendation for each syndrome according to the medical
records. This knowledge can greatly expand the TCM textbook and help junior doctors bet-
ter understand syndromes. Since our dataset only contains 12 unique syndromes, we only
took into account their related herb prescriptions. We applied proTCM to the lung cancer
dataset and treated each syndrome as a disease in our model. Four TCM physicians manu-
ally verified the results and annotated the associations consistent with their knowledge. We
also found that most of these associations are consistent with existing knowledge, reflect-
ing proTCM’s ability to mine underlying TCM knowledge from medical records. Among
the 12 syndromes, the phlegm syndrome and the lung syndrome show promising overall
performance. Since this analysis is applied to a lung cancer dataset, the phlegm and lung
syndromes appear for many patients. Our model successfully captures the herbs associated
with these two syndromes. In addition, our method also obtains good performance on a rela-
tively rare syndrome, the moisture syndrome. All five of its identified herbs were verified by
TCM doctors. By using the proposed probabilistic model, we successfully mined knowledge
of these rare syndromes by solving the mixed prescription challenge in the dataset. Note
that the performance of yin deficiency is worse than that of other syndromes. This decreased
performance is possibly due to the obscure and diverse properties of this syndrome across
different patients. Overall, our method achieves a 0.79 accuracy in identifying the best herb
prescriptions for each syndrome.
5.1.4 Related Work
Mining TCM clinical data has steadily gained popularity in the past decade. A number of
studies have been devoted to clustering or determining the hidden structures of symptoms.
For example, Zhang et al. proposed an unsupervised latent tree model to learn diagnosis
structures from TCM datasets with symptom variables [244]. The study showed that natural
clusters exist in the datasets and these clusters correspond well to syndrome types.
Chen et al. performed a comparative study of five classification methods (e.g. support
vector machines, neural networks, decision trees, etc.) for syndrome differentiation in coro-
nary heart disease using 1,069 clinical epidemiology survey cases [252]. The results showed
that support vector machines (SVM) performed best in the prediction task. For the herb
regularities, He et al. proposed an approach for discovering functional groups of herbs from a
large set of prescriptions recorded in TCM texts [253]. Guang et al. constructed prescription
association networks by mining literature datasets [254].
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Two studies most similar to our work are of note [247, 249]. Zhang et al. proposed the
Symptom-Herb-Diagnosis topic modeling approach to discover the common relationships
among symptom-herb combinations and disease diagnoses [247]. In another study, Zhang et
al. proposed a topic model to automatically extract the hierarchical latent topic structures
with both symptoms and herbs in TCM clinical data [249]. Although these works also
use topic model-based approaches to mine TCM data, none of them explicitly model the
asymmetric causal relations among symptoms, diseases, and herbs.
5.1.5 Discussion
We presented a new probabilistic model which captures the asymmetric causal relations
of symptoms, diseases, and herbs in TCM patient records. Compared to previous models
that analyze similar data, ours captures the asymmetry in the causal relations more accu-
rately. The model discovers disease-symptom distributions and disease-herb distributions
from medical records in a completely unsupervised manner.
Four experienced physicians judged our experimental results to be meaningful, suggest-
ing that the proposed method is effective in discovering latent knowledge in TCM medical
records. Such knowledge can be very useful as references, especially to inexperienced doc-
tors in clinical applications. The derived symptom-herb associations are also meaningful
and provide useful insights and knowledge that can help personalize prescriptions according
to the patients’ individualized symptoms. Moreover, syndromes, which are the main TCM
descriptors in clinical practice, are inferred based on patient symptoms as well as laboratory
tests. Consequently, a thorough understanding of TCM syndromes facilitates future work
in generalizing the proposed probabilistic model for TCM clinical knowledge discovery.
Our current model is general and completely unsupervised, so it can be used to analyze
large amounts of medical records collected by the TCM Data Center. This will be a major
future direction for us to explore. Another important future work is to perform natural
language processing on the symptom descriptions to better understand the effectiveness of
prescriptions. This information, coupled with the proposed model in this paper, will further
enable us to distinguish groups of herbs that effectively treat a disease from ineffective ones,
directly advancing our understanding of treatments.
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5.2 MINING ADVERSE DRUG REACTIONS NETWORK FROM ONLINE HEALTH
FORUMS
Automatic discovery of medical knowledge using data mining has huge benefits in im-
proving population health and reducing healthcare cost. Discovering adverse drug reaction
(ADR) is especially important because of the huge damage of ADR to patients. Recently,
more and more patients describe the ADRs they experienced and seek for help through online
health forums, creating great opportunities for mining health forums to discover previously
unknown ADRs. Here, I used the proposed generative model to tap into the increasingly
available health forums to mine the side effect symptoms of drugs mentioned by forum users.
Existing approaches to mine ADRs from health forums are all based on supervised learning
and thus require manually created labeled data, which is expensive to create. They also can-
not distinguish side effect symptoms from treated symptoms. Our approach overcomes both
deficiencies of previous work with a novel probabilistic mixture model of symptoms, where
the side effect symptoms and treated symptoms are explicitly modeled with two separate
component models, and discovery of side effect symptoms can be achieved in an unsuper-
vised way through fitting the mixture model to the forum data. Extensive experiments on
online health forums demonstrate that our proposed model is effective for discovering the re-
ported ADRs on forums in a completely unsupervised way. The mined knowledge using our
model is directly useful for increasing our understanding of long-term side effects, drug-drug
interactions, and rare side effects. Since our approach is unsupervised, it can be applied to
mine large amounts of growing forum data to discover new knowledge about ADR, helping
many patients understand possible ADRs that they should be aware of.
5.2.1 Experimental Results
In this subsection, we perform extensive experiments on real-world online health forum
to evaluate the effectiveness of our model. We perform both qualitative evaluation and
quantitative evaluation. In the qualitative evaluation, we show the top side effect symptoms
we have mined. In the quantitative evaluation, we compare our model with baselines on
two ground truth labeling sets. We further use our model to mine some more challenging
ADRs, such as long-term side effects, drug-drug interactions and rare side effects. Finally,
we give a detailed comparison between the side effect symptoms we have mined and the side
effect symptoms reported in the FDA database. We show that our model has mined some
suspicious ADRs which have not caught enough attention by FDA.
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Data Collection and Preprocessing
We crawl data from a real-world online health forum HealthBoards (www.healthboards.
com). HealthBoards is an online health forum that allows patients to discuss their condi-
tions. It has been rated as one of the top 20 health information communities, with over 10
million monthly visitors, 850,000 registered members and over 4.5 million messages posted.
We crawl a large text collection of 330,305 threads. We then extract 886 threads from a
board called “Drug Interation/Side Effects.” Existing NLP tools perform reasonable well
when we extract drugs from the raw text. We use Metamap [255] to extract 287 drugs
from all the 886 documents. Each thread has on average 336 words. As we have mentioned
before, each thread may describe more than one drug. In our data, we find an average of
3.18 drugs per thread. We filter the stopwords in the text and use a large medical phrase
dictionary to extract all the medical related phrases. We also remove the high-frequency
and low-frequency phrases. In total, we build a dictionary with 2107 phrases.
We use the large corpus of 330,305 threads to build the phrases distribution of the back-
ground topic. We also use these 330,305 threads to build a unigram model as a prior for the
disease symptom topic of each kind of drug. The disease symptom topic would be further
updated by the training collection.
Qualitative Evaluation
We first show the side effect symptom topics discovered from the health forum using Side-
EffectPTM. On one hand, some drugs are related to common diseases such as depression
so that they appear frequently in the corpus. On the other hand, some drugs appear infre-
quently in the corpus because they are used to treat some uncommon diseases. Since the
online health forum is a mixture of drugs with different frequencies, it is important for our
model to handle all of them. Therefore, we show the results of drugs with high-frequency,
middle-frequency and low-frequency. We list each drug with the medical phrases that have
the highest P (w|Rm).
From Table 5.2, we see that SideEffectPTM mines side effect symptom topics success-
fully for drugs with different frequencies. Most of the mined top symptoms are side effect
symptoms instead of the disease symptoms. This proves our model’s ability to distinguish
side effect symptoms from disease symptoms by explicitly modeling two parts separately.
The extracted symptoms are also general enough to cover a wide range of symptoms from
common symptoms, such as headaches and weight gain, to rare but severe symptoms, such
as kidney stones and diabetes. Specifically, for the anti-depressant drug Wellbutrin(R), our
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Table 5.2: Top-15 Phrases of Side Effect Symptom Topic
Drug(Freq) Drug Use Symptoms in Descending Order
Zoloft(R)(84) antidepressant weight gain, weight, depression,




Wellbutrin(R)(48) antidepressant wellbutrin, Wellbutrin, seizures,
depression, seizure, sleep,
mgs, weight loss, period,
enery crashes, pharmaceutical,
high doses, dosages, crash, depressed
Ativan(R)(33) anxiety disorders ativan, sleep,seroquel,
doc prescribed seroquel,
raising blood sugar levels,
anti-psychotic drug, diabetic, constipation,
diabetes, 10mg, benzo, addicted,
Ativan, plans, vertigo




seizures, liver problems, kidney stones
Zocor(R)(3) lipid-lowering agent small pill, membranes, adverse reactions,
muscle cramps, peripheral neuropathy,
memory problems, memory loss,
heart palpitations, healthy diet,
reactions, vomiting, tablets,
anemia, dizziness, dizzy
Ephedrine(2) stimulant dizziness, stomach, benadryl,
dizzy, tired, lethargic,
tapering, tremors, panic attack,
head, pshaw, advil cold,
stomach symptoms, cold sweats, bpm
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Table 5.3: Comparison of Side Effect Symptom Topic and disease symptom Topic
Seroquel(R) Trazodone(R)
Rm Tm Rm Tm
seroquel seroquel sleep sleep
sleep sleep side effects anxiety
diabetes depression trazadone depression
side effects anxiety trazodone trazodone
seroquel pdoc dry mouth fibro
doc prescribed seroquel bipolar tired side effects
raising blood sugar levels side effects anti-depressant tired
anti-psychotic drug diagnosed christina diagnosed
ambition depressed blood sugars pdoc
mood swings lithium heart racing head
diabetic mania muscle twitches insomnia
constipation weight blood tests depressed
blood work seroquel blood pain meds
weight lamictal pill weight
model extracts seizures as the most likely side effect. Seizures are known as one of the
most important ADRs of Wellbutrin(R) in medical literature [256]. Ativan(R) is used to
treat anxiety disorders and is reported to cause high blood sugar in 1.16% of patients who
have side effects when taking Ativan(R) [257]. Ephedrine only appears in two threads in
our data set. However, our model still successfully captures its side effect such as dizziness,
tired, tremors, headaches, panic attack and lethargy. These side effects are all verified by
the medical literature [258]. The side effect results of Topamax(R) contain several severe
symptoms such as liver problems and kidney stones. Recent study shows that treatment
with Topamax(R) has been proved to increase the propensity to form calcium phosphate
stones [259]. This proves that our model is able to not only mine the common side effects
(e.g, headache, weight loss), but also find uncommon severe side effects.
To further demonstrate that our model can separate side effect symptom topics from
disease symptom topics, we show both topics of three different drugs in Table 5.3. From
Table 5.3, we can naturally guess that Seroquel(R) is used to treat depression from the top
phrases in its disease symptom topic. On the other hand, in its side effect symptom topic,
only the word “anti-psychotic drug” is related to depression. Trazodone(R) is used to treat
depression and insomnia. Its disease symptom topic matches this usage with phrases such
as “insomnia”, “sleep” and “depression”. Its side effect symptom topic shows its side effect
such as “dry mouth” and “high blood sugars”. Besides these drugs, our model can separate
the side effect symptoms from the disease symptoms for most of the drugs and achieve an
100
Table 5.4: Top-10 Most Reported Side Effect Symptoms
Symtpoms #Reported Symtpoms #Reported
anxiety 93 depression 79
sleep 74 weight 45
depressed 40 headaches 39
stomach 36 tired 21
sick 19 heart 17
average cosine similarity of 0.00567. Such a low cosine similarity indicates a large difference
between treated topic and side effect topic.
We also extract the most reported side effect symptoms from our experimental results to
study the common symptoms. Table 3 is the top 10 most reported side effect symptoms
from our experiment results. Most of these symptoms are easy to observe (e.g., weight gain,
headaches) or occur frequently in everyone’s daily life (e.g., depression, anxiety). A previous
study also discovered this phenomena and explained that people are more conscious of issues
that they can directly observe [260]. We think that patients may connect these symptoms
with the drug they are using incorrectly because of the anxiety when they are searching
for medical information on the internet [261]. At the same time, patients are not able to
detect symptoms that can only be observed with the help of physicians or medical devices,
such as liver problem or hypertension. These rare unobserved symptoms may be the actual
side effect symptoms which cause those common observed symptoms. For example, a liver
problem may cause an eating disorder and weight loss. So if a patient reports weight loss
and eating disorder, we should also suspect the patient of having a liver problem. Therefore,
it is important to mine the potential rare side effects which are hidden behind these common
side effects.
Quantitative Evaluation
The main goal of the quantitative evaluation is to see how accurately our model is for
mining the side effects. Our proposed model is completely unsupervised which does not
require any labeled data for training. To perform quantitative evaluation, we construct the
following two ground truth sets.
• Human Annotation : We first build a human annotation ground truth set. Two Ph.D.
students manually extracted the side effects appearing in that thread. Due to the limited
manpower, we only labeled threads for four drugs including Zoloft(R), Wellbutrin(R),
Tylenol(R) and Topamax(R). These four drugs appear frequently in our collection so that
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they can provide us more convincible evaluation results. We labeled 96 threads in total.
According to the labeling results, each thread contains 9 side effect symptoms on average.
• FDA Database : We use the FDA database as the ground truth set. The FDA database
doesn’t always use the same terms as in the health forum, thus there is a mismatch
between professional medical term and the plain English term (e.g., dyspnoea) used
by patients (e.g., difficulty breathing) [262]. We address this problem by simply doing
keyword-matching between mined side effect phrases with those reported side effects to
FDA database. Although this is not entirely reliable, it allows us to evaluate our method
with many more drug instances. Besides, such a simple matching strategy unlikely in-
troduces any systematic bias, thus it is still useful for performing relative comparisons
between different methods.
There is no existing unsupervised approach which mines ADRs from online health forums.
We use the following two baselines for comparison.
• Basic SideEffectPTM (Basic) : This approach does not incorporate prior in our Side-
EffectPTM model.
• PhraseMatch (PM) : This is the model similar to the approach in [260]. Although they
focus on short messages which are less noisy and shorter, we can still apply it to forum
text. They assign a score to each phrase in the document according to its similarity to a
symptom phrase. We used our dictionary to make this approach match our corpus better.
This model is unable to separate side effect symptoms from disease symptoms.
We want to use these two baselines to answer two questions. First, is the prior of disease
symptom topic beneficial to our model? We compare Basic SideEffectPTM with our model
to answer this question. Second, is it necessary to explicitly build two language models for
both side effect symptoms and disease symptoms? We compare our model with PhraseMatch
to answer this question.
Since our method would be able to nominate candidate side effects of each drug for human
experts to further verify, the task is essentially an ADR retrieval task. Therefore, we can
use standard retrieval measures to evaluate our method. We use the following information
retrieval measures: Precision, Recall and Mean Average Precision (MAP). From Table 5.5,
we see that our method outperforms all the baselines on all evaluations on both ground truth
labeling sets. Our method improves Basic SideEffectPTM by 212% in Precision@3 and 150%
in Precision@10 based on the Human Annotation ground truth. This demonstrates that the
prior of disease symptom topics can greatly improve the performance when we mine ADRs.
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Table 5.5: Compare our model with baselines. * represents the improvement of our model
over the corresponding baseline is statistically significant.
Human Annotation FDA Databse
Basic PM Our Basic PM Our
Prec@3 0.1667 0.1667 0.5000 0.1188 0.0991* 0.1282
Recall@3 0.0032 0.0032 0.0122 0.0030 0.0017* 0.0039
MAP@3 0.0032 0.0016 0.0072 0.0015* 0.0013* 0.0020
Prec@10 0.2000 0.2500 0.5000 0.1192 0.0951* 0.1262
Recall@10 0.0191 0.0260 0.0497 0.0103 0.0084* 0.0137
MAP@10 0.0083 0.0058* 0.0280 0.0039 0.0027* 0.0046
Our method improves PhraseMatch by 212% in Precision@3 and 100% in Precision@10.
This proves that explicitly modeling side effect symptoms and disease symptoms separately
can make the extracted ADRs more accurate.
We also observe that the improvement on FDA database results is less significant than the
improvement on human annotation ground truth. Although there are mismatches between
the terms in the FDA database and health forum, this may indicate that some of our
extracted side effects from the health forum haven’t been approved by the FDA. Therefore,
we further compare our experiment results with FDA database and find some previously
unknown side effects that haven’t been included by FDA in subsection 5.2.1.
Mining Challenging Adverse Drug Reactions
Besides normal side effects, we also apply our generative model to mining three kinds of
more challenging side effects.
From the final top-10 extracted long-term side effect candidates, we detect three potential
long-term side effects and show them in Table 5. All of these symptoms have been reported




Phentermine bone and joint pain
as potential long-term side effects in the medical literatures or in surveys. Phentermine has
been reported to cause bone and joint pain after using it for 9 month on average[263]. Below
is a patient’s thread about the side effect of Cipro(TM) to him.
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Figure 5.3: Patient’s Thread Reports the Long-term Side Effect of Cipro(TM)
Table 6 shows the top extracted drug-drug interactions we have mined through our
model. Most of these drug pairs have been reported to be dangerous when taken together.
Methadone and Xanax(R) are reported to have potentially life-threatening effects if taken
together [264]. A recent review of Methamphetamine suggests that Zoloft(R) might not be
effective in the treatment of methamphetamine addiction and might even worsen the condi-
tion [265]. Valium(TM) has been reported as one of the major interactions with Zoloft(R)
and the level of medication in the bloodstream should be monitored closely when taken them
together[266].
Table 5.7: Drug-drug Interaction
Drug1 Drug2 Drug1 Drug2
Xanax(R) Zoloft(R) Methadone Xanax(R)
Valium(TM) Zoloft(R) OxyContin(R) Methadone
Wellbutrin(R) Celexa(TM) Methamphetamine Zoloft(R)
Levaquin(R) Avelox(R) Lamictal(R) Concerta(R)
Table 7 is the extracted rare side effects. These top extracted drug-symptom pairs reveal
some potential rare side effects. For example, Prozac(R) has been reported to have the sexual
side effect, especially ejaculation problems [267]. The anti-inflammatory drug Solaraze(R)
has been reported to cause rare but significant cases of serious hepatotoxicity in medical
literature [268].
Discovering Unknown ADRs
To further demonstrate the effectiveness of our model and prove that health forums are
good information sources to collect ADRs, we compare the top extracted ADRs with the
FDA database. Since there is a mismatch between phrases in two corpus (e.g., “difficulty
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breathing” in forum, “dyspnoea” in FDA database) [262], we manually check the extracted
ADRs. Table 8 is the potential ADRs listed in our experiment results but not listed in the
FDA database.
Prozac(R) has been reported to have “sexually inappropriate behaviour” in FDA database.
Our method further narrows this symptom to “ejaculate problem” which has been proved
in the medical literature [267]. Ativan(R) doesn’t have symptoms related to “blood sugar”
or “diabetes” in FDA database. We have discussed its ADRs in subsection 5.2.1. Although
there are some existing medical literatures or surveys demonstrate these ADRs, we still need
more professional medical tests to help patients understand the possible danger that they
should be aware of.
Table 5.9: Discovering Unreported ADRs
Drug Symptom
Prozac(R) ejaculate
Ativan(R) raising blood sugar levels, diabetic, constipation
Adderall(TM) lost weight
We notice that the FDA database often covers more ADRs than the ADRs mined from
health forums by using our proposed model. However, our approach still has the following
advantages. First, our model could successfully mine some previously unknown ADRs that
haven’t been collected by FDA database. Second, although we return fewer ADRs, we still
maintain results of high quality and accuracy based on both qualitative and quantitative
evaluations. In addition, our model can mine ADRs for new drugs more efficiently than the
FDA database and link the ADRs to the corresponding documents.
5.2.2 Conclusion and Future Work
We use the abundant text information from online health forum to mine adverse drug
reactions. Our proposed SideEffectPTM is the first approach that separates side effect
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symptoms from disease symptoms when mining ADRs. We successfully mine many mean-
ingful ADRs from real-world online health forum. Some of them have never been reported
in FDA database. Furthermore, we also mine some more challenging side effects such as
long-term side effects, rare side effects and drug-drug interactions, which are generally very
hard to detect.
The voluntary participation of huge amounts of patients and the rapid growth of online
health forums will bring us more and more forum text data. Our method can be continuously
applied to these growing data to discover new ADRs reported and link the extracted ADRs
to the corresponding documents. Our approach can be further improved by addressing the
data quality problem of the forums, such as misspelled words, different forms of the same
word and unrelated information being brought up in a single thread.
5.3 INCORPORATING KNOWLEDGE NETWORKS IN ELECTRONIC MEDICAL
RECORDS ANALYSIS
With the increasing adopting of electronic medical record systems in United States, there
is an urgent need to analyze the massively generating electronic medical record (EMR)
data. To support clinical decision making, we have developed novel data mining algorithms
for important clinical applications such as patient clustering [83], EMR visualization [82],
similar patient records retrieval [81], and survival analysis [80]. To address the noisy and
missing value challenges in mining EMR data, we use a network-based approach to integrate
external knowledge from genomics data with electronic medical records. Our methods have
been demonstrated to be effective in tens of thousands of patient records.
5.3.1 Method
We propose to create the heterogeneous medical record network (HEMnet) to address the
challenges of EMR analysis. The basic idea is to leverage information from several external
sources in order to supplement the knowledge contained in clinical data.
Definition of HEMnet
The HEMnet is a network that consists of nodes and edges associated with different types
of information. Formally, we define the HEMnet as a graph G = (V,E,R), where V is the set
of typed nodes (i.e., each node belongs to a specified type), E is the set of typed edges, and
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R is the set of edge types. An edge e ∈ E in the HEMnet is an ordered triplet e = {u, v, r},
where u, v ∈ V are typed nodes and r ∈ R is the corresponding edge type.
The network in this study utilizes four distinct categories of edges. The first three cat-
egories are drawn from external databases, while the last category draws directly from the
EMR database.
(1) Protein-protein interaction network: this network is based on an external gene
network of protein-encoding genes, called HumanNet [269]. For a functional linkage
between two proteins p1 and p2, we create a node for p1, a node for p2, and an undirected
edge {p1, p2} in the HEMnet. This is the molecular interaction network.
(2) Drug targets: this database contains drugs and the proteins they target, curated
from expert knowledge and medical literature. We create a node h, a node p, and an
undirected edge {h, p} if a drug h targets a protein p. This is domain knowledge.
(3) Drug-symptom dictionary: this database is a TCM textbook consisting of drugs and
the symptoms they treat, also curated from expert knowledge and medical literature.
We create a node h, a node s, and an undirected edge {h, s} if a drug h treats a symptom
s in the dictionary. This is domain knowledge.
(4) Electronic medical records: we directly add co-occurrence edges from each medical
record. For example, if a patient is diagnosed with cancer type c and prescribed a drug
d, then we create a node c, a node d, and an undirected edge {c, d}. We repeat this for
all elements in each patient’s medical record.
All edges are unweighted and undirected. Because we only use 133 sparse patient records,
the external information is critical in discovering relationships among EMR entities that
may otherwise be completely hidden. Overall, |V | = 11, 911, |E| = 379, 715, and |R| = 23.
It is important to note that there are only 449 actual features in the EMRs, and that the
remaining nodes are proteins that are only used in the HEMnet.
Feature Matrix Enrichment
After generating low-dimensional vector representations of nodes in the HEMnet using
ProsNet, we can tackle the problem of missing data and semantic mismatches in the patient
records.
The patient record matrix M is a 133×449 feature matrix, since we have 133 patients and
449 features. Each row of M consists of a patient record with binary, categorical, discrete,
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Figure 5.4: The pipeline for the HEMnet, our proposed heterogeneous information network
consisting of electronic medical records, molecular interaction networks, and domain
knowledge. We train network embedding vectors on the HEMnet, obtaining
low-dimensional vector representations for each node. With these vectors, we enrich the
original medical records and cluster them into two groups.
or continuous column values, depending on the corresponding feature. For example, drugs
may be continuous features because they are recorded as dosages, while metastasis sites
are categorical features that may indicate multiple locations in the body. In this study, we
binarize the categorical features.
In order to impute missing features, we construct a similarity matrix, S. S is a 449× 449
matrix such that Sij is the absolute value of the cosine similarity between feature i and feature
j’s embedding vectors. Furthermore, we set a threshold such that any entry Sij is set to 0
if Sij is less than the threshold. We empirically set this threshold to 0.3. After creating S,
we can generate the enriched patient record matrix M ′ with the following operation:
M ′ = M × S (5.8)
With this operation, we can simultaneously solve the problems of incomplete data and
semantic mismatches by filling in missing values that are highly similar to existing features
for each patient. For example, a patient that has “halitosis” in his or her patient record will
receive a non-zero value for “bad breath”, as these two symptoms are likely to have very
similar embedding vectors.
5.3.2 Patient stratification and survival analysis
clustering squamous-cell carcinoma patients into two sets using HEMnet-enriched feature
matrices, clong has 28 patients and cshort has 15 patients. By the log-rank test, clong’s survival
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clong 28 20.7 2.01 22.7
cshort 15 11.0 1.60 11.0
function is significantly better than cshort’s with a χ
2 statistic of 10.79 (p-value = 0.001020).
We show the cluster summary statistics in Table 5.10, with u = 33.3.
In contrast, when using the baseline feature matrix, clong has 25 patients and cshort has 18
patients. Here, the survival functions are not significantly different at the 1% significance
level, with a χ2 statistic of 6.214 (p-value = 0.01267).
When using feature matrices with mean imputation, clong has 25 patients and cshort has
18 patients. Here, the survival functions are not significantly different with a χ2 statistic of
2.489 (p-value = 0.1148).
Of all significant features, only “Karnofsky performance status” has a higher mean in
clong than in cshort. This is expected, as a higher KPS score indicates a relatively healthier
cancer patient [270]. All other significant features have lower means in clong than in cshort.
This makes sense for symptom features, as patients with longer survival rates should be in
better health. On the other hand, it might seem, at first, as if the higher values of drugs in
cshort indicate their ineffectiveness. However, patients with more life-threatening conditions
require higher dosages of treatments.
The baseline method did not find sputum and cough to be symptoms that are statistically
different between clong and cshort, while our method did. However, they are very common
symptoms in lung cancer patients that tend to be more severe in patients with lower survival
rates. Furthermore, the other three features that our method discovered are all drugs. We
can interpret these features’ higher values in cshort as potential drug-symptom relationships.
In the drug-symptom dictionary, sulphurweed is known to treat both cough and sputum,
while umbrella polypore only treats urinary tract-related symptoms and A. tataricus simply
does not appear. Despite this, a study showed that a naturally occurring compound derived
from umbrella polypore mycelia induces apoptosis in human lung cancer cells [271]. Fur-
thermore, a recent study showed that a polysaccharide isolated from A. tataricus inhibits
the growth of cancer cells [272].
Our method was able to capture these meaningful drug-symptom relationships while the
baseline methods could not. This is due to the fact that the HEMnet integrates external drug
information in the form of drug-protein targets and protein-protein interaction information.
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5.3.3 Electronic medical records retrieval
We present a study of electronic medical record (EMR) retrieval that simulates situations
in which a doctor treats a new patient. Given a query consisting of a new patient’s symptoms,
the retrieval system returns the set of most relevant records of previously treated patients.
However, due to semantic, functional, and treatment synonyms in medical terminology,
queries are often incomplete and thus require enhancement. In this paper, we present a
topic model that frames symptoms and treatments as separate languages. Our experimental
results show that this method improves retrieval performance over several baselines with
statistical significance. These baselines include methods used in prior studies as well as
state-of-the-art embedding techniques. Finally, we show that our proposed topic model
discovers all three types of synonyms to improve medical record retrieval.
BiLDA-based mixed query expansion achieved the best retrieval performance among all
expansions. For NDCG@5, 10, 15, and 20, it performed better than the baseline with no
query expansion with p-values of 2.842 ×10−3, 4.784 ×10−3, 6.852 ×10−7, and 1.929 ×10−6,
respectively. Furthermore, BiLDA mixed expansion performed better than all of the runner-
up methods at the 5% significance level.
Mixed expansion was only the best-performing expansion type for BiLDA. This is due to
the fact that all other methods do not separately mine symptom and treatment synonyms.
On the other hand, BiLDA-based query expansion considers symptoms and treatments to
be from separate topics, and therefore it successfully added in mixed query terms.
Dictionary-based expansion’s poor performance can be explained by the fact that it adds
too many treatment synonyms, which dilutes the original query’s symptoms. On average,
dictionary-based expansion nearly doubled each query in size. We show an example of a
mixed query expansion from BiLDA. In the patient query in Table 5.11, the five expansion
terms include three symptoms and two treatment drugs.
5.3.4 Electronic medical records visualization
Here, we present VisAGE, a method that visualizes electronic medical records (EMRs) in a
low-dimensional space. Effective visualization of new patients allows doctors to view similar,
previously treated patients and to identify the new patients’ disease subtypes, reducing the
chance of misdiagnosis. However, EMRs are typically incomplete or fragmented, resulting in
patients who are missing many available features being placed near unrelated patients in the
visualized space. VisAGE integrates several external data sources to enrich EMR databases
to solve this issue. We evaluated VisAGE on a dataset of Parkinson’s disease patients. We
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Table 5.11: Example of an expanded query created by the BiLDA method. Different query
terms are separated by semicolons.
















qualitatively and quantitatively show that VisAGE can more effectively cluster patients,
which allows doctors to better discover patient subtypes and thus improve patient care.
Two-Dimensional Visualization with UPDRS
Using the two-dimensional representations of patient records, we labeled each record ac-
cording to its unified Parkinson’s disease rating scale (UPDRS) scores. The UPDRS consists
of six subsections, each containing survey questions that evaluate a patient’s physical and
mental condition [273]. The questions deal with topics ranging from anxiety to sleeping
problems, with scores scaled from 0 to 4. A higher score indicates more severe impairment
or disability. As in previous work, we labeled each patient with the sum of his or her UPDRS
scores [274].
The main difference between VisAGE and the baseline is that in Figure 5.5, moderately
impaired patients (orange circles) on the right side of the plots were clustered more distinctly
in the VisAGE visualization, while the same patients were less structured in the baseline
visualization. The most severe Parkinson’s disease patients are marked by red squares, and
were clustered more tightly together in the VisAGE visualization than in the baseline. The
baseline’s worse performance can be attributed to the data sparsity of the EMRs.
Qualitative Evaluation: Drug and Symptom Enrichment
We qualitatively evaluated the visualization results by computing drug and symptom
enrichments for each cluster. We used symptoms and drugs because they are strongly con-










Figure 5.5: The two-dimensional representations of patient records, plotted with color
labels determined by each record’s UPDRS scores. VisAGE’s visualization identifies more
clusters for moderately impaired patients, and more tightly groups severely impaired
patients.
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or drug, then doctors will have a general idea of the cluster’s disease subtype. We first
clustered the two-dimensional patient representations with DBSCAN [275], which is robust
to outliers and does not need to specify the number of clusters. Because the PPMI dataset
contains control patients to simulate noise, DBSCAN’s robustness to outliers is especially
desirable. Additionally, not having to specify the number of clusters a priori is useful for
our application, as we do not know the exact number of patient subtypes beforehand.
For the DBSCAN parameters, we set ε = 1 and minPts = 10. In the baseline method,
patients were placed into 10 clusters. With VisAGE, patients were placed into 18 clusters.
For each cluster c and each symptom or drug b, we computed Fisher’s exact test to determine
if c was significantly enriched in b. We only used symptoms and drugs with binary values to
avoid medical tests for which all patients had non-zero values (e.g., the Epworth Sleepiness
Scale [276]).
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CHAPTER 6: SUMMARY AND FUTURE DIRECTIONS
In this thesis, I systematically studied the problem of mining knowledge networks for
precision medicine. I used three different network models to tackle the challenges in min-
ing knowledge networks. For small-sized network, I applied the diffusion model to capture
the topologic similarity of nodes in the network. For larger networks, I proposed novel
network embedding approaches to reduce the noise of the diffusion state. The proposed
network embedding approaches also enable us to obtain low-dimensional features that can
alleviate overfitting in downstream prediction tasks. This thesis covers three important pre-
cision medicine tasks: gene function annotatin, drug discovery, and clinical decision support.
Promising results on these three tasks show the power of using knowledge networks to ad-
vance precision medicine. In particular, I show the promising performance of the proposed
approaches in precision medicine tasks, including drug symptom relation detection, adverse
drug reaction detection, gene function prediction, drug target prediction, drug pathway as-
sociation identification, gene set annotation, and electronic medical record analysis. While
these applications demonstrate the encouraging future of mining knowledge network for pre-
cision medicine, there are certainly many other research problems we can explore in this
direction. This thesis has prepared a solid basis to pursue such a long-term goal, and in my
future research I envision quite a few opportunities to extend my current research:
6.1 KNOWLEDGE NETWORK-SUPPORTED BIOLOGICAL FINDING
INTERPRETATION
As biomedical data has been massively generated, many predictive models have been
developed to guide drug discovery and disease diagnosis. For example, one can train a
classifier to identify genes whose expression values are significantly correlated with drug
response. Despite the improved prediction performance, many of these models are not
interpretable. Consequently, we can gain very limited insight of drug mechanism from these
predictive models. Several modern machine learning methods try to interpret the prediction
results by finding important features (e.g., genes). However, even if we know that certain
gene is crucial to accurately predict the response of a drug, the underlying mechanism and
functions are still unclear. The setbacks may be due to restricting the models to only look
for interpretations from the limited input feature sets.
I plan to use the knowledge from knowledge networks to build an end-to-end knowledge
network-assisted interpretable predictive model. The ideal output of our model would be a
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subnetwork of the original knowledge network. This subnetwork reflects how a drug gradually
affects the expression of genes through certain functions and pathways. By using the external
information from other datasets, this subnetwork would be much more informative than a
simple list of selected features.
6.2 REFINING KNOWLEDGE NETWORKS WITH EXPERIMENTAL DATA
Knowledge networks could be noisy due to experimental errors and lack of enough exper-
iment replicates. Consequently, the resulted knowledge networks could also be noisy and
need to be further refined. I plan to develop novel machine learning approaches to refine and
validate knowledge network. I want to use different data sources to cross validate each other.
I also plan to use limited high-quality experimental data to exclude potential false-positive
links in knowledge networks. The resulted high-quality knowledge networks could empower
better data mining applications for precision medicine with less false-positive results.
6.3 UNCOVERING DISEASE MECHANISMS THROUGH NETWORK BIOLOGY
My work on mining cancer genomics data has shown encouraging results in understand-
ing cancer heterogeneity using a novel network-based approach. I have recently applied
this approach to Parkinsons disease, which is also driven by a combination of genes, and
obtained preliminary but promising results in patient subtyping based on whole exome se-
quencing data. In the future, I want to further explore this direction and apply it to a
broader range of human diseases. While significant efforts to date have focused on specific
genes that interact with compounds and confer observed cellular phenotypes, there has been
relatively little progress in studying the interactions of genes in response to the presence of
compounds. Comprehensively understanding gene interactions requires us to take a network
biology perspective and consider information from different data sources. One direction I
plan to explore is to transfer disease-related discovery from model organisms to humans by
aligning the molecular interactions in different species. In addition, I am also interested in
integrating clinical data with genomics data in the hopes of building an intelligent system
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